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Abstract 
Introduction: herbal medicines (HMs) are popular and have become increasingly used in the 
prevention, diagnosis, and treatment of minor medical conditions and life-threatening illnesses. 
Patients are reluctant to link herbs with a risk of adverse effects. Adverse drug reactions (ADRs) 
are a common cause of hospital admission and make a significant contribution to healthcare 
costs. ADRs resulting from herb-drug interactions have been identified as significant factors 
responsible for patient morbidity and mortality. 
Research aim: there was a limited pool of information on HM safety and no studies of the 
context of use, for example alone or in combination with other herbs or allopathic medicines, in 
the UAE. The present research sought to address this. 
Methods: in order to quantify usage of HMs in a primary care setting in the UAE, the attitudes 
and beliefs of UAE Nationals visiting the Al Rowda Clinic, one of biggest Primary Healthcare 
settings in Abu Dhabi city were sought through a questionnaire. The research was then 
extended to a three-month,· prospective study of secondary care patients attending the 
Nephrology Clinic in Sheikh Khalifa Medical City (SKMC), Abu Dhabi. Data was obtained from 
several sources besides the patient interview, including medical notes, drug charts and the 
patients' doctors. Potential links between HM use and ADRs were assessed by a consensus 
panel of investigators using the Naranjo algorithm. 
Results: in primary care, the use of HMs was widespread; three quarters of the sample had 
experience of HM use; with a point-prevalence of current HM use of 38%. A wide range of herbs 
was used to treat a large number of disorders. Most herbal remedies were in the crude form, 
often used in mixtures and frequently obtained from unregulated sources. A large majority of 
users considered the HMs they were taking to be effective, natural and therefore safe; but an 
appreciable proportion ( 11 % ) cited adverse reactions which they thought were due to the HMs 
they were taking. Most of herb users were recommended by users' family or friends. 
The use of herbs was again widespread among patients visiting the nephrology clinic in SKMC, 
with 468 of 688 patients (68%) reporting use at the time of interview. Over 100 different HMs, 
many of them mixtures, were being used. More patients in this setting were also taking 
prescription medicines (PMs) (70% vs 39%) and 323 (69.0%) were taking three or more herbal 
preparations. Approximately 70% of patients in both studies had not informed their doctors that 
they were using HMs. 
Interestingly, 28 ADRs to HMs were identified in 26 patients (5.6%); 13 (46.4%) were judged to 
be probably related and 15 (53.6%) possibly related to the HM. Seven (25%) involved HMs 
alone and 21 involved a HM / PM interaction. Even though an association was judged to be 
present in 28 cases (in 26 patients) it was still often difficult to determine which, of the range of 
HMs taken by the patient, was the culprit. In three cases HMs contributed to existing renal 
disease. 
Conclusions: HMs contain a myriad of pharmacologically active compounds that, when used 
by people with or without chronic concomitant disease, may be hazardous. Both the primary and 
secondary care studies contribute information on the widespread use and popularity of HMs in 
the UAE and show that use is not without risk. The reluctance of subjects to inform their 
healthcare professionals about current HM use lead the author to recommend that thorough 
drug histories should be taken on clinic visits or admission to ensure that the attending clinician 
is aware of all potentially harmful preparations being taken by the patient. Pharmacists may 
have an important role to play in this process 
As the pharmacovigilance scheme to be adopted in UAE is developed, HM safety should be 
monitored alongside that of PMs. 
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Chapter One: Introduction 
1.1 The UA E - A General Overview 
The United Arab Emirates (UAE) is a young country, only established on 2nd December 
1971. It is unique in terms of political structure and diversity of population. The country 
flourished for more than 30 years under its first president, Sheikh Zayed Bin Sultan Al 
Nahyan, who died in November 2004. The current president is his son, Sheikh Khalifa bin 
Zayed AI-Nahyan.1 The constitution of the UAE is outlined in Section 1.3. 
The UAE is part of the Arabian Peninsula and lies to the east of the Arabian Gulf. It is 
bordered by Saudi Arabia to the west and south, and by Oman to the east. In the north, the 
UAE has a short frontier with Qatar. Its climate is very dry, with little rain, vegetation and 
animal life, with average summer temperatures of 40°C, but reaching 48°C. In winter, 
average temperatures are approximately 18°C. 
Most of the UAE is an arid desert land particularly in the inner western region. There are 
many famous oases in that desert region such as AI-Ain and Liwa oases. UAE territorial 
water is generally shallow, which is a feature of the Arabian Gulf coastline. The UAE 
territorial water is fringed with coral reefs and is rich in pearl oyster ,  which was traditionally a 
major source of revenue for the UAE. There are many islands and small sandy islets, 
including 200 islands for the emirate of Abu Dhabi, the most important of which is the island 
of Sir Bani Yass which was made into a natural refuge for rare animals. 
UAE is not particularly hilly with mountains taking up only a few percent of the total territory, 
most of which is in the emirate of Fujairah. These mountains form part of World Wide Fund 
for Nature's Arabian Highland Woodlands and Shrublands Ecoregion and are an officially 
protected zone (as of June 2008). 
1 .1 .1  UA E Population 
In 2004, the total estimated population of the UAE was 4.25 million; however, the UAE 
population is predicted to hit 5 million by 2010. 2 The population has risen dramatically in 
recent years due to an influx of male foreign workers and their dependants; for example the 
total labour force rose from 1.2 million in 1995 to 2 million in 2002.2 National UAE citizens 
account for approximately 25% of the population. The remaining 75% come primarily from 
I 
the Indian sub-continent (50%), the Arab nations, notably Egypt (10%), and Iran (15%). 
There are also small minorities from Europe and the Philippines. 
The labour force has seen commensurate increases, mimicking the immigration of workers, 
but also the number of women in work has also increased, rising from 19% in 1995 to 28% in 
2003. 3 The population of the UAE is concentrated primarily in the major cities along both 
coasts, although the interior oasis settlement of Al-'Ain has grown into a major population 
centre. 
The official language of the UAE is Arabic, but English, Urdu, Hindi and Farsi are also 
spoken. 
1.2 A Brief History of the UA E 
The UAE and Oman share much of their ancient history and cannot be separated from the 
greater history of Oman and the Arabian Gulf, which stretches back for thousands of years. 
However, its more recent history is influenced by the British dating back to the mid-18th 
century, as British naval power began to dominate the Gulf. At this time, two important tribal 
confederations dominated the coast; the Qawasim and the AI-Busaids (who are now the 
ruling family of Oman). In 1798 the British signed a treaty with the AI-Busaids. This was seen 
by the Qawasim as the British allying themselves with their enemy and they began to attack 
the British. The British interpreted this as simple piracy and dubbed the west coast of the 
present day UAE as the 'pirate coast'. Attacks on the British continued until 1819 when the 
British decided to resolve the situation by destroying and capturing the Qawasim ships. This 
led to a maritime truce in 1835 that later became known as the Treaty of Peace in 
Perpetuity' thus giving the British responsibility for arbitrating disputes among the sheikhs. 
What is now the UAE became known as the Trucial coast. In 1968, Britain announced it 
would leave the Gulf by the end of 1 971. The British began work on forming a single state 
consisting of Bahrain, Qatar and the Trucial coast. This proposal failed and Bahrain and 
Qatar formed independent states. Finally, in July 1971, six of the Trucial emirs (Abu Dhabi, 
Dubai ,  Sharjah, Umm al Qiween, Ajman and Fujairah) agreed on a federal Constitution for 
achieving independence as the UAE. The emirs agreed to a formula under which Abu Dhabi 
and Dubai would carry the most weight in the federation but each emir would remain largely 
autonomous. 
The new country came into existence on 2nd December 1971. The remaining sheikhs of Ras 
Al Khaimah joined the UAE in February 1972. On achieving state-hood, Shiekh Zayed took 
I 
office as the first President of the UAE. On the 6 th of December 1 971  the UAE became the 
eighteenth member of the League of Arab States and on the 9th of December 1 971  it 
became the 1 32nd member of United Nations. The UAE was an original member of the 
Cooperation Council for the Arab States of the Gulf (GCC) founded in May 1 98 1 .  The GCC 
remit is to achieve greater political and economic integration between Gulf countries. 
1 .3  Current UAE Structure 
The UAE is comprised of a federation of the seven states of Abu Dhabi, Dubai, Sharjah, 
Ajman, Umm Al Qiween, Ras Al Khaimah and Fujairah. Key statistics are shown in Table 
1 . 1 
Emirate Estimated Area % of UAE Ruler 
population (2007) (km2) landmass 
(Excluding 
the islands) 
Abu Dhabi 1 .85 million 67,340 86.7 Sheikh Khalifa bin Zayed 
Bin Sultan Al Nahyan 
Dubai 1 .4 million 3,885 5.0 Sheikh Mohammed bin 
Rashid Al Maktoum 
Sharjah 750,000 2,590 3.3 Sheikh Sultan Bin 
Muhammad al-Qasimi 
Ajman 275,000 259 0.3 Sheikh Humaid bin Rashid 
AI-Nuaimi. 
Ras Al- 230,000 1 ,680 2 .2  Sheikh Saqr bin 
Khaimah Muhammad AI-Qasimi 
Fujairah 1 30,000 1 , 1 65 1 .5 Sheikh Hamad bin 
Muhammad AI-Sharqi 
Umm-AI- 75,000 777 
I 
1 .0 Su'aod Bin Rashid Al 
Qiween 
I 
Mu'alla 
Table 1.1 :  Key statistics for the UAE. 4•5 
3 
I 
: I I 
1 .4 UA E Government Structure and Constitution 
Over the course of 2007, major reform of the government structure occurred, at both federal 
and local level. These steps were designed to make it both more responsive to the needs of 
the country's population and to ensure that it was better equipped to cope with the 
challenges of development. The most important development during 2007 was the formal 
launching of a UAE government strategy for the years ahead in six areas: social 
development, economic, public sector, justice, safety, infrastructure and rural areas. 
1.4. 1  Federal and Local Government 
In parallel with the federal institutions, each of the emirates has its own local government. All 
have expanded significantly as a result of the country's growth, though they differ in 
complexity from emirate to emirate, depending on factors such as population, geographical 
size and degree of development. The powers of the various federal institutions and their 
relationship with the separate local institutions have evolved since the establishment of the 
state. Under the terms of the constitution, rulers may relinquish certain areas of authority to 
the federal government. 
The highest federal authority in the UAE is the Supreme Council of Rulers, which comprises 
the hereditary rulers of the seven emirates. It elects the President and Vice-President from 
among its members; both appointments are elected for five-year terms. The President 
appoints a Prime Minister and a Council of Ministers. Proposals submitted to the Council 
require the approval of at least five of the Rulers, which must include those of Abu Dhabi and 
Dubai. The Council is responsible for general policy matters involving communications, 
education, defence, foreign affairs and development, and for ratifying federal laws. Reporting 
directly to the supreme council is the Federal National Council. This council, formed under 
the Constitution, is composed of 40 members appointed by each emirate (eight each from 
Abu Dhabi and Dubai, six each from Sharjah and Ras al-Khaimah, and four each from 
Ajman, Fujairah and Umm al-Qiween) who each serve a two year term. The Council review 
laws proposed by the Council of Ministers and has authority to reject, amend and initiate 
those laws. 
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1.4.2 Justice and Security 
The constitution calls for a legal code based on Shari'ah ( Islamic) law. In practice, the 
judiciary blends Western and Islamic legal principles. At the federal level, the judicial branch 
consists of a supreme court and several lower courts: the former deals with emirate-federal 
or inter-emirate disputes and crimes against the state, and the latter cover administrative, 
commercial , and civil disputes between individuals and the federal government; other legal 
matters are left to local judicial bodies. 
1 .5 Religion 
The cultural traditions of the UAE are rooted in Islam and identify with the wider Arab world. 
Islam is the official religion in the UAE; although other faiths are respected and practiced, 
including Christianity. The majority of nationals are Sunni Muslims with a minority of Shi' I 
Muslims. Strong cultural ties are maintained with the neighbouring Arabic Gulf states and 
tribal identities remain fairly strong , despite urbanisation; the family is still considered the 
strongest and most cohesive social unit. 
1.6 Economy of the UA E 
The official currency of the currency is the Dirham (AED) which is currently equal to $3.68 
and £6.125 (day of exchange rate quoted is June 22nd 2009). The UAE nominal GDP (gross 
domestic product) in 2006 was 600 billion AED according to the UAE Central Bank.2 Key 
factors are the continued oil market, establishment of a number of major developments and 
infrastructure projects and further expansion of free zones. Oil and gas, primarily from Abu 
Dhabi, contribute approximately 37% to GDP. The remainder of GDP is derived mainly from 
the manufacturing and construction industries, real estate and government services. 
Trade has long been important to the UAE. Even before the discovery of oil , Dubai's 
prosperity was assured by its role as the Arabian Gulf's leading city due to its location and 
safe port facilities. For centuries Dubai was known as 'the city of the merchants'. Today the 
UAE has over 20 ports, although the three main ports are located in Dubai ,  Abu Dhabi ,  and 
Sharjah. 
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Oil was first discovered in Abu Dhabi in 1958 and commercial export started in 1962. Under 
the leadership of Sheikh Zayed, the emirate set up the Abu Dhabi National Oil Company 
through which it nationalised concession agreements in the 1970s. The Dubai emirate also 
struck oil in 1966 with production beginning in 1969. Although oil has been found in other 
emirates, (e.g. AI-Sharjah and Ras al-Khaimah) Abu Dhabi and Dubai account for the 
overwhelming majority of production. Indeed, Abu Dhabi is the third largest oil producer in 
the Gulf, after Saudi Arabia and Kuwait. 
The UAE has attempted to diversify its economy to avoid complete dependence on oil. 
Significant natural gas reserves have been discovered and Abu Dhabi has begun to extract 
this for both local use and export. Additionally, tourism has been a major area of economic 
growth in the UAE, with Dubai becoming a holiday destination and major airline hub between 
Europe and South East Asia. This success is now being replicated in Abu Dhabi. As part of 
the UAEs diversification away from oil dependence the UAEs manufacturing base now 
includes cement, ceramics, textiles, pharmaceuticals, gold and jewellery. The UAEs strategic 
location and transportation infrastructure has also helped to attract foreign investors to set 
up headquarters. Important factors in attracting companies to invest in the UAE are the 
existence of numerous free zones where conditions for operating business enterprises are 
highly attractive. 
Agriculture production is centered largely in the emirates of Ras AI-Khaimah and AI-Fujairah. 
The enclaves of Ajman and the oasis area of AI-Ain have expanded considerably through 
increasing use of wells and pumps to provide water for irrigation. Dates are a major crop, as 
are tomatoes, cucumbers, and aubergines. The country is reliant on imports for certain 
foodstuffs, most notably grains, but now produces enough eggs, poultry, fish, and dairy 
products to meet its own needs. Commercial fishing is concentrated in the emirate of Umm 
Al Qiween. 
Exports are dominated by oil, shipped primarily to Japan, the United States, and Western 
Europe, who are also UAE's main trading partners, as well as Australia, Singapore and 
neighbouring Gulf countries. Main imports, apart from foodstuffs include machinery and 
transport equipment, chemicals, and crude minerals. 
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1 .  7 Education 
The rapid rise in population has necessitated considerable investment in education. Today, 
the UAE offers comprehensive education to all; from kindergarten to university. Education for 
the country's citizens is free at all levels. Much has been achieved since the early 1970s but 
efforts are now being made to improve the educational environment for all pupils, in line with 
a re-evaluation of the role of government. 
The educational system of the UAE is broadly similar to that of the UK. The existing structure 
is a four-tier system: 
• 4 to 5 year-olds attend kindergarten; 
• 6 to 11 year-olds attend primary schools; 
• 12 to 14 year-aids attend preparatory schools; and, 
• 15 to 17 year-aids attend secondary schools. 2 
Over 40% of pupils attend private schools. Some of these offer foreign language education 
geared towards expatriate communities, usually preserving the culture and following the 
curriculums of the students' countries of origin. 
Ninety-five per cent of women and 80% of men who are enrolled in the final year of 
secondary school apply for admission to a higher education institution in the UAE or study 
abroad. The Al Ain-based United Arab Emirates University (UAEU) continues to be the 
country's flagship national institution of higher education, whilst newer institutions such as 
Zayed University, which has campuses in Abu Dhabi and Dubai, were established in 1998 
by the Federal Government, to educate national women and prepare them to actively 
participate in society. In addition to university education there are 1 2  Higher Colleges of 
Technology (HCT) that offer a more technically oriented education. Besides UAE institutions, 
there are a number of private institutions, including the American Universities of Sharjah and 
Dubai, Sharjah University and the Ajman University of Science and Technology. 
The country has also established schools for adult UAE citizens to overcome illiteracy. 
Students can enrol in public higher institutes and universities after they have attained their 
high school certificate. Consequently, four-fifths of the UAE population is now literate with · 
the female literacy rate exceeding that of males. 
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1. 8 The UA E Healthcare System 
At the time of the country's formation, the UAE health infrastructure was limited to seven 
hospitals and 1 2  primary healthcare centres (PH Cs) throughout the country. 6 By 2000, The 
World Health Organisation (WHO) ranked the UAE healthcare system 2ih best out of 191 
countries, 7 and by 2006, government statistics showed that: 
• in the northern regions there were 13 hospitals and 61 PHCs;8 
• in Abu Dhabi, there were seven hospitals and 45 PHCs;9 and, 
• in Dubai, there were three hospitals and 18 PH Cs. 1 0  
In addition, there are three government dental clinic centres in Abu Dhabi and six in the 
northern emirates. This increase in healthcare provision has seen increasingly complex and 
diverse management of the healthcare sector, currently managed by a mix of federal and 
local government. 
1.8.1  Federal Healthcare System 
The Federal Ministry of Health (MoH) manages government-run hospitals and PHCs, 
including their private counterparts, in all emirates except Abu Dhabi and Dubai, which have 
their own local healthcare arrangements. 
1 .8.2 Local Healthcare Systems 
These arrangements apply to the emirates of Abu Dhabi and Dubai. Dubai established a 
Department of Health and Medical Services (DOHMS), now called the Dubai Health 
Authority (DHA). In Abu Dhabi the General Abu Dhabi Health Service (GAHS) was 
established in 2001; 1 1  this oversaw the running of all Abu Dhabi's hospitals and PH Cs, and 
additionally regulated the private pharmacy sector, which includes community pharmacies 
and medical stores. GAHS was replaced in 2007 by two organisations, the Health Authority 
of Abu Dhabi (HAAD) and Abu Dhabi Health Services Company (SEHA).9 
1.8.3 Private Healthcare System 
1.8.3.1 Dubai Healthcare City 
The Government of Dubai is developing Dubai Healthcare City (DHCC), with the goal of 
creating a regional centre of excellence for medical services, medical education, and life 
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science research and development in the Middle East. DHCC has links with internationally 
respected institutions in healthcare delivery, education, and research and development and 
is organised into four divisions: Dubai Healthcare City Free zone; Centre for Healthcare 
Planning and Quality; Harvard Medical School Dubai Centre and Dubai Harvard Foundation 
for Medical Research. 1 2  
DHCC has two complementary communities; the medical community and the wellness 
community. The medical community focuses on clinical services for disease treatment and 
prevention, whilst the wellness community encompasses hospitals, outpatient clinics and 
luxury spa resorts. 
1 .8.3.2 Health Insurance 
Up until May 2003, all residents regardless of nationality were entitled to free treatment and 
healthcare services. However, a supreme cabinet resolution declared that free healthcare 
services would stop due to financial considerations. Since then non-GCC nationals have had 
to pay a pre-determined sum for each service used. 
Currently, the MoH is studying the implementation of a health insurance system to cover 
healthcare costs for non-UAE and non-GCC nationals in both government and privately run 
healthcare sectors. 
In September 2005, it became law for employers and business owners in Abu Dhabi to 
provide compulsory health insurance cover for their expatriate employees and their families. 
Daman was the first specialised national health insurance company to be formed in the 
UAE.1 3 This venture represented a milestone in the history of healthcare for the Emirate of 
Abu Dhabi. 
The new (mid 2008) health insurance programme "thiqa" (or "trust") entitles UAE nationals to 
a comprehensive range of healthcare services at all public and private sector healthcare 
facilities in the thiqa Network. Enrolment in thiqa is free of charge and is for UAE nationals of 
all ages. Thiqa is managed by a health insurance company, Daman, and supported by the 
Health Authorities HAAD and SEHA.1 4  In 2008, HAAD and SEHA started to offer "Weqaya" 
( or "protection") health checks to protect UAE nationals who have risk factors for developing 
hypertension, diabetes and hypercholesterolaemia. UAE nationals over the age of 1 8  can 
complete their Weqaya health check at the same time as enrolment into thiqa. Free Weqaya 
health checks are offered every two years. The government of Abu Dhabi will pay the cost of 
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these health services if it is listed within the Daman scheme. Non-UAE nationals can 
approach public hospitals and clinics of SEHA in the Abu Dhabi Emirate through their 
Daman Health cards. Recently Daman and HAAD declared that they would pay half the cost 
of the dental healthcare services and medicines supplied by the private healthcare sector for 
UAE nationals. 1 5  
In 2008, the MoH established a new department for health insurance, responsible for 
regulating health insurance and implementing the health insurance systems throughout the 
country. Public healthcare providers such as SEHA and DHA have already implemented 
their own health insurance systems in their hospitals and PHCs. 16 A drafted federal law on 
health insurance has been submitted to the UAE Ministers' Cabinet for further discussion 
and approval. It is expected that the new health insurance law will be ratified by the end of 
2009. 
1.9 Comparison of the Healthcare Systems in the UA E and UK 
1.9. 1 Overview of the UK Healthcare System 
The UK National Health Service (NHS) was established by the then Health Minister Aneurin 
Bevan in 1948 to provide comprehensive care for everyone, based on a person's clinical 
need, not their ability to pay. This central tenet still holds true today.1 7  The NHS is split into 
various tiers of management responsibility known as Trusts, either in primary care, known as 
primary care trusts (PCTs) or in secondary care, known as hospital healthcare trusts (HCTs). 
These take responsibility for running the different NHS services in four local regions of the 
UK: Scotland, England, Wales and Northern I reland. 
1.9. 1 .1  Pr imary Care Trusts 
Primary care is the care provided to patients when they first have a health problem. These 
health needs are met by PCTs (and now as PCTs merge, strategic health authorities) and 
are responsible for managing health services in a specified local area in the UK.1 8  They work 
with local authorities and other agencies that provide health and social care to make sure the 
community's needs are being met. Healthcare may be delivered by a range of providers, 
including doctors, dentists, nurses, opticians and pharmacists. NHS Walk-in Centres, and 
the phone line service NHS Direct, are also part of primary care services. PCTs receive 75% 
of the total NHS budget and are responsible for all health services provided. 
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1.9.1.2 Hospital Healthcare Trusts 
If a health problem cannot be managed by primary care, or if an emergency exists, patient 
care is managed by HCTs. Patients are usually referred to the hospital by a doctor based in 
primary care, except in emergencies. 1 9  
1 .9.2 The UA E Healthcare System 
The UAE healthcare system has many similarities to the UK system, in that there is a 
network of primary care outlets (e.g. doctors, dentists and pharmacists) managing the day­
to-day welfare of patients, and secondary care services in hospitals that look after the more 
complex problems or acute medical emergencies. The range of staff and services offered is 
comparable to the UK; however the way in which a patient would access these services 
differs. In the UAE the patient is free to choose one of three treatment plans described 
below. 
1 .9.2 . 1  Treatment Plan A 
This plan is most similar to UK practice. A patient would visit a PHC to seek help, advice and 
treatment on illness and disease ranging from acute self-limiting conditions to the 
management of long-term chronic conditions. The general practitioners (GPs) in the PHC 
would diagnose the disease and prescribe essential medicines for the patient. However, 
unlike the UK, if the patient is not satisfied with the GP's treatment plan, he or she may 
follow treatment plan B or C independently of the GP's knowledge or recommendation. If the 
patient were a new patient or not registered with a secondary care healthcare institution, 
then they would require a referral from the GP at the PHC or a doctor from an accident and 
emergency department. 
1 .9.2.2. Treatment Plan B 
In Plan B, the patient would go directly to hospital without the doctor's knowledge whether 
for acute illness or serious/chronic disease. They will be seen by either doctors solely 
working at the hospital or by GPs who still spend time in secondary healthcare institutions. 
Here they would receive treatment regardless of the type of disease even though they may 
have a minor il lness. If the patient feels that the prescribed treatment was ineffective, they 
may return to the same hospital or they could choose to go to another government hospital, 
see a GP in a PHC or follow treatment plan C. 
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1.9.2.3. Treatment Plan C 
The patient would chose to see any doctor, either a GP or specialist, for minor illness or 
major disease in a private medical centre or hospital, without referral from any doctor from a 
government run primary or secondary healthcare institution. The patient would pay all costs 
for services provided to him or her in the private sector. unless it is covered by health 
insurance. 
There are no links or co-ordination between doctors who work for government and private 
institutions, in primary or secondary care. Thus there is no sharing of patient notes or any 
other patient information between government and private healthcare providers. 
1.9.3 The Lay Healthcare System in the UA E 
A variety of non-prescription products are available to patients through a number of retail 
routes. Pharmacies, as in the UK, provide patients with access to medication and advice. 
Pharmacies are regulated by the MoH and therefore provide certain standards of quality. 
This is not the case if patients chose non-pharmacy outlets to get their remedies and 
treatment. These routes are uncontrolled and non-regulated by the MoH .  Many of the 
practitioners and healers working from such outlets have inadequate education and 
experience to allow them to deal with healthcare problems, and their treatment. Traditional 
healers are found throughout the country; most of them are not licensed by MoH.  
Access to non-Western medicines and practitioners is common in the UAE and people visit 
traditional healers either at their homes or at special centres. Traditional healers will 
prescribe treatment and prepare the remedy for them. Although still widely used, this 
traditional way of obtaining medicines is becoming less common in the UAE. Alternatively, 
the public may visit special shops known as condimental shops, health food shops, 
alternative medicine and herbal centres, supermarkets and even gym clubs. Pharmacy 
establishments are considered by the MoH to be the only conventional route to purchase 
medicines. 
1.9.4 Regulation of Pharmacies in the UAE 
Pharmacies are regulated and licensed according to the UAE Federal Law No. 4 (1983) for 
the pharmaceutical profession, which states that: 
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• no person is permitted to practice the pharmaceutical profession without obtaining a 
licence according to the provisions of UAE Pharmacy law. (Articles 1 ,  2); and, 
• no person is permitted to open a pharmacy before obtaining a licence from the 
ministerial pharmaceutical licence committee according to the provisions of pharmacy 
law (Article 18).20 
These laws do not stipulate that medicines can only be found, sold and supplied to the public 
through pharmacies. 
1 .9.4.1 Community Pharmacies in the UAE 
There are approximately 1,300 community pharmacies in the UAE. (Drug Registration and 
Control Department - Ministry of Health statistics for October 2008). Their distribution is 
shown in Table 1.2. 
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UAE Region No. of % of No. of % of No . of % of Pharmacy 
pharmacies Pharmacies Pharmacists Pharmacists Pharmacy Technicians 
Technicians 
Abu Dhabi 433 32.8 748 29.7 326 27.7 
Dubai 421 3 1 .9 931 36 .9 473 40.2 
Sharjah 274 20.8 489 1 9 .4 240 20.4 
Ajman 84 6.4 1 46 5 .8 64 5.4 
Um AI Qiween 1 4  1 . 1 26 1 .0 1 0  0.9 
Fujairah 29 2.2 45 1 .8 24 2.0 
Ras Al Khaimah 65 4.9 1 35 5.4 39 3.3 
Total 1320 100 2520 100 1176 100 
Table 1 .2: Numbers and Distribution of Community Pharmacies in the UAE 
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1.9.4.2 Role of Community Pharmacies in UAE 
The UAE Federal Law No. 4 (1983) for the pharmaceutical profession and institutions does 
not clearly specify the roles and responsibilities of the pharmacist; however it does state that 
the pharmacist should carry out his or her duties in conformity with regulations and 
guidelines of the pharmacy profession as per article 16: 
• the pharmacist shall not conduct any practices against the honour of the 
profession; 
• the pharmacist shall keep confidential the disease, which he may come to know 
through the medical prescription presented to him or through any means related 
to his or her practicing work; and, 
• the pharmacist shall abide by the laws and regulations of the profession. 
The Drug Registration and Control Department (DRCD) of the UAE MoH has issued 
minimum good pharmacy practice guidelines for the pharmacy profession in 2003, which 
highlighted the basic rules for dispensing prescriptions and controlled medicines.21 
The minimum service standards of pharmacy in UAE are concerned mainly with dispensing 
medicines and selling pharmaceutical products to the public. Currently, there is a limited role 
for pharmacists in advising the public on medicines compared to pharmacists in the UK. This 
is primarily due to a lack in interest and knowledge among pharmacists practicing in the 
UAE.22 In addition, commercial pressures on community pharmacists and a lack of 
enforcement of the regulations governing pharmacy practice contribute to the problem. 
1 .9.5 Non-Pharmacy Outlets 
These shops sell pharmaceutical products or products which may have pharmacological 
actions s imilar to conventional pharmaceutical products. Some of these non-pharmacy 
outlets are regulated by local government departments (municipalities) of each emirate that 
are mainly responsible for regulating food and health products.23 
1 .9.5.1  Condimental Shops 
These are shops licensed and regulated by the municipality of each emirate except Abu 
Dhabi where they are regulated by the Abu Dhabi Food Control Authority. Condimental 
shops are shops that sell foodstuffs, cereals and condiments, e.g. spices, flavours and 
edible herbs. These shops are very common in the UAE and represent the culture of the 
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traditional community. Sellers, with no formal training, will recommend and sell products to 
treat a wide range of medical conditions. According to UAE economic data there are 
approximately 2000 condimental shops in the UAE. 
1.9.5.2 Herba l Centres 
Herbal centres are licensed and regulated by the MoH as a medical clinic for traditional 
complementary and alternative medicines (CAM). Healers, working in such centres, should 
be licensed by the MoH for specific CAM therapy e.g. Ayurvedic, Unani, Sida or Chinese 
herbal medicines. All medicines used by those practitioners on their patients should be 
registered and licensed by the MoH. No medicines can be sold in these centres but healers 
or CAM practitioners can issue prescriptions for herbal medicines for patients, which must be 
supplied through pharmacies. 
1.9.5.3 Alternat ive Therapy Centres 
Similarly to herbal centres, these centres are regulated by the MoH and the healers and 
practitioners are licensed by the MoH. They mainly offer types of CAM therapy other than 
herbal medicines e.g. homoeopathy and reflexology. In this context, a healer is licensed by 
the MoH to practice traditional medicine, but practitioners are licensed to practice according 
to specific alternative/complementary systems of treatment. 
1.9.5.4 Health Food Shops 
Health food shops are licensed and regulated by the municipalities within each emirate. 
They are allowed to sell some products registered by the MoH, which are mainly dietary and 
herbal supplements e.g. vitamins, minerals, amino acids and herbal teas. Medicated 
cosmetics and herbal medicines that are registered by the MoH as over the counter products 
can be sold in such shops after obtaining the necessary approval. Sellers in these shops are 
not licensed in any way. The majority, are unqualified sellers or traders without any 
background in nutrition. 
Many health food shops sell unlicensed herbal medicines. Herbal medicines are classified in 
UAE as medicinal products and treated as other conventional medicines, hence they are 
evaluated according to their risk level. High risk herbal products have the same status as 
prescription only medicines, moderate risk as pharmacy medicines and low risk as general 
sale products. 
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1 .9.5.5 Supermarkets 
These are licensed by municipalities and are allowed to sell food and home products to the 
public. No medicines should be offered for sale unless the MoH has given authorisation 
(Law No. (4) For 1983 of Pharmacy & Pharmaceutical Institutions). In practice, supermarkets 
openly ignore this requirement and sell a range of unlicensed herbal and general sale 
products which are imported via municipalities. 
1 .9.5.6 Gyms and Spa Clubs 
These are regulated and licensed by the respective municipalities and no medicinal products 
are permitted to be sold; although anecdotally, this appears to be frequently ignored. Muscle 
pain balms for massage, and aromatherapy products can be used inside such clubs but 
cannot be sold. Practitioners, operating from these premises are not regulated by the MoH 
but this is currently under review. 
1 .1 0  Medicines Leg islation in the UAE 
The DRCD is the main government agency responsible for enforcing the regulations of 
medicines in UAE; it is supported by a number of committees that play an important role in 
the regulation of different classes of medicines. The main legislation governing medicines in 
the UAE is the Federal Pharmacy Law no 4 (1983), which established a national system of 
control for medicines. 
In addition, a number of ministerial Decrees also regulate the registration and pricing of 
products, 24·25 the dispensing of controlled medicines and the licensing requirements for 
pharmaceutical establishments. 26·27 
1 .1 0.1 Definition of Conventional Medicines 
Within UAE law a conventional medicine is technically defined as a drug used in or in 
connection with: 
1. preventing, diagnosing, curing or alleviating a disease, ailment, defect or injury; or 
2. influencing, inhibiting or modifying a physiological process; or 
3. testing the susceptibility of persons to a disease or ailment; or 
4. influencing, controlling or preventing conception; or 
5. testing for pregnancy; or 
6. the replacement or modification of parts of the anatomy. 
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Medicinal products in the UAE generally belong to one of six dispensing categories:26 
1. General Sale List for Supermarket (GSLS) 
2. Pharmacy Medicines (P) 
3. Prescription Only Medicines (POM) 
4. Controlled Drugs - Control Drug Class B (CD- B) 
5. Controlled Drugs - Control Drug Class A (CD- A) 
6. Controlled Drugs - Narcotics 
GSLS - these contain substances in pack sizes that do not require a prescription e.g. cold 
and mild fever medicines containing drugs such as paracetamol. This group also contains 
products such as toothpaste, shampoo and antiseptics. GSLS items are freely sold in 
pharmacies and some large supermarkets. 27 
Pharmacy Medicines (P) these are preparations sold or supplied by a pharmacist for 
therapeutic use, which are substantially safe in use but where advice or counselling is 
available if necessary. Products that can be prescribed by pharmacists include antacids, 
vitamins, mild analgesics, some cold preparations and eye wash lotions. 
Prescript ion only medicines (POMs) - must only be sold/supplied with a medical 
prescription and include such products as injectable preparations, antibiotics, and anti­
inflammatories. However, it is common practice within the UAE for pharmacists and their 
staff to breach this law and sell such products over-the-counter. 
CD-B medicines - these include anti-depressants, anti-convulsants, some sleep inducers, 
anti-psychotics and other non-habit inducing medicines. They are sold only with a "Special 
Control" white medical prescription, which is valid for 30 days. 
CD-A medicines - these medicines are sold only with a 'CD-A' medical prescription, which 
is valid for 30 days. Benzodiazepines, some appetite suppressants and other habit-inducing 
controlled medicines are examples of CD A medicines. 
Narcotics Medicines - These are International Narcotic Control Bureau (INCB) controlled 
medicines and are most tightly controlled. Sale/supply is only through hospitals and 
prescriptions must be written on a Narcotic Medical Prescription Form. The prescription is 
valid for 28 days and must be issued by a consultant physician. Amphetamines and other 1 8  
stimulants (such as methylphenidate), opioids (such as morphine and oxycodone) and other 
strong habit-forming controlled medicines are designated as narcotic medicines. 
1.10.1. 1  Licensing, Inspection and Enforcement of Medicine Supply 
The DRCD regulates a wide range of materials from medicines and medical devices to blood 
and therapeutic products/services; one of the main activities of the DRCD is licensing and 
enforcement. The objectives being to ensure that the import, manufacture, sale, supply, 
management, and use of pharmaceuticals, cosmetics and healthcare products comply with 
UAE standards. The DRCD ensures this by: 
• enforcing legislation through various UAE laws; 
• following international convention, e.g. implementing INCB provisions on 
psychotropic substances; 
• licensing regulations to ensure the import, storage, sale and supply are carried out by 
qualified or fit persons; 
• controlling narcotics, pyschotropics and precursor chemicals for legitimate use; 
• controlling medicine advertising ; 
• inspection at entry points to ensure drugs, cosmetics and chemicals are imported by 
legitimate importers; and, 
• inspection of premises of license holders and professionals, including pharmacists to 
ensure compliance with the law and regulations. 
The DRCD is also responsible for ensuring the quality of medicines and pharmaceutical 
products. Samples are sent for testing in quality control laboratories via registration, 
surveillance or enforcement activities. 
1.10.2 Definit ion of General Sale Products (GSPs) 
GSPs are pharmaceutical preparations containing non-prescription ingredients but which 
have health or medical claims. These are described below: 
1. Dietary supplements and health foods 
In the UAE a dietary supplement is defined as any product containing a dietary ingredient 
manufactured in a pharmaceutical dosage form, including natural ingredients, or composed 
from partially synthesised elements, or both, with exact doses of vitamins and/or mineral 
1 9  
salts, proteins, carbohydrates or fats intended for human use. Dietary supplements include 
the following: 
• dietary ingredients allocated for some conditions connected with malnourishment, 
such as diets for diabetes patients; high or low calorie containing diets or diets 
containing low quantities of sodium, gluten, or lactose content diets; 
• special dietary ingredients specifically used for certain disease states, such as: 
hypertension , hypercholesterolaemia and hyperallergic conditions due to certain 
foods; herbal teas and artificial sweeteners used as sucrose alternatives; and, 
• dietary ingredients used at periods characterised by physiological changes, such as 
reinforced and special diets for suckling babies and weaning children; elderly and 
geriatric diets; royal jelly products; milk formulas having health or medical claims in 
certain diseases; and diets for athletes. 
2. Medicated Cosmetics 
Medicated cosmetics are defined as topical preparations intended to treat and/or prevent 
diseases, or otherwise affect the structure or functions of the human body. 
3. Antiseptics 
Antiseptic preparations are defined as preparations for external use intended for local 
application on the human body to eradicate microbial contamination. 
4. Other pharmaceutical products 
These include natural extracts, anti-lice products, herbal lozenges and volatile oils e.g. 
menthol, camphor, and eucalyptus oil preparations for topical use. 
1 . 1 0.2. 1  Registration Rules for GSPs 
A number of rules control GSPs. For example, it is prohibited to sell products either 
manufactured locally or imported, before registration by the MoH. The registration of the 
product can be cancelled if: 
• it is proved that the submitted registration documents are forged; 
• the manufacturer is listed among boycotted companies; 
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• the manufacturer repeats violations or fails to adhere to good manufacturing 
practice; 
• the product proves to be toxic or having serious side effects; 
• the manufacturing, registration, or marketing of the product is terminated or 
suspended in the country of origin. 
1 . 1 1 The Place of CAM in the UAE Healthcare System 
Widespread systems of traditional medicine and CAM are practised within the UAE; these 
have been classified by the WHO as follows:28 
1 . 1 1. 1  Ayurveda 
Ayurveda originated in the 10th century BC, but its current form took shape between the 5th 
century BC and the 5th century AD. In Sanskrit, ayurveda means "science of life". Ayurvedic 
philosophy is attached to sacred texts, the Vedas, and based on the theory of 
Panchmahabhutas "all objects and living bodies are composed of the five basic elements: 
earth, water, fire, air, and sky". Similarly, there is a fundamental harmony between the 
environment and individuals, which is perceived as a macrocosm and microcosm 
relationship. As such, acting on one influences the other. Ayurveda is not only a system of 
medicine, but also a way of living. It is used to both prevent and cure diseases. Ayurvedic 
medicine includes herbal medicines and medicinal baths. It is widely practised in South Asia, 
especially in Bangladesh, India, Nepal, Pakistan, and Sri Lanka. 
1 . 1 1 .2 Traditional Chinese Medicine (TCM) 
The earliest records of traditional Chinese medicine date back to the 8th century BC. 
Diagnosis and treatment are based on a holistic view of the patient and the patient's 
symptoms, expressed in terms of the balance of yin and yang. Yin represents the earth, 
cold , and femininity. Yang represents the sky, heat, and masculinity. Traditional Chinese 
medicine encompasses a range of practices, including acupuncture, herbal medicines, 
manual therapies, exercises, breathing techniques and diets. Surgery is rarely used. 
Chinese medicine, particularly acupuncture, is the most widely used traditional medicine. 2 1  
1 .11.3 Chiropractic 
Chiropractic was founded at the end of the 19th century in Iowa, USA. Chiropractic is based 
on an association between the spine and the nervous system and on the self-healing 
properties of the human body. 
1 .11.4 Homoeopathy 
Homoeopathy was first mentioned by Hippocrates (462-377 BC), but it was a German 
physician, Hahnemann (1755-1843), who established its basic principles: law of similarity, 
direction of cure, principle of single remedy, the theory of minimum diluted dose, and the 
theory of chronic disease. In homoeopathy, diseases are treated with remedies that in a 
healthy person would produce symptoms similar to those of the disease. Rather than fighting 
the disease directly, medicines are intended to stimulate the body to fight the disease. 
1 .11 .5  Unani 
Unani is based on Hippocrates' (462-377 BC) theory of the four bodily humours: blood, 
phlegm, yellow bile, and black bile. Galen (131-210 AD), Rhazes (850-925 AD), and 
Avicenna (980-1037 AD) heavily influenced unani's foundation and formed its structure. 
Unani draws from the traditional systems of medicine of China, Egypt, India, Iraq, Persia, 
and the Syrian Arab Republic. 
1 .11 .6 Herbal Medicine 
Herbal medicine can be broadly classified into four basic systems: traditional Chinese 
herbalism, Ayurvedic herbalism, Western herbalism (which originally came from Greece and 
Rome to Europe and then spread to North and South America) and Arab traditional 
medicine, which forms the basis for alternative and herbal medicine in use today.29 
Herbal medicines, according to the WHO, are preparations or finished herbal products that 
contain as active ingredients, parts of plants, or other plant materials, or combinations. 
Terminology associated with herbal medicines includes: 
Herbs: crude plant material such as leaves, flowers, fruit, seed, stems, wood, bark, roots, 
rhizomes or other plant parts, which may be entire, fragmented or powdered. 
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Herbal materials: these are found in the following forms; fresh juices, gums, fixed oils, 
essential oils, resins and dry powders of herbs. In some countries, these materials may be 
processed by various local procedures, such as steaming, roasting, or stir-baking with 
honey, alcoholic beverages or other materials. 
Herbal preparations: are the bases for finished herbal products and may include 
comminuted or powdered herbal materials, extracts, tinctures and fatty oils of herbal 
materials. They are produced by extraction, fractionation, purification, concentration, or other 
physical or biological processes. They also include preparations made by steeping or 
heating herbal materials in alcoholic beverages and/or honey, or in other materials. 
Fin ished herba l products: are herbal preparations made from one or more herbs. If more 
than one herb is used, the term herbal product mixture can also be used. Finished herbal 
products and herbal product mixtures may contain excipients in addition to the active 
ingredients. However, finished products or mixed products to which chemically defined 
active substances have been added, including synthetic compounds and/or isolated 
constituents from herbal materials, are not considered to be herbal. 
Traditional use of herbal medicines : refers to the long historical use of these medicines. 
Their use is well established and widely acknowledged to be safe and effective, and may be 
accepted by national authorities. 
Active ingredients of herbal medicines: refer to ingredients of herbal medicines with 
therapeutic activity. In herbal medicines where the active ingredients have been identified, 
the preparation of these medicines should be standardised to contain a defined amount of 
the active ingredients, if adequate analytical methods are available. In cases where it is not 
possible to identify the active ingredients, the whole herbal medicine may be considered as 
one active ingredient. 
1. 1 2  The Uptake and Use of Herbal Medicines 
The use of herbs for medical benefit has played an important role in nearly every culture on 
earth. Herbal medicine has been practiced by ancient cultures in Asia, Africa, Europe and 
the Americas. 
Herbal medicines are widely used in the prevention, diagnosis, and treatment of diseases. 
According to a WHO report, one-third of the world's population and over half of the 
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populations of the poorest parts of Asia and Africa do not have regular access to essential 
(conventional) medicines,30 and it is reported that more than 60% of the world's population 
use herbal medicines.31 I n  rural areas, cultural beliefs and practices often lead to self-care, 
home remedies or consultation with traditional healers. 
Herbal medicines constitute a major part of some cultures healthcare; for example China, 
where TCM still accounts for around 40% of all healthcare delivered. I n  I ndia, 65% of the 
population in rural areas use Ayurveda and medicinal plants and in some African countries, 
e.g. Ghana, Mali, Nigeria and Zambia, herbal medicines have been shown to be first-line 
treatment for children with high fever.32 
Herbal medicine has also been used in the treatment and care of such life-threatening 
illnesses as malaria and HIV/AIDS. Studies in Africa and North America have shown that up 
to 75% of people living with H IV/AIDS use traditional medicine alone or in combination with 
other medicines for various symptoms or conditions. 33 Over the last 20 years, herbal 
medicine has become increasingly used;34 for example herbal usage in United States (US) 
has increased by 380% between 1990 and 1997,35 and in 2002 roughly two-thirds of US 
adults were reported as using herbal medicines.36 
Prevalence data according to the WHO also suggest widespread use in other Western 
countries. Studies have reported use on at least one occasion, prevalence rates of 48% i n  
Australia, 31 % i n  Belgium, 70% i n  Canada, and 49% i n  France.33 Furthermore a U S  national 
health survey in 2002 involving 30,617 adults showed that 5,787 (19%) took herbal 
medicines in the previous 12 months, and of those, 3,315 (57%) used herbal medicines to 
treat a specific health condition. 36 
Other data from the US has shown that 46% of adolescents had used dietary supplements 
and herbal medicines in their lifetime, with almost 29% using such a therapy in the previous 
month and 9% reported concurrent use of supplements and conventional prescription 
medication.37 
In Australia, Foster et al 38 found that the use of herbal supplements in pregnant women was 
relatively high; 36% (n=588) took at least one herbal supplement, the most common being 
raspberry leaf (14%), ginger (12%) and chamomile (11 %). 
The increased use by Western society of herbal medicine has made them an important 
economic commodity. Within  the European Community, herbal medicines represent annual 
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sales of US$7 billion and in the US, the sale of herbal products has risen from $200 million in 
1 988 to $3 .3 billion in 1997. Such widespread use throughout the world has raised serious 
questions concerning the quality, safety and efficacy of these products.30 
The recent rise in popularity of herbal medicines in Western culture has been attributed to 
the belief that herbal medicine can provide some benefit over and above conventional 
Western medicine.39 Consequently, there have been numerous studies looking at specific 
d isease states and people's use of herbal medicines. As this thesis concerns mainly the 
safety of use of such products in a UAE context, this aspect is not considered further here. 
1.12.1 Middle Eastern Perspective 
The historical importance of Arab medicine has been wel l  documented in the l iterature. 
Historical and current studies indicate that the Eastern region of the Mediterranean and the 
near east has been endowed throughout the generations with a rich inventory of medicinal 
herbs. Indigenous Arab medicine has contributed greatly to the development of modern 
medicine in Europe and remains one of the closest forms of original European medicine. 
Several surveys and studies reveal that 200-250 herbs are used in treating human 
d isease.40 
There are a number of papers from various countries showing the strong use of herbal 
medicines by people from this region. In Pakistan, substantial use of folk remedies for 
different medical conditions has been documented.41 Herbs commonly used included 
cinnamon, ginger, cloves, cardamom, sesame oil , poppy seeds and honey and lemon that 
are used to treat minor medical conditions such as the common cold, cough and flu through 
to more serious conditions such as asthma, jaundice and heat stroke. 
In Jordan, Afifi et al 42 interviewed over 1 00 inhabitants from seven villages in 2006. Results 
showed over 20 plant species were used to treat at least 1 8  different ailments. Five herbs 
were used by more than 50% of the interviewees; these were golden chamomile, 
wormwood, thyme, Syrian marjoram and sage. Interestingly, the results showed that over 
half the inhabitants practiced folk medicine without referring to anyone with relevant 
qualifications, and half (57%) grew or collected the medicinal plants themselves. 
In Egypt, El Mahalli et al 43 conducted a 2004 survey with 337 households comprising of 
1 480 people. Twenty-five percent of people used complementary medicine, of which herbal 
medicine was the most popular. A further study in 2003 by Abdel Hady et al 44 looked at 25 
patient knowledge, attitude and use of traditional remedies. This showed that 36% of 
respondents had used complementary medicine. Again, herbal remedies were used most 
frequently. It was also found that three-quarters of the respondents did not consult any 
conventional health care professionals before using these remedies. 
In  Iran, knowledge, attitudes, and practice of complementary medicine were investigated by 
Sadighi and Ziai amongst 4,123 people.31 Results showed that 76% of respondents had 
some knowledge of herbal therapy and over half had used herbal medicine at least once. 
Commonly, herbal medicines were used to help relieve problems associated with gastro­
intestinal, respiratory and nervous system diseases and most reported treatment to be very 
effective. Married women and the elderly were the most frequent users and the majority did 
not refer to physicians before using treatment. 
A further I ranian study 45 was conducted to estimate the prevalence of herbal medicine use 
amongst 447 pregnant women. Overwhelmingly (92%), respondents had positive attitudes 
toward the use of herbal medicines during pregnancy and over half (52%) reported using 
them during pregnancy. The most commonly reported uses were for common cold (29%), 
abdominal pain ( 1 7%) and induction of labour ( 1 2% ). Of those who had used herbal 
medicines 56% had not reported use to their doctor. Common reasons for non-disclosure 
were the belief that herbal medicines were natural and safe (39%) and that doctors never 
asked about them (35%). Family and relatives were the main source of information on the 
herbs they used. 
A Turkish survey in 2004 46 determined that 76% of 19,022 respondents had used herbal 
medication at least once. Herbal medicines were used to treat a wide range of problems 
including hair loss, haemorrhoids, skin problems, peptic ulcer, gastritis and infertility. 
Products most commonly used were nettle, St. John's wort, rosemary, sage and hawthorn. 
In addition, ginger was observed to be frequently used in Ayurvedic therapy in a Turkish 
population.47 
Traditional and folk medicine continue to be used in many developing countries, including 
the Kingdom of Saudi Arabia.4849 Studies in the Arabian Gulf countries also show high use of 
herbal medicines. A 2003 survey (published in 2008)50 conducted amongst 1,408 Saudi 
Arabian residents showed that 68% of the respondents had used alternative medicines; the 
Holy Quran as a therapy (e.g. prayer) was the most frequently used (50%), however herbal 
medicines were also commonly used, for example, black seed (39%) and myrrh (35%). A 
further study51 that interviewed 300 diabetic patients in four hospitals in Riyadh in 1999 
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reported that 51 people (17%) used some form of herbal medicine. The commonest herbs 
used were myrrh, black seed, helteet, fenugreek and aloe. Almost three-quarters (73%) of 
herb users did not inform their doctor. 
Al Saeedi et al 49 also interviewed 1,039 diabetic patients about their beliefs in traditional 
herbal remedies. Findings showed that one-third of patients were using traditional remedies, 
1 6% believed they were safe and effective and 26% thought they were beneficial. Similarly, 
a 2004 Bahrain study by Nasser et al 52 was conducted on 300 people with diabetes. Data 
showed that 44% of patients had or were using herbal medicines over the previous year; 
more than 30% did not know the names of the herbs they were using and over 60% obtained 
their herbs from friends or relatives. 
Studies from other Arab nations e.g. Tunisia and Morocco, have shown that herbal medicine 
use is popular.53-55 For example, a study by Eddouks et al 55 for example, sought opinion 
from 700 people, including diabetic patients, patients with hypertension and cardiac 
disorders and traditional herbal healers from different areas of Eastern Morocco. The results 
indicated that 80% of people interviewed used medicinal plants to treat their conditions as 
they believed that herbal medicines were cheaper (58%), more efficient (40%) and better 
(65%) than modern medicine. 
1 .13 Herbal Medicine Safety 
Herbal remedies often contain highly active pharmacological compounds and are therapeutic 
at one dose and toxic at another. With increasing use it is important for public safety that 
herbal medicines are scrutinised as carefully as conventional medicines. The perception that 
herbal remedies are natural and therefore safe is widespread among users.56 However, 
toxicity related to herbal medicines is becoming more widely recognised as these remedies 
become more popular and examples of serious iatrogenic disease involving herbs have 
been reported.57·58 Most reports of adverse effects are associated with hepatotoxicity 
although reports of toxic effects in other systems including kidney, nervous system, blood, 
cardiovascular, skin, and mutagenicity and carcinogenicity have also been published. 59·60 
Recent concern over reports of serious hepatotoxicity attributed to the herb kava kava in 
several European countries is a case in point;61 this led the German authorities to legislate 
for the move of products containing the herb from general sale to prescription only status. 
Further examples include recurrent health warnings on the use of St John's wart with certain 
allopathic medicines due to serious drug interactions 62·63 and the withdrawal of aristolochia 
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preparations due to serious renal effects, including cancer.64 Serious psychiatric and 
neurological adverse effects with fatalities have also been recorded.65 
Adverse reactions may be caused by improper use, toxicity of the herbal ingredients 
themselves, and herb/conventional drug interactions but also due to ingredients introduced 
as contaminants or deliberate adulteration. Such occurrences raise serious quality control as 
well as safety issues.65 
1.13 .1  Adulteration of Herbal Products 
Heavy metal contamination, adulteration with Western pharmaceuticals and inclusion of 
prohibited animal and plant ingredients are regularly reported in herbal medicines.65-67 
This can affect the efficacy and/or safety of the herbal products being used. Current product 
quality ranges from very high to very low due to intrinsic, extrinsic, and regulatory factors. 
Intrinsically, species differences, organ specificity and diurnal and seasonal variations can 
affect the qualitative and quantitative accumulation of active chemical constituents in the 
source medicinal plants. Extrinsically, environmental factors such as field collection 
methods; cultivation, harvest, post-harvest transport and storage; manufacturing practices; 
inadvertent contamination and substitution; and intentional adulteration are contributing 
factors to the quality of herbal medicinal products. Source plant materials that are 
contaminated with microbes, microbial toxins, environmental pollutants, heavy metals or 
finished products that are adulterated with foreign toxic plants or synthetic pharmaceutical 
agents can lead to adverse events. Substandard source materials or finished products will 
yield therapeutically less effective agents. 
Herbal medicine quality can also be attributed to regulatory practices. In a number of 
countries, herbal medicines are unregulated, which has led to product quality differences. 
Product quality improvement may be achieved by implementing control measures from the 
point of medicinal plant procurement under good agricultural practices (GAPs) and the 
manufacture of the finished botanical products under good manufacturing practices (GMPs), 
plus post-marketing quality assurance surveillance.68 
Adulterations with conventional or synthetic drugs are common problems with herbal 
medicine, and many serious adverse events reported relate to problems of contamination or 
adulteration.69·7° For example, contamination or adulteration of Chinese star anise ( l l licium 
verum Hook), with Japanese star anise (lllicium religiosum) resulted in the poisoning of one 
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child. 71 Japanese star anise is a neurotoxic plant as it contains sesquiterpenic lactones 
which led to the poisoning. I t  has also been reported that adulteration of Chinese herbal 
medicines with inferior species is on the increase.72 
Ensuring the quality of expensive products such as ginseng is important as adulteration with 
cheaper substances is tempting and traditional means of authentication via smell, taste or 
physical appearance are unreliable. 73 It is therefore important to determine the presence of 
contamination in herbal medicines to ensure patient safety.74 
Within the UAE, the MoH has a duty to ensure medicines are not adulterated and Table 1.3 
highlights those herbal medicines that have been found to contain substances that should 
not be present. The data show a wide range of products, often unlabelled, from a wide 
variety of sources and containing a variety of potent prescription medicines (e.g. sildenafil 
and hypoglycaemic agents) or poisons (e.g. mercury). 
Because of the widespread use of herbal medicines, the MoH has warned consumers about 
the potential health risks involved in using unregistered medicines. This came after the 
finding from one MoH study that 37 unregistered herbal medicines were being sold through 
pharmacies, where supply is supposed to be controlled.75 
Also, the Health Authority of Abu Dhabi (HAAD) has cautioned the public not to use an 
unbranded natural product promoted for use in diabetes as it could pose health risks. 76 
Further to this, medical officials in the emirate of Ras Al Khaimah issued a warning against 
the use of herbal medicines to treat diabetes in children. This follows instances of certain 
shops in the emirate claiming that these medications were the only effective remedy. 77 29 
- -- -· 
Product Name Origin if known Adulterated substances Product Name Origin if known Adulterated substances 
Unknown samples A&B - glibenclamide Furunbao China tadalafil 
Sandhivat tablets - phenylbutazone, Titanic K-2 India sildenafil 
salicylamide 
Satibo capsules China sildenafil in capsule-shell Tongkat Ali Power Plus Malaysia sildenafil 
Unknown capsules - sildenafil Golden Bull capsules Swiss sildenafil 
WellLong capsules China tadalafi l ,  caffeine Unknown powder - si ldenafil 
Unknown tablets - glibenclamide , iron Unknown tablets - glibenclamide, metformin 
YongGang tablets China tadalafil Unknown capsules (2 - caffeine 
cases) 
King's capsules China tadalafil Unknown tablets (3 cases) - chromium picolinate 
Unknown capsules - sildenafil Unknown capsules and - chromium picolinate, 
tablets + Reductil capsules caffeine 
Unknown tablets - glibenclamide Royal Herbs capsules China tadalafil 
An Fu tablets China tadalafil Unknown tablets and - Tablets : chromium & 
capsules capsules: herbs 
Titanic-K-2 capsules India sildenafil Dragon 1 (unknown) China tadalafil 
Satibo capsules China sildenafil Dia tech 2000 capsules Canada metformin 
Trex China sildenafil Amira Magic cream KSA mercury (Hg) positive 
Dongfang chaoneng China tadalafil Rose Cream For Spots & Lebanon Hg positive 
tablets acne 
Royal Honey Malaysia tadalafil Unknown cream - Hg positive 
Ginseng Kianpi pil China cyproheptadine, Argussy Whitening Cream Thailand Hg positive 
dexamethasone 
Phyto-Andro capsules Canada sildenafil Diana cream Lebanon Hg positive 
Table 1 .3: Identification of adulterated herbal products and GSPs by Quality Control Laboratories in UAE Ministry of Health (2001 -2008). 30 I I I I I I I I I - - .. I I I I I I I I I I I I I I 
Product Name Origin if known Adulterated substances Product Name Origin if known Adulterated substances 
Stillmans cream USA Hg positive Unknown tablets. - glibenclamide 
(glibenclamide) 
YOKO Herbal cream Thailand Hg positive Ideal cream-30ml Jar Lebanon Hg positive 
YOKO Herbal Fruty cream Thailand Hg positive Unknown Pills (black) - metformin, glibenclamide 
YOKO Whitening cream Thailand Hg positive Unknown pills - metformin,  glibenclamide,  
iron 
Zang bion bio capsules - sildenafil Unknown black pil ls - metformin & iron, 
Ginseng Kianpi Pil China dexamethasone, Hair strengthener spray (2 Lebanon minoxidil 
capsules cyproheptadine cases) 
Unknown (Herbal) powder - Counterfeit with anti Tonic Liquid Lebanon minoxidil 
rheumatic product 
Unknown (Herbal) powder - metformin, iron Satibo capsule - sildenafil (Viagra) or 
sildenafil derivatives 
Unknown (Nairuz) cream - mercury, hydroquinone Yonggang capsule - tadalafil (Cialis) 
Ideal cream Lebanon Hg positive Ginseng Kianpi pill - Cyproheptadine, 
,dexamethasone 
Ideal FAIR cream Lebanon Hg positive Phytoshape - sibutramine (Reductil) 
Phytoshape capsules (2 Malaysia sibutramine Golden Bull - sildenafil (Viagra) 
cases) 
Abeer beauty salon Hanna UAE Hg positive Tongkat Ali capsule - sildenafil (Viagra) or 
cream sildenafil derivatives 
Unknown tablets. - gl ibenclamide Power capsule - sildenafil (Viagra) or 
(glibenclamide) sildenafil derivatives 
Phyto shape capsules (4 Malaysia sibutramine Herbal pills - I ron, metformin, 
cases) gl ibenclamide 
Abeer beauty salon Hanna UAE Hg positive Zein Herbal Tonic liquid Lebanon minoxidil (Regain) 
cream 
Table 1 .3 continued: Identification of adulterated herbal products and GSPs by Quality Control Laboratories i n  UAE M inistry of Health (2001 -2008). 
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1.14 Herbal Medicine Use in the UAE 
Like other Arab countries, the UAE has a long history of using herbal medicine. The MoH 
has a duty to regulate and control their use and therefore has created its own set of 
definitions surrounding herbal medicines along WHO lines. 25 
A herbal medicine is defined as a finished, labelled medicinal product that contains as 
active ingredients, aerial or underground parts of plants, or other plant materials or 
combinations thereof, whether in the crude state or as plant preparations intended for 
prophylactic or therapeutic or other human health benefits. 
A traditional herbal medicine (THM) is defined as a finished medicinal product intended for 
self-medication that contains, as the active principle(s), herbal ingredients that have received 
relatively little attention in the world scientific literature, but for which traditional or folkloric 
use is well-documented. 
A medic inal p lant is defined as a plant, either cultivated or growing wild, used for its 
medicinal value. 
The term plant orig in excludes all synthetic and semi-synthetic active ingredients. Such 
products should be evaluated and registered in accordance with the current legislation on 
pharmaceuticals. 
Plant materials are either the whole plants or parts of medicinal plants in the crude state. 
Plant preparations are defined as herbal ingredients present in a form other than the crude 
medicinal plant material, including powdered plant material, balsams, dried and fluid 
extracts, tinctures, essential, oils, fatty oils, gums and resins and expressed juices, prepared 
from plant material, and plant preparations obtained by fractionation ,  purification or 
concentration, without chemically defined isolated constituents and regardless of whether or 
not its therapeutical ly active constituents have been identified. 
Medicinal (active) ingredients are those herbs or their constituents that are responsible for 
the therapeutic action of the product. All medicinal ingredients should contribute to the 
intended effect(s) indicated on the product label. The actions of similarly acting herbs (e.g. 
sedatives) are considered additive in nature, and some herbs, although present in small 
1 ') .,_ 
amounts, will be considered medicinal ingredients if, according to the supporting references, 
they contribute to the overall effect of the THM product. 
The MoH has advised that combinations of medicinal herbs should be rational such that 
different herbs do not exert different effects that form an i l logical or contradictory 
combination. 
1. 14. 1 Herbal Medicine Regulation in the UAE 
Registration of herbal medicines is only granted to topical, oral or rectal formulations. 78 
Three main principles guide herbal product regulation: 
• s ingle ingredient herbal products are preferable and more acceptable for registration in 
the UAE; 
• labels for herbal medicines should enable the consumer to judge the purpose of a 
product and use it wisely; and, 
• the presentation of the herbal medicines should not encourage false belief that they are 
foods or that, because of their herbal source, they are innocuous or in any way better 
than allopathic medicines. 
For a company to gain registration of its herbal product, the applicant must submit two files. 
The first details the quality control laboratory features, such as the manufacturing method, 
composition and quality control of the finished product, stability studies and the quality of raw 
materials. The second file includes information about the mode of action of the product, 
indications, toxicity and expected side-effects and interactions. 
1. 14.2 Sources of Herba l Medicines 
Herbal medicines are generally sold from pharmacies as prescription and over-the-counter 
medicines and in special outlets (e.g. condimental shops). However, many herbal products 
and food supplements are also imported under special permits from the municipalities and 
sold in health food outlets. A new national committee, chaired by the MoH, was formed in 
late 2008 to regulate herbal medicines and General Sale Products through the municipalities 
and local health authorities. 
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1 . 1 4.3  Main Uses of Herbal Medicines in the UAE 
The number of herbal medicines and their uses within the UAE are not constrained by 
modern day land boundaries. Medicinal herbal plants span the Arabic gulf countries.56 Table 
1 .4 and Appendix 1 highlight the main (known) herbal medicines used. 
Number of 
Disease Examples 
plants used 
40 A/chem ii/a vulgaris, Anchusa strigosa, Calotropis 
Skin diseases 
procera 
Kidney and urinary 27 
system 
Ammi visnaga, Brassica napus, Glycyrrhiza glabra 
Diabetes 26 Achi/lea millefo/ium, Allium cepa 
23 Ceratonia siliqua, Foeniculum vu/gare, Micromeria 
Digestive system 
myrtifo/ia 
Liver disease 22 Alfium cepa, Asparagus officina/is, Cynara sco/ymus 
Respiratory system 16 Anchusa strigosa, Brassica oleracea 
Cancer 13 Al/ium cepa, Arum pa/aestinum, Brassica oleracea 
Table 1.4: Medicinal herbs and their uses to treat various diseases according to A rab 
medicine. 56 
It is known that the number of crude herbs, herbal medicines and dietary supplements 
imported into the country far exceeds the number of conventional medicines. The MoH, has 
registered 2,000 dietary supplements and herbal products compared to 5,200 conventional 
products; but roughly 30,000 dietary supplements and general sale items are freely imported 
into the country which are unregistered. Those that are registered and therefore regulated 
(and therefore available on prescription or through a pharmacy) have set costs, with the 
exception of dietary supplements and medicated cosmetics; those which are not controlled 
have no fixed price. 
1 . 14.4 Herbal Medicine Use by UA E Cit izens 
Herbal medicines are widely used by UAE citizens yet very little research has been 
conducted in this area. In 2000, Hassan et al, 79 investigated alternative medicine taking 
amongst students, doctors and their friends and relatives. They found that almost 73% of 
students indicated personal use of herbal medicine and 76% reported use by a friend or 
relative. Two further studies looked at particular groups. AI-Mazroui et a/,80 found 51 % of the 
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221 mothers interviewed had fed their babies local herbal drinks. Another study by Al Attia 
and Bakir 81 found that 26% of educated diabetic patients believed in the superiority of herbal 
medicine over the conventional hypoglycemic agents as compared to the uneducated (10%). 
Although not a herb, it is interesting to note that nearly 30% of all patients believed in honey 
as a useful remedy for diabetes regardless of their level of education. There are no specific 
data on the use of herbal medicines, alone or in combination, with conventional medicines, 
by the UAE community. The first stage of this research sought to address this information 
gap. 
1.15 Monitoring the Safety of Medicines 
Drug safety is a major public health priority. During the last few decades, it has been 
demonstrated that medicine-related morbidity and mortality is one of the major health 
problems. 82lt has been estimated that adverse effects from medicines are one of the leading 
causes of mortality in some countries,83 and the percentage of hospital admissions due to 
such reactions has been reported to be between 10 and 20%.84 Consequently, there is a 
high economic impact on health care services, with some countries spending upward of 20% 
of their healthcare budget on drug-related problems.85 
Many of these risks are identified in pre-market testing and can be managed as "expected" 
or "tolerable" side effects that are outweighed by the product's benefits. However, once a 
product is made available on the market, new unexpected or undesirable adverse drug 
reactions (ADRs), are sometimes discovered when the product is used in "real world" 
conditions. ADRs may occur even when a product is being used within its licensed 
indications. A reaction may occur within minutes after exposure or it can take years to 
develop. Reactions can range from minor irritations, like a skin rash, to serious and life 
threatening reactions, such as a heart attack or liver damage. Most often, the magnitude of 
an adverse reaction is unknown and is not necessarily mentioned in the product literature. 
Many regulatory authorities have a legal duty to protect their populations from harm, and 
usually have statutory functions to ensure new products brought to the market have been 
assessed for quality, efficacy and safety. These data inform the authorities to issue licences 
for products and allows the licensing authority to amend, suspend or revoke a license if new 
information on the product comes to light after it has entered the market. 
A well-organised drug safety management service is therefore a prerequisite for the early 
detection of the risks of drugs, prevention of ADRs and aiding health professionals and 
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patients to make the best benefit/risk assessment for safe and effective pharmacotherapy. 
Medicine induced morbidity and mortality can be substantially reduced through an integrated 
strategy for drug safety monitoring which includes:84 
• education and training of health care professionals on benefit/risk assessment and 
rational use of drugs; 
• behaviour change amongst patients and healthcare workers to decrease 
unnecessary and irrational use of drugs; and, 
• establishing pharmacovigilance services. 
Pharmacovigilance is the science of collecting, monitoring, researching, assessing and 
evaluating information from healthcare providers and patients on the adverse effects of 
medications, biological products and traditional medicines with a view to: 
• identifying new information about hazards associated with medicines; and, 
• preventing harm to patients.86 
1 .15. 1  ADR Reporting 
The greatest ADR disaster was the thalidomide tragedy of 1 961 -1 962. Thalidomide had 
been introduced as a safe and effective hypnotic and anti-emetic drug;  it rapidly became 
popular for the treatment of nausea and vomiting in early pregnancy. Tragically, the drug 
proved to be a potent human teratogen that caused major birth defects in children in the 
countries in which it was used in pregnant women.87 
The thalidomide disaster led to the establishment of the drug regulatory-mechanisms of 
today. These programmes require that new drugs should be subject to a benefit versus risk 
assessment by the well-established regulatory authorities before being granted a marketing 
authorisation (licence) and introduced into clinical usage.88·89 This, it might be thought, would 
have made medicines safe, or at least acceptably so. However, no drug which is 
pharmacologically effective is without hazard; furthermore, not all hazards can be known 
before a drug is marketed. All these factors led to the development of the concept of 
pharmacovigilance. 90 
The WHO set up a programme for international drug monitoring in 1968 after the thalidomide 
disaster. Since 1 978, the Uppsala Monitoring Centre (UMC) - a WHO Collaborating Centre 
for International Drug Monitoring, has carried out this work. As of 2004, it had a membership 
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of 94 countries and 28 associate members.9 1 ·92 To participate in this  programme, each 
member country must have its own national pharmacovig ilance centre. The UMC receives 
records from these countries and centrally processes them via a WHO database. This 
subsequently informs all member countries on drug safety issues. 
International regulatory authorities e.g. the Food and Drug Administration (FDA) in the US, 
Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK, European 
Medicines Agency (EMEA) for countries in the European Union and Therapeutic Goods 
Administration (TGA) in Australia, continue to monitor the safety, effectiveness and quality of 
health products after they reach the marketplace. These organisations routinely evaluate 
adverse reaction reports and selected foreign reports, from manufacturers, health 
professionals and consumers. 
Pharmacovigilance is needed in every country because there are differences between 
countries (and even regions within countries) in the occurrence of ADRs and other drug­
related problems. This may be due to differences in drug production, distribution, use 
(indications, dose), genetics, diet and traditions of the people.93 
These evaluations may include a comprehensive reassessment of the benefit-risk profile of a 
product. If a safety issue is identified, perhaps by noting an unexpected/increased number of 
reports of a particular event (a signal) appropriate action is taken. Such actions range from 
distributing new product safety information to the public and/or the health care community, to 
recommending changes to the product's labelling or requesting the removal of the product 
from the market. 
1.15.2 Current state of ADR Reporting 
ADRs are a significant cause of morbidity and mortality and contribute to increased 
healthcare costs. Healthcare providers need to understand their role and responsibilities in 
the detection, management, documentation, and reporting of ADRs; all essential activities for 
optimising patient safety.83 
Centres are more likely to receive reports from healthcare professionals on serious or rare 
ADRs and ADRs associated with newly marketed drugs yet under-reporting is a common 
phenomenon. 94-95 There is significant and widespread under-reporting of ADRs to 
spontaneous reporting systems including serious or severe AD Rs. 97 Issues identified that 
affect the decision to report or not to report by healthcare professionals are whether the 
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reaction was considered well-known or not, the severity of the reaction, hesitance to report 
only on suspicion, lack of confidence in recognising ADRs, knowledge of existing rules, 
excessive workload and lack of time to report ADRs. 98 
Correcting for under-reporting is difficult as the extent is unknown and very variable. Several 
countries that have participated for many years in the WHO Drug Monitoring Programme 
receive 200 or more adverse reactions per million inhabitants annually, but even at 
established centres the reported proportion of serious reactions may not be more than 
10%.93 In many other countries the reporting rates are much lower.99· 1 00 
In the last ten years, pharmacovig ilance of herbal products has become a priority with 
several organisations due to increasing concern over the quality and safety of herbal 
medicines. 92 This has led to a growing interest in developing spontaneous reporting systems 
for herbal medicines by organisations such as the WHO and individual countries, including 
the UK and Germany. 1 0 1 · 1 02 
1 .1 5.3 Pharmacovigilance in the UA E 
A national pharmacovig ilance committee has only very recently (late 2008) been formed in 
the UAE. At present, ADR monitoring is in its infancy. An ADR form has been developed and 
distributed to hospitals. clinics and pharmacies in the private and public sectors. Reporting is 
voluntary and the MoH has received few reports from practitioners. 
According to the DRCD, the current vision toward development of a medicines safety system 
in the UAE is to establish an independent federal medicines monitoring centre and to 
become a partner of the WHO-UMC. To realise this vision the DRCD has identified a 
number of objectives that need to be met for the UAE to have a national programme: 
• to organise the monitoring for domestic ADRs, including collection, analysis, 
supervision and communication of suspicious case reports on ADRs; 
• to liaise and coordinate with WHO regarding ADR case reports; 
• to offer drug information services to healthcare providers and exchange of data and 
information of ADRs. 
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This latter service wil l  be tasked with: 
• distributing ADR forms; 
• sending ADR reports to the reporting centre of ADRs at WHO; 
• providing an effective way to collect and assess ADR information to share with 
reg ional and international centres; 
• alerting health professionals, manufacturers and public in case of risk; 
• advising healthcare providers on how to deal with cases of drug interactions with 
drug , herbs, food, additives and medical devices; 
• integrating with regulatory affairs decisions on the marketing of suspicious products 
and interactions of drugs; 
• promoting educational and training courses for coordinators and healthcare 
professionals; 
• providing drug safety assessments 
1 .1 6  Conclusion and research plan 
There is a growing global trend for greater use of herbal medicines to treat acute and chronic 
conditions, yet there is a limited pool of information on their safety. This has promoted some 
countries to put mechanisms in place to identify potential problems associated with herbal 
medicines. However , in the context of M iddle Eastern countries (and in particular countries 
such as the UAE) where Western medicine is playing a growing part in healthcare provision 
alongside traditional use of herbal medicines, no data is known on uptake, usage and safety. 
The use of herbs as medicines remains high in the UAE. They are available from a variety of 
outlets subject to varying degrees of control and there have been no systematic studies of 
the context of use, for example alone or in combination with other herbs or allopathic 
medicines or indeed the safety of such use. The aims of the present research were firstly to 
look at the extent and nature of herbal use within the Abu Dhabi population in general 
(Chapter 2) and then investigate a method of studying herbal ADRs in a more focussed, 
secondary care setting at a nephrology clinic (Chapter 3). An overall discussion of the 
findings and recommendations on herbal ADR monitoring in the UAE appears in Chapter 4. 
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Chapter Two: 
Uptake and use of herbal medicines in a sample of primary 
care c l in ic patients i n  Abu Dhabi. 
As indicated in Chapter 1 ,  at the time of conducting this research ,  there were no data 
relating to the uptake, usage or safety of herbal medicines from within the UAE .  In a 
country such as the UAE, where herbal usage appears to be common, the need for 
accurate, current information on uptake and safety is of national importance. The 
initial stage of this research explored herbal use by a cross-section of UAE citizens 
and their attitudes to this type of medicine. 
2.1 A im and objectives 
The aim of this phase of this study was to gain baseline data on the incidence of 
herbal medicines (HMs) used by UAE nationals. The research had the fol lowing 
objectives. 
• To determine UAE nationals' views and beliefs on safety, quality and efficacy 
of HMs. 
• To determine where nationals purchase HMs. 
• To identify their reasons and influencing factors over purchasing or obtaining 
HMs. 
• To gain their views on the relative benefits of HMs compared to conventional 
medicines. 
2.2 Methodology 
2.2. 1 Background 
The plan of investigation for the first stage of the research was to conduct a cross 
sectional survey of nationals residing in Abu Dhabi. Abu Dhabi Emirate was chosen 
as population statistics for the Emirate were reflective of National figures. 
The sampl ing frame was to be drawn from an electoral register and randomly 
selected with sample size determined by an appropriate power calculation. 
A number of sampling options were investigated. Most of the available data sources 
lacked the basic requirement of people's names and addresses and were abandoned 
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as avenues from which to draw the sample. The following options were investigated 
and reasons for their de-selection are given. 
1 .  Using an electoral register 
An electoral register was considered the most obvious listing of people to in itially 
pursue. Unfortunately, at the time of this research, the UAE government did not keep 
such a list for UAE nationals. 
2. Telephone listings 
Directories of telephone numbers were explored for lists of nationals. However, very 
few nationals had their numbers listed. This was probably due to UAE culture, where 
privacy is considered so important that most of the national families do not register 
their home phone numbers .  
3.  Post offices lists 
The post offices in Abu Dhabi were approached to obtain  postal addresses of UAE 
nationals. U nfortunately, the post office management refused to disclose this 
information for confidentiality and privacy reasons. 
4. Federal Ministry of Planning 
It was d iscovered that the Federal Min istry of Planning had a database of the UAE 
citizens, generated for a UN report in 1 999. However, the sample contained no 
private postal addresses and telephone numbers were obsolete due to a change in 
digit length. 
5. Local department of planning for Abu Dhabi 
In 2001 a census of 1 000 households was undertaken . This collected limited 
information such as name and age but postal addresses were absent. 
6. Abu Dhabi Water and Electricity Distribution Company and Etisalat 
As with the post office, these companies refused to provide details of Abu Dhabi 
nationals for confidentiality reasons. 
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7. Health Card Registration Centre for public hospitals and PHC clinics of Abu 
Dhabi 
This body is responsible for issuing health cards for Abu Dhabi residents and 
nationals but most available data derived from 1 998 and up-to-date information on 
UAE citizen postal addresses was unreliable. 
8. Health Card Database in the IT Department of the Ministry of Health 
The department had very old data but was too incomplete to be considered reliable. 
9. Ministry of the Interior 
The Ministry of the Interior was approached for information; however access was 
refused for security and confidentiality reasons. 
10. Commercial mailing lists 
No mailing lists could be obtained from commercial firms that were reliable enough to 
be used in this study . 
As a result of the above, an alternative sampling methodology was sought; primarily 
by opportunity sampling from a public space or by targeting a PHC. After consultation 
between the researcher, a Ministry of Planning statistician, the UAE MoH and the 
author's supervisors, it was decided that recruitment at one of the main PHCs in Abu 
Dhabi City , was the most pragmatic and reliable solution; it was felt that the 
demographic profile of attendees would be similar to that of the population as a 
whole. A structured interview was considered the most direct and useful method of 
data collection. 
2.2.2 Survey development 
From January to March 2004, themes were identified initially by the researcher and 
her supervisors. Themes were categorised in six broad areas: 
• demographic information; 
• details of herbal medicines taken by respondents; 
• subjects' views on why they took herbal medicines; 
• information on where subjects bought them from and what influenced their 
purchasing decisions; 
• views on the relative benefits of herbal and conventional medicines; and , 
• attitudes toward healthcare providers. 
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Following identification of the themes, survey items for each theme were developed 
by the researcher and reviewed by an advisory panel of three plus the author's local 
supervisor. The advisory panel members were employed at the Drug Regulatory 
Department in MoH. One member was in charge of regulating herbal products; the 
second was in charge of regulating dietary supplements and general sale products; 
and the third was a pharmacy advisor to the Department. 
The final survey, which was produced in English, was agreed in May 2004 before 
being translated into Arabic. It was then reviewed again by two of the advisory panel 
members and the local supervisor (all native Arabic speakers) to ensure the survey 
questions had not lost their meaning. 
An English version of the final survey and associated cover note are shown in 
Appendix 2. 
2.2.3 Description of survey quest ions 
The survey contained 45 questions; they were a mixture of open, closed, single and 
multiple items. The survey was accompanied with a covering letter. The letter 
explained the aim of the research, provided instructions on completion, contact 
details of the researcher and defined some terms used in the survey in lay language. 
The questions within the six themes on the survey were as follows. 
1. Demographic information ( questions 1 to 12) 
These included questions on gender, age, living area, educational, marital and 
income status and occupation. 
2. Herbal Medicine Use (questions 13  to 22) 
Respondents were asked for details of herbal medicines they took. Questions 
included the number and types used; perceived effectiveness and incidence of side­
effects experienced. 
3. Reasons for taking and frequency of use (questions 23-25) 
It was important to gain an insight into why respondents took herbal remedies and 
also the extent of their exposure. 
43 
4. Purchasing patterns and disclosure (questions 26 to 36) 
This section of the survey explored respondent views on where they !:>ought herbal 
medicines and what influenced their purchasing decisions from specific outlets, and if 
they discussed this with their doctor. 
5. Views on herbal medicines (questions 37 to 43) 
Respondents' views of herbal medicines were sought ranging from efficacy to safety, 
and a comparison with conventional medicines was explored. 
6. Attitudes toward different healthcare providers (questions 44-45) 
These questions were asked to evaluate respondents' views on the practitioners from 
which they received their medicines. 
2.2.4 Research setting and sample size 
The Al Rawdha Primary Healthcare Clinic, Abu Dhabi was eventually selected for the 
survey setting. This PHC was the largest in Abu Dhabi and only provided services to 
UAE nationals. The centre offered a wide range of services, including, general 
medicine, mother and child healthcare, emergency medicine, immunisation, diabetes 
care and dental services. 
Taking advice from a statistician from the Ministry of Planning using the Abu Dhabi 
Statistics Data on nationals, it was determined that 300-400 subjects would constitute 
a sufficient sample size for the survey. 
The exclusion criteria were as follows: 
1. any non-UAE national ;  
2. patients unable to com municate in Arabic; 
3. patients with severe communication problems such as deafness; 
4. patients with obvious mental impairment or other diseases preventing clear 
com munication; and, 
5. patients less than 15 years old. 
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2.2.5 Ethics approval 
University of Portsmouth Biosciences Research Ethics Committee approval was 
obtained for this study in  March 2004. Approval was also obtained from the UAE 
MoH Health Ethics Review Committee (ref 200/2004) on 28th March 2004. To 
facil itate the researcher's work in a PHC in Abu Dhabi, a letter (ref 1 20/2004, dated 
22/304) was issued by the Director of Primary Healthcare and Motherhood & 
Childhood Department from the MoH to the Directors of PHCs in  Abu Dhabi, advising 
them of the research work and requesting their co-operation. 
2.2.6 Informed consent and data confidentiality 
Patients had the choice not to participate in the survey, and were not coerced into 
agreeing to take part. Patient confidentiality was maintained by each person being 
assigned a unique number, only known to the researcher, which was used to identify 
ind ividual data. Data were stored securely and patient identity was obscured in all 
reports and databases. 
2.2. 7 P ilot Work 
Before commencing the survey, the author visited the clin ic to talk with med ical staff 
and determine the most acceptable way of conducting it with minimal disruption to 
day-to-day operations of the PHC. 
The cl in ic bui lding was d ivided in  to two; one section for men and another for women. 
Patients were split by gender and treated separately because of UAE cultural 
customs. The clinic operated from 7.30 am till 1 1 .30 pm in two shifts. It was closed at 
weekends, except for emergency cases. On average, the number of patients visiting 
the clinic daily included 1 50 females, 70 males and 60 children . 
I n  May and June 2004 pilot work was conducted. Patients were recruited by 
opportunity sampling and most were interviewed by the researcher in a dedicated 
room. The clinic nurses called each patient to the room in turn as they arose. The 
questionnaire was piloted in 35 patients. Fifty-one patients were approached ; 40 
female patients were asked to be interviewed, of which 23 agreed, seven self­
completed and 1 O refused because they were either in a hurry, waiting to see a GP 
or were in pain .  Eleven male patients were asked to be interviewed; only two agreed, 
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three insisted on filling in the survey by themselves and 6 refused because they were 
in hurry or waiting to see a GP. 
A number of barriers were identified which hindered the recruitment of people to 
participate in the survey. 
1 . Patients were reluctant to be seen in a separate room as they liked to wait at 
the doctor's door; some people refused to come for interview as they were 
afraid they would miss their turn to see the doctor. 
2. Male subject participation was very low. It was apparent that men did not 
want to be interviewed by the female lead researcher for cultural reasons. 
3. Some people did not want to complete the survey face-to-face with the 
researcher. Time was quoted as a factor in non-participation. 
As a result of the above, a number of changes were proposed to the logistics of 
recruiting people to the study, these are described below. 
1 . The possibility of using a trained male investigator to help the lead researcher 
recruit male patients was considered; however, at the time this proved 
impossible. This problem was discussed with the director of the clinic and 
nurse in charge and it was agreed that approaches to men would also be 
made by nursing and medical staff. This necessitated people recruited in this 
way to self-complete the survey, either at the clinic or at home; in the latter 
case returning it by pre-paid mail . The approach of offering self-completion 
would hopefully a lso accommodate those people that had declined to be 
involved due to time commitments. 
2. The lead investigator was advised to wear a white coat instead of casual 
dress to enhance patient perception of the researcher and hopefully increase 
participant recruitment. 
3. Some subjects who were reluctant to be interviewed in a separate room were 
approached in the waiting areas. 
4. A small number of survey items were reworded to simplify the Arabic phrases. 
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2.2.8 Main study conduct 
Subjects were recruited over a 4 month period (August to December 2004 ). A 
sampling frame was constructed over this time to ensure that people were recruited 
on all working days (except the weekends - the clinic was closed) and opening hours 
of the medical practice to reduce sampling bias. Opportunity sampling was 
employed. 
Two approaches to recruitment were conducted. Female patients were approached 
by the researcher or clinic nurse whi lst they were sitting in the waiting area; for males 
the doctors and nurses requested patients to complete the survey whilst waiting for 
their appointment. For those subjects that were interviewed by the lead researcher 
the process took approximately 1 5  minutes. Interviews and written surveys were 
conducted in Arabic. 
2.2.9 Data analysis 
Each completed survey was given a unique identifying number and entered i nto an 
SPSS database (Version 1 1  ). Two research assistants, both pharmacists, helped the 
lead researcher in coding and data entry. Assistants were fully trained on how to use 
SPSS and enter the data. The author reviewed the whole database before analysis 
was performed. The majority of data was analysed using descriptive statistics. W here 
necessary, more sophisticated techniques used an acceptable level of statistical 
significance of p<0.05. 
2.3 Results 
2.3.1  Response rate 
A total of 560 surveys were d istributed to the target population; 37 4 surveys were 
completed or returned , yielding a response rate of 66.8% (n=374/560). However, 44 
were unusable due to being incomplete, therefore 330 surveys were analysed 
(usable response rate of 330/560, 59%). A breakdown of how the 330 surveys were 
collected is as follows: 
• 1 32 (40%) via doctor and nurse support; 
• 90 (27%) by direct interview by the researcher; 
• 54 ( 1 6%)  self-completed at the PHC; and , 
• 54 ( 1 6%)  self-completed and returned via post. 
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2.3.2 Demographic characteristics of respondents 
The demographic profile of participants is shown in Table 2.1 .  Subjects were 
predominantly female (70%) and came from a wide age range that was skewed 
towards a younger age profile; over half who gave their  age were aged 25 years or 
younger. Approximately 75% of those who indicated their place of residence lived in 
urban surroundings. Of the 328 respondents who indicated their marital status, 1 50 
(46%) were married, 1 72 (52%) single and 6 (2%) were divorced or widowed. Of the 
1 00 married females, 36 were either pregnant or breastfeeding. The majority of 
participants (7 4%, n=237 /322) belonged to family units of between 4 and 1 2  people 
and most were educated to at least high school level (84%, n=273/324). 
Nearly half were employed in a full time job working in the government sector (44%, 
n= 1 45/328), although the sample did contain a high proportion of students (39%, 
n= 1 27/328). Income analysis revealed that 46% (n=136/296) of participants had an 
average monthly income of between 8,000 and 1 3,999 Ohs. 
When compared to national statistics (Table 2.2) significant differences (at the 
p<0.05 level) were found in respect to all variables where comparable data were 
available, namely gender (increased proportion of females), age range (a skew to 
more younger subjects), residence (a greater proportion of urban dwellers), marital 
status (a greater proportion of single subjects), education (better educated) and 
occupation (more employed and more students) .  
From 329 respondents who identified their health status during the last month, 85%, 
(n=279/329) said that their health was either excellent or good; only 5% (n=14/329) 
declared that their health was weak or very weak. 
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Parameter Basic Description (n and % values) 
Gender (n= 330) 
Male 
Female 
Age Distribution (n=276) 
15 - 25 years 
26 - 35 years 
36 - 45 years 
46 - 55 years . 
56 - 65 years 
Location Distribution (n=232) 
Urban 
Rural 
Marital Status of respondent (n=328) 
Single 
Married 
Divorced or widow 
Status of Married Female (n=100} 
Pregnant 
Lactating 
Neither 
Total number of family members (n=322) 
1-3 
4-6 
7-9 
10-12 
More than 12 
Education status (n=324) 
Cannot read nor write 
Can read and write only 
Less than high school 
High school 
Undergraduate 
Graduate (hiQh) 
Employment of respondent (n=328) 
Work in Government sector 
Private business 
Unemployed 
House wife 
Retired 
Student 
Work in government and private sector 
Other 
Monthly income of family in UAE currency Dhs* (n=296} 
< 5000 
5000-7999 
8000-10999 
11000-13999 
1 4000-16999 
1 7000-19000 
> 20000 
Table 2.1 :  Demographic characteristics of respondents 
*1 Pound=?.3 Ohs; 1 $=3 .6 Ohs; 1 Euro=5.4 Ohs. 
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98 (29.7%) 
232 (70.3%) 
158 (57%) 
79 (28.6%) 
29 (10.5%) 
6 (2.2%)  
4 (1.5%) 
175 (75.4%) 
57 (24.6%) 
172 (52.4%) 
150 (45.7%) 
6 (1.8%) 
14 (14%) 
22 (22%) 
64 (64%) 
33 (10.3%) 
79 (24.5%) 
79 (24.5%) 
79 (24.5%) 
52 (16.2%) 
3 (0.9%) 
9 (2.8%) 
39 (12%) 
121(37.3%) 
146 (45.1%) 
6 (1.9%) 
145 (44.2%) 
1 (0.3%) 
6 (1.8%) 
38 (11.6%) 
8 (2.4%) 
127 (38 .7%) 
2 (0.6%) 
1 (0.3%) 
20 (6 .8%) 
71 (24%) 
89 (30.1%) 
47 (15.9%) 
21 (7.1%) 
16 (5.4%) 
32 (10.8%) 
l 
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Data Survey Findings Abu Dhabi National Statistics 
Parameter Frequency Valid Percent (%) frequency Val id Percent (%) 
Gender 
Male 98 29.7 175178 50.4 
Female 232 70.3 172293 49.6 
Total 330 100 347471 100 
Age 
15 - 25 years 158 57.2 100174 49.1 
26 - 35 years 79 28.6 52514 25.8 
36 - 45 years 29 10.5 27135 13.3 
46 - 55 years 6 2.2 15804 7.7 
56 - 65 years 4 1.5 8307 4.1 
I Total of Aqe 276 100 203934 100 
Location 
i Urban 175 75.4 167939 51.7 
Rural 57 24.6 157149 48.3 
Total 232 100 325088 100 
Marital status 
Single 172 52.4 89305 42.5 
Married 150 45.7 110648 52. 7  
Divorced o r  widow 6 1.8 10169 4.8 
Total of Marital Status 328 100 210122 100 
i Family Size 
No comparable data 
· Education Level 
Cannot read nor write 3 0.9 20986 8.3 
Can read and write only 9 2.8 23265 9.2 
Less than High school 39 12 93058 36.8 
Got high school 121 37.3 88651 35 
Undergraduate 146 45.1 241 31 9.5 
Graduate (high) 6 1.9 3008 1.2 
Total of Education 324 100 253099 100 
Employment 
Work full time (government) 145 44.2 70902 34.5 
Private business 1 0.3 5096 2.5 
Unemployed 6 1.8 4309 2.1 
house wife 38 11.6 49054 23.9 
Retired 8 2.4 5871 2.9 
Student 127 38.7 61925 30.2 
Do not want to work N/A N/A 4509 2.2 
Unable to work NIA N/A 3576 1.7 
work Full time + Private full time 2 0.6 N/A N/A 
Total of employment 328 99.6 205242 100 
Table 2.2: Comparison of demographic resu lts to Demographic Data for UAE 
Nationals in Abu Dhabi Emirate* 
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2.3.3 Use of herbal medicines 
Three quarters of respondents (76%, n=250/330; 95%CI: 70.8-80.2%) had previously 
used herbal remedies with 38% (n=94/248; C l: 31 .8-44.3%) currently taking some 
form of herb. Those from rural areas were more likely to be or have been, taking HMs 
(Chi2=5.455; p=0.02). Most herbal remedies were not Western 'off the shelf' or 
proprietary herbal products ( 1 8%, n=44/241 ;  Cl :  1 3.6-23.7%) but herbs in the crude 
form (63%, n= 1 52/241 ;  Cl :  56.6-69.2%) or as compounded/mixed forms (36%, 
n=87/241 ;  C l :  30.0-42.5%). Liquids (58%, n= 1 38/240; Cl: 51 .0-63.8%) and herbal 
teas (55%, n= 1 3 1 /240; Cl: 48.1 -6 1 .0%) were the most common ways of taking the 
herb. A wide range of herbs was used (Table 2.3) for a large number of complaints 
(Table 2.4 ); two hundred and three reported taking 65 different types of herbs to treat 
48 different conditions. 
Herb Frequency (n=463)* 
N (%; 95%CI) 
Thyme 73 ( 1 5.8%; 1 2.6-1 9.4%) 
Senna 48 ( 1 0.4%; 7.7-1 3.5%) 
Black seed (n=32) and black seed with honey (n= 1 0) 42 (9. 1 %; 6.6- 1 2. 1  %) 
Ginger 31 (6.7%; 4.6-9.4%) 
Chamomile 30 (6.5%; 4.4-9. 1 %) 
Sage 22 (4.8%; 3.0-7. 1 %) 
Anise 1 7  (3.7%; 2.2-5.8%) 
Unnamed herbal products 1 6  (3.5%; 2.0-5.5%) 
Aloe 1 6  (3.5%; 2.0-5.5%) 
Fenugreek 1 5  (3.2%; 1 .8-5.3%) 
Myrrh 1 5  (3.2%; 1 .8-5.3%) 
Peppermint 1 1  (2.4%; 1 .2-4.2%) 
Green tea 1 0  (2.2%; 1 .0-3.9%) 
Other products (values less than 1 . 5%) 1 17 (25.2%; 2 1 .4-29.5%) 
Table 2.3. Herbs taken by respondents 
* Some respondents mentioned more than one herb 
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Condition Frequency (n=463)* 
N (%;95%CI) 
Abdominal problems 72 (15.5%; 12.4-19.2%) 
Cold/flu/throat infection 64 (13.7%; 10.8-17.3%) 
Constipation 46 (9.9%; 7.4-13.0%) 
Cough 39 (8.4%; 6.1-11.3%) 
Dysmenorrhoea 31 (6.7%; 4.6-9.4%) 
General health 26 (5.6%; 3.7-8.1%) 
Slimming 24 (5.2%; 3.4-7.6%) 
Anti-flatulent 22 (4.7%; 3.0-7.1%) 
Asthma 12 (2.6%; 1.4-4.5%) 
Dermatological problems 12 (2.6%; 1.4-4.5%) 
Relaxation 11 (2.4%; 1.2-4.2%) 
Dermatologica l  cosmetics 9 (1.9%; 0.9-3.7%) 
Hair tonic 9 (1.9%; 0.9-3.7%) 
Acne 6 (1.3%; 0.4-2.8%) 
Diarrhoea 6 (1.3%; 0.4-2.8%) 
Headache 6 (1.3%; 0.4-2.8%) 
Eye problems 5 (1.1 %; 0.4-2.5%) 
Hyperacidity/ulcer 5 (1.1%; 0.4-2.5%) 
Other conditions 61 (13.1%; 10.2-16.6%) 
(with values less than 1 % ) 
Table 2.4 Conditions which correspondents were treating with herbs 
* Some respondents mentioned more than one condition 
When asked about the effectiveness a large majority of respondents (88%, 
n=198/225; Cl: 83.0-92.0%) thought that the last herbal remedy they had used was 
either effective or very effective. Respondents who were currently taking HMs (n=94) 
were asked how many types they were consuming. Most (n=38, 40%) were taking 
only one HM, but 35 (37%) were taking two or three, 9 (10%) between four and five 
different HMs and 1 2  (13%) were taking five or more. 
Respondents tended to store their HMs in one place (n=217, 92%), with storage in 
cupboards (n=108, 42%) being the most common; although a fifth (n=55, 21%) kept 
them in a fridge. 
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Self-reported rates for adverse events associated with herbs was 1 1  % (n=27/240). 
Twenty people went on to describe the nature of the adverse event. Ten people 
experienced gastrointestinal effects (e.g. nausea/vomiting, diarrhoea, abdominal pain 
and constipation). Other adverse events reported included allergic reactions (2), 
kidney pain ( 1  ) ,  fever (1 ), spasm (2), anaemia ( 1  ), acne ( 1 ) and decreased breast 
milk production (2). Interestingly, this latter effect was observed in both cases with 
people taking thyme. Figure 2. 1 details what action they took on experiencing an 
adverse event. 
Action taken when experienced Adverse Event 
0% 
0% 
6% 
II Continue taking medicines & 
see if symptoms resolved,  n=4 
■ Stop taking medicines, n= 1 4  
D Consult Doctor, n=4 
o Consult pharmacist,n=0 
■ Consult sale person in 
condiment shop,n=0 
Consult herbalist,n=2 
■ Go to hospital ,n=3 
o Admit to hospital ,n=2 
■ Other,n=2 
Figure 2.1 :  Respondent action taken when adverse events experienced. 
Thirty-seven people (37, 39%) were taking herbal medicines concurrently with 
Western medicine. Multiple herbal use was common;  1 32 products were cited by 
these 37 people. In addition, the majority of these respondents (28, 76%) were taking 
herbal medicines for the same condition being treated with Western medicine. Of 
these, at least five cases involved chronic conditions: diabetes (2), obesity (2) and 
chronic cough ( 1  ). 
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2.3.4 Reasons for taking herbal medicines and frequency of use 
Those respondents who said they took HMs were asked to state why they did so. 
Some of the 275 responses received contained more than one reason; but three 
main reasons emerged: 
• they thought they were effective (n=99, 36.0%); 
• safe (n=94, 34.2%); and, 
• from natural sources (n=82, 30.0%). 
Other less frequently cited reasons included 'heritage' (n=20), ease of availability 
(n=13), had trust in them (n=11) and a 'prophet' medicine (n=?). 
Only 9% (n=22/240; Cl: 5.8-13.6%) stated they took herbs every day with the 
majority of the remainder taking them on an occasional / when needed basis (75%, 
n=181/240; Cl: 69.5-80.1 %). Where herbal medicines were used as a finished 
product, a majority read the associated label information (82%, n=156/190). 
2.3.5 Sources of HMs obtained by respondents 
Respondents most frequently bought herbal medicines from condimental shops 
(58%, n=141/243), followed by supermarkets/grocery stores (33%, n=80/243), and 
herbal medical centres (22%, n=54/243). Pharmacies (17%, n=40/243) and health 
food shops (15%, n=37/243) were less frequently cited sources. Other outlets such 
as the internet were very rarely used (1.6%, n=4/243). Repeat purchasing patterns 
reflected the respondents' preferences for particular outlets (see Table 2.5). 
However, no clear pattern emerged from the frequency of purchasing, although it 
appears that respondents were more frequent repeat buyers from grocery shops and 
supermarkets compared to other outlets. 
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Number of visits made over the last 1 2  months 
1 2 3 4 5 > 5 
Herbal Medical centre 29 18  9 1 0 7 
(n=64) (45.3%) (28.1 %) (1 4. 1  %) ( 1 .6%) (0%) ( 1 0.9%) 
Health food shops 1 8  7 1 0  1 2 2 
(n=40) (45%) (17 .5%) (25%) (2.5%) (5%) (5%) 
Condimental shops 44 28 1 4  1 1  4 1 1  
(n=1 1 2) (39.3%) (25%) (1 2.5%) (9.8%) (3.6%) (9.8%) 
Pharmacy 29 23 8 4 3 9 
(n=76) (38.2%) (30.3%) (1 0.5%) (5.3%) (3.9%) ( 1 1 .8%) 
Grocery/ supermarket 1 7  25 1 5  5 6 26 
(n=94) ( 1 8. 1 %) (26.6%) (1 6%) (5.3%) (6.4%) (27.7%) 
Gym club 6 2 1 2 0 6 
(n=1 7) (35.3%) ( 1 1 .8%) (5.9%) ( 1 1 .8%) (0%) (35.3%) 
Other places 6 2 7 1 1 0 
(n=1 7) (35.3%) ( 1 1 .8%) (41 .2%) (5.9%) (5.9%) (0%) 
Table 2.5. Frequency of visits to purchase herbal medicines 
Almost three-quarters of respondents stated that they received advice from the seller 
on how to take the medicine (74%, n= 1 76/238). A number of further questions were 
posed that explored participants' purchasing patterns and responses are summarised 
in Table 2.6. The two primary reasons people chose a particular outlet were because 
it had an experienced herbal practitioner present (42%, n=98/232) and had a wide 
choice of herbal remedies (41 %, n=95/232). Other factors which shaped their 
decisions were closeness to home (22%, n=5 1 /232) and proximity to other stores 
( 1 8%, n=4 1 /232). Price (9%, n=20/232}, customer friendly attitude of staff (8%, 
n= 1 8/232), obtaining free samples (4%, n=9/232) and appearance of the store (3%, 
n=6/232) appeared to be minor influences. 
Respondents were then asked to select from a list what influenced their purchasing 
decisions. Recommendations by family or friends (76%, n= 1 82/240) were clearly the 
most influential; but reading articles in magazines (28%, n=67/240) or through other 
reading such as books, leaflets and posters (23%, n=55/240) and radio and TV 
advertising (22%, n=53/240) were also cited; although the internet was less used 
( 1 0%, n=25/240). Over twice as many respondents said they gained information from 
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herbal practitioners (19%, n=46/240) as from health care professionals (9% ,  n= 
22/240). 
Statement Basic Description 
(n and % values) 
Reasons for buying from that particular outlet (n=232), responses n=360* 
There is an experienced herbal practitioner 98 (42.2%) 
The shop is big & has various types of H.M 95 (40.9%) 
It is close to my home 51 (22.0%) 
The shop is located in big shopping centre / food market 41 (17.7%) 
Other reasons 22 (9.5%) 
The prices are cheaper than other places 20 (8.6%) 
The sale person in that shop is kind to me 18 (7.8%) 
I got free samples when I buy 9 (3.9%) 
It is tidy and elegant 6 (2.6%) 
Table 2.6. Influences on purchasing patterns 
* % greater than 1 00% as responders could chose more than 1 response 
When respondents were asked how they choose between herbal products when 
there was more than one choice (see Table 2. 7), recommendation from family and 
friends was again the most important (50%, n=116/232). This is in stark contrast to 
recommendations by staff (12%, n=27/232). This reliance on using family and friends 
is not unsurprising given that 64% (n=195/303) of respondents stated that they knew 
some of their family members used herbal medicines. Decisions on which to 
purchase were also driven by media exposure (seen or heard most about, 42%, 
n=97 /232) and what they thought to be the most effective product (21 %, n=48/232). 
Interestingly, more respondents would choose a stronger version (40%, n=93/232) 
over brand confidence (13%, n=29) or those which required less doses a day to be 
taken (14%, n=32/232). 
A substantial minority of respondents (34%, n=90/263; Cl: 28.5-40.3%) had visited a 
herbal practitioner at some time. It was also found that those people who lived in  
rural areas as opposed to urban areas were significantly more likely to visit a 
herbalist (Chi2=10.904, p=0.001). Seventy-eight went on to say where they saw them 
(see Table 2.8). The most visited places were condimental shops and herbal medical 
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centres (69%, n=54/101 ), followed by a government hospital (14%, n=11/101 ); while 
the least visited place was the herbal practitioner's home (8%, n= 6/101 ). 
How respondents chose between HMs (n=232), responses = 51 5* 
It has been recommended by a friend/ family 116 (50%) 
It is the product which I have seen / heard most about 97(41.8%) 
It is the strongest version available 93(40.1 %) 
I t  is  the one I believe to be most effective 48 (20.7%) 
It has the most informative label 38(16.4%) 
The one which requires least doses per day 32(13.8%) 
It has the brand name which inspires the most confidence 29(12.5%) 
It has been recommended by staff 27(11.6%) 
Other reason 14 (6%) 
Because of flavour 11(4.7%) 
The one which comes in largest quantity 8 (3.4%) 
The cheapest 2(0.9%) 
It has the most attractive label 0(0%) 
Table 2.7:  Influences on choice when more than one product available 
* % greater than 100% as responders could chose more than 1 response 
Where do you meet the Herbal Practitioner? (n=78), responses = 1 01 
Condimental shop 27 (34.6%) 
Herbal centre 27 (34.6%) 
Government hospital 11 (14.1%) 
Pharmacy 8 (10.3%) 
Patient's home 8 (10.3%) 
Private hospital/clinic 7 (9.0%)  
Health food shop 7 (9.0%) 
Herbal practitioner's home 6 (7.7%) 
Table 2.8: Places where respondents saw herbal practitioners 
* % greater than 100% as responders could chose more than 1 response 
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2.3.6. Respondents' views on HM compared to Western (conventional) 
medicine 
Eighty-four percent (n=260/3 1 1 )  of respondents had taken conventional medicines to 
treat previous i l lnesses, and most (82%, n=2 1 3/259) said that treatment using 
conventional medicine was effective or very effective. Yet over three-quarters (78%, 
n=258/330) of respondents had taken herbal medicines concurrently with 
conventional medicines. The range of conditions that were reported to be treated with 
conventional medicines is shown in Table 2.9. The most common symptoms / i l lness 
treated concurrently were coughs and colds (26%, n=32/1 24), headache/migraine 
( 1 0% ,  n=1 2/1 24) and fever (7.2%, n=9/1 24). This is reflected in the l isted names of 
Western medicines the respondents were able to recall . Fifty-three respondents were 
able to give details of 95 medicines that they took. Medicines taken ranged from 
corticosteroids to appetite suppressants but analgesics (27%, n=26/95;  paracetamol 
(n= 1 7) and NSAIDs (n=9), antibiotics ( 1 7%, n=1 6/95), acne and cough preparations 
(both 7%, n=?/95) were the most commonly taken medicines. 
Disease Cateaory {n=1 24} n {%) 
Respiratory Tract 45 (36.3%) 
Central Nervous System 2 1  ( 1 6. 9%) 
Gastrointestinal 1 5 ( 1 2. 1 %) 
Endocrinoloav 9 (7.3%) 
ENT 8 (6.5%) 
Infection 8 (5.6%) 
Skin 5 (4.0%) 
Joint and Musculoskeletal 7 (4 .0%) 
Card iovascular 3 (2.4%) 
Nutrition and Blood 2 ( 1 .6%) 
Gynaecological 1 (0 .8% ) 
Table 2.9: Conditions (per BNF category) being treated with conventional 
medicines. 
Respondents were also asked a series of nine statements that encouraged the 
comparison between herbal and Western medicine; these are summarised in Table 
2. 1 0. 
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Statement Agree and No opinion Disagree 
strongly {%) and 
agree {%) strongly 
d isagree 
(%) 
a) I have more confidence in herbal 60 24 1 6  
medicine than conventional medicine. 
(n=299) 
b) Herbal medicines are safer to use 75 1 6  9 
than conventional medicines .  (n=307) 
c) Herbal medicines are more effective 48 37 1 5  
than conventional medicines. (n=301 )  
d) Herbal medicines work as quickly and 39 36 25 
effectively as conventional medicines. 
(n=300) 
e) There are no problems taking herbal 42 38 20 
medicines with conventional medicines. 
(n=291 )  
f) Herbal medicines have no place in 21  22 57 
modern medicine. (n=292) 
g) Herbal medicines have been more 55 29 1 6  
useful for me when treating a previous 
ailment than conventional medicines. 
(n=292) 
h) Herbal medicines treat the whole 59 33 8 
body to make a person better, not just a 
problem. (n=304) 
i) Herbal medicines should contain a 87 1 0  3 
leaflet of similar information to 
conventional medicines. (n=300) 
Table 2 . 10: Responses to statements comparing herbal to Western medicine. 
Statements a to e and statement g (Table 2. 1 0) directly compared HM to Western 
medicine. Statements a, b, c and g showed respondents to be strongly in support of 
herbal medicines; Statements d and e, relating to onset of action and potential for 
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interactions, although more positive toward herbal medicines, did have large neutral 
values. For statements that were not direct comparisons (f, h and i) these too were 
positive toward herbal medicines. 
Further statements explored respondents' views on HMs with respect to safety. 
Respondents were asked to choose a preference between HM and Western 
medicine  (Table 2.11 ). 
Statement Herbal Western Both ( H Ms 
medicines medicines & WMs) 
{HMs) {WMs) 
a. Safe to use. (n=288) 231(80.2%) 51 (17.7%) 6 (2.1%) 
b. Processed Chemical 28 (11.4%) 216 (88.2%) 1 (0.4%) 
Manufacturing.  (n=245) 
c. Has no side effects . (n=267) 227 (85%) 33 (12.4%) 7 (2.6%) 
d. Cannot get addicted. (n=254) 218 (85.8%) 34 (13.4%) 2 (0.8%) 
e. Can prevent a person from 162 (60%) 85 (31.5%) 23 (8.5%) 
getting sick. (n=270) 
f. Can improve and maintain a 197 (72.2%) 57 (20.9%) 19 (7%) 
person's health. (n=273) 
g. Is safe to be g iven to 195 (78%) 50 (20%) 5 (2%) 
pregnant women. (n=250) 
h. Is safe to be g iven to 193 (79.4%) 44 (18.1%) 6 (2.5%) 
breastfeeding mothers (n=243) 
I. Is safe to be g iven to children 176 (66.9%) 72 (27.4%) 15 (5.7%) 
below 12 years old (n=263) 
Table 2.1 1 :  Respondents' perceptions of comparative safety between herbal 
and Western medicines. 
Respondents were much more inclined to favour HM over Western medicine for all 
statements .  In particular, approximately 80% or more of respondents favoured HM in 
relation to their overall safety (statement a), having no side effects (c) and being safe 
to g ive whilst either pregnant or breastfeeding (g, h). Interestingly, sub-analysis 
showed that more women than men thought HM was safer (Chi2=8.420, p=0.004) 
and had no side effects (Chi2=9.409, p=0.002). Additionally, almost all women 
(n=24/25) who were currently pregnant or breastfeeding would continue taking HM. 
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The majority of respondents (77%, n= 1 60/207) also stated that HM would be their 
treatment of choice. 
Those respondents that took HMs (76%, n=250/330) were asked if they consulted a 
doctor first before taking them. The majority, (69%, n= 1 64/238) said they did not 
inform a doctor ; reasons for not doing so are shown in Table 2.1 2. 
Statement n=147 
Did not think to mention it to the doctor. 60 (40.8%) 
Don't think my doctor believes in herbal medicines so would 
46 (31 .3%) 
not take me seriously. 
Don't think my doctor needs to know about medications I 
44 (29.9%) 
take unless it's medication that they prescribed for me. 
Other reasons: 
(variable answers, although 5 respondents mentioned they 34 (23. 1 %) 
were safe and therefore the doctor did not need to know).  
Table 2 .12 Reasons why respondents did not disclose HM taking to their 
doctors. 
It is clear from those who disclosed their reasons that many (41 %) had not thought to 
talk to their doctor, although approximately 30% thought that they would not be taken 
seriously or believed it was not for the doctor to know about as they had not 
prescribed the medicine. For those people that took HM and did speak to their doctor 
first (n=74, 3 1 . 1 %) seventy went on to state why. The commonest reasons for 
disclosure was they believed their doctor should be fully aware of all medicines they 
took (n=45/70, 64.3%) and that they wanted to discuss any new medication with their 
doctor before taking it (n=29/70, 4 1 .4%). 
Respondents were also asked to state whether herbal medicine or conventional 
medicine would be their first choice treatment for a range of conditions. Responses 
are shown in Table 2.1 3. 6 1  I I 
Condition (n=respondents Herbal medicine Western medicine 
expressing an opinion) � (%) (%) 
Herbal medicine preferred 
Weight loss (n=260) 74 26 
General well being (n=263) 73 27 
Weight gain (n=255) 73 27 
Stomach/digestive disorders (n=261 )  66 34 
Opinion equally divided 
Colds and flu (n=270) 56 44 
Fatique (n=261 )  5 1  49 
Insomnia (n=262) 50 50 
Sexual disorders (n=234) 47 53 
Wes tern medicine preferred 
Anxiety/depression (n=254) 43 57 
Immunity/nutrients disorders (n=253) 43 57 
Diabetes (n=255) 4 1  59 
Bruises/injuries (n=268) 40 60 
Back/neck pain (n=274) 39 6 1  
Skin disorders (n=253) 37 63 
Infertility (n=233) 37 63 
High cholesterol (n=253) 36 64 
Arthritis (n=254) 34 66 
Asthma/lung disorders (n=255) 33 68 
High blood pressure (n=259) 33 67 
Headache/migraine (n=274) 28 72 
Cancer (n=232) 21 79 
Table 2.1 3 :  Respondents' preferred choices for treating specific conditions 
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From the 2 1  conditions listed, herbal medicine was only strongly preferred in four 
conditions: 
• Weight loss; 
• General well being; 
• Weight gain; 
• Stomach/digestive disorders; and, 
In comparison, conventional medicines were strongly preferred in thirteen conditions: 
• Diabetes; 
• Bruises/injuries; 
• Back/neck pain; 
• Skin disorders; 
• Infertility; 
• High cholesterol; 
• Arthritis; 
• Asthma/lung disorders; 
• High blood pressure; 
• Headache/migraine; 
• Cancer; 
• Anxiety and depression; 
• Immunity and nutrient disorders. 
No significant differences were found in those conditions in which opinion was 
equally divided. 
2.3.7 Views on Health Professionals and others who sel l / supply herbal 
medicines 
A series of questions was asked of the respondents regarding herbal practitioners, 
doctors and other healthcare providers. Table 2.1 4  highlights statements comparing 
respondents' views between herbal practitioners and doctors. The responses showed 
very few polarised viewpoints, with most statements having large neutral responses. 
The final series of questions looked at whether respondents had been 
recommended, prescribed or given advice on HMs, as well as referral on to a herbal 
practitioner. The results are summarised in Table 2. 1 5. 63 
Agree or strongly No Opinion Disagree or 
Statements comparing Agree strongly Herbal Practitioner to 
Physician disagree 
Visit to Herbal Practitioner is 
cheaper than to a Physician. 115 (38%) 119 (40%) 67(22%) 
(n=301) 
Herbal Practitioner shows more 
counselling skills than 97 (32%) 139 (46 %) 67(22%) 
Physician. (n=303) 
Herbal Practitioner offers more 
promises of cure than 148 (50%) 107 (36 %) 42(14%) 
Physician. (n=297) 
Medications given by Herbal 
Practitioner are never out of 176 (59%) 80 (27 %) 40 (14%) 
stock. (n=296) 
Medications given in 
Healthcare centres/ hospital is 90 (31%) 70 (24%) 130 (45%) 
often out of stock. (n=290) 
Herbal Practitioner discourages 
me from visiting a Physician. 55 (19%) 108 (37%) 126 (44%) 
(n=289) 
Physician discourages me from 
visiting a Herbal Practitioner. 81(28%) 99 (34%) 114 (39%) 
(n=294) 
Physician discourages me from 
72 (24%) 88 (30%) 136 (46%) 
taking HM. (n=296) 
Herbal Practitioner discourages 
72 (24%) 107 (36 %) 119 (40%) 
me from taking. CM (n=298) 
Table 2.1 4: Respondents' comparisons of Herbal Practitioners and Doctors. 
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Advising Suggest to Suggest to see Have Have given 
person use HM Herbal prescribed an advice o n  
(n=31 8) Practitioner HM (n=288) how to take 
(n=205) HM (n=289) 
Doctor 
(n=78) 
25 (8%) 10 (5%) 22 (8%) 21 (7%) 
Pharmacist 
(n=50) 
15 (5%) 6 (3%) 13 (5%) 16 (6%) 
Dentist 
(n=11) 
5 (2%) 2 (1%) 2 (0.7%) 2 (0.7%) 
Nurse 
(n=19) 
4 (1%) 5 (2%) 5 (2%) 5 (2%) 
Herbal 
Practitioner 44 (14%) n/a 79 (27%) 65 (23%) 
(n=188) 
Sale person in 
condiment shop 40 (13%) 44 (22%) 42 (15%) 41 (14%) 
(n=167) 
Sale person in 
health food 15 (5%) 15 (7%) 10 (4%) 15 (5%) 
shops (n=55) 
Other* (family 
and friends) 170 (54%) 123 (60%) 115 (40%)** 124 (43%) 
(n=532) 
Table 2.1 5: Respondents Response to Recommendations and referrals 
relating to HMs from other people. 
* On analysis, 'other' was primarily friends and family and is reported as such. 
** in this context, the author interprets prescribe as 'given' 
Results from Table 2.15 show that the respondent's family and friends was the 
majority group suggesting that the respondents use HM (54%, n=170/318); this is far 
higher than any other group, with herbal practitioners (14%,n=44/318) ranked second 
and sales people i n  condimental shops being third (13%, n=40/318). Likewise, family 
and friends suggested visiting a herbal practitioner more than any other group (60%, 
n= 123 /205); referrals by healthcare professionals was very low (physician, 5%, 
n=10/205; pharmacist 3%, n=6/205; nurse, 2%, n=5/205; and dentist, 1 %, n= 2/205). 
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Predictably, herbal practitioners were the group to have prescribed HM to 
respondents the most (27%, n=79/288); yet a high proportion of family and friends 
appear to have 'g iven' HMs to respondents (40%, n= 1 1 5  /288). Yet again, when it 
came to advice on administration, family and friends were the most influential (43%, 
n= 1 24/289). 
2.4 D iscussion 
This phase of the work has shown that the majority of UAE nationals rely heavi ly on 
herbal medicines to treat both acute and chronic conditions. The prevalence rate 
seen in this data is much higher than those studies conducted in Western 
countries. 23,32.33 ,35,36, 1 o3 , 1 o4. 1 05 
This is further underlined by these findings being purely based on herbal use 
whereas most Western studies have used umbrella terms such as 'complementary' 
or 'alternative' medicine, that encompass other forms of treatment such as massage, 
homoeopathy, spiritual healing and acupuncture, to name but a few. In Western 
studies where prevalence rates for herbal remedy taking are specified, then rates are 
much lower, ranging between 1 0  and 20%. 1 03· 1 06 • 1 07 This was partly expected due to 
the different cultures of UAE and Western countries. As stated previously, the UAE is 
an emerging nation which is embracing Western approaches to health care but it is 
steeped in traditional healing using herbal products. Prevalence studies from other 
African and Middle Eastern countries support high HM taking. Ogur et al 46 and 
Eddouks et al 55 reported similarly high rates to these findings (between 75 and 
80% ), whilst other reports from Iran 31 and Bahrain 52 also described prevalence rates 
of approximately 50%. In addition, other ethnopharmacological surveys in Morocco, 
Israel and Egypt show that traditional herbal medicines available for people to buy 
are extensive.105-1 1 0  
Crude formulations sold from traditional 'cond imental ' stores that were then made 
into infusions and teas were most popular. No control over the quality of these 
products exists in the UAE. This raises questions over the safety of such products. 
Adulteration of herbs is a real concern and a number of cases have been reported to 
and investigated by the UAE MoH (see Chapter 1 ,  section 1 . 1 3 . 1  ) .  In addition to 
adulteration, the lack of standardisation of crude herbs also increases the likelihood 
that patients will experience i l l  effects or reduced efficacy from them. 66 
Faith in herbal remedies was strong, both from the standpoint of effectiveness and 
safety. This faith is probably a product of heritage. Generation after generation have 
used these products, with no attributed harm and a perception of much good. The 
cultural mindset is reinforced by family and friends being the main influences on 
respondents' purchasing patterns. This, however, is not culturally unique as others 
have shown that relatives are also instrumental in shaping decisions regarding the 
purchase of med icines . 1 1 1  
The range of herbal medicines taken was large. The most frequently cited herbal 
medicines were those which have been used in healing for many centuries, for 
example thyme, sage, aloe, senna and fenugreek. This is in contrast to Western 
herbal medicine taking where products such as echinacea, ginkgo and garlic 
supplements have gained much media attention regarding their purported effects and 
are now frequently used . 1 06 It appears because of respondents' confidence in herbal 
medicine, that they infrequently inform their medical practitioner and use remedies for 
a wide range of conditions. However, herbal remedies are not without unwanted 
effects and possible interactions. An appreciable proportion of people ( 1 1  % ) reported 
an adverse event whi lst taking a herbal product. However, because most took 
multiple remedies and the survey relied on recall ,  it is almost impossible to establish 
causality. Two cases involved thyme and a reduction in breast milk although this 
appears not to be a documented adverse event. The natural medicines 
comprehensive database states 'there is insufficient reliable information available 
about the safety of thyme when used in medicinal amounts during pregnancy and 
breast feeding' . 1 1 2  From these study findings further investigation seems prudent. 
Reports of herb usage during pregnancy are scarce. Nordeng and Havnenan 1 1 3  
surveyed 400 postpartum women at a Norwegian University Hospital about herbal 
product use. Over a third (36%) reported using herbs during pregnancy, often 
combining several preparations; use increased progressively from the first to the third 
trimester. The authors considered a significant proportion (39%) to be potential ly 
harmful or lacking supporting safety information and concluded that more safety data 
are required . A further Iranian study conducted amongst 447 pregnant women 
reported 52% of women took herbal medicines whilst pregnant. 45 A recent review of 
the safety of traditional Arab herbal medicine recognised the lack of safety data on 
many preparations in common use and the need for further investigation using 
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modern techniques including cell culture.59 These study findings together with th is 
data suggest that further investigation is required. 
The Arab world has always made extensive use of herbs as medicines, drawn from a 
rich inventory of indigenous natural ingredients; indeed, traditional Arab medicine has 
contributed much to the development of modern European medicine. I t  is estimated 
that 200-250 plant species are sti l l  in use.40,56 The cultural beliefs and attitudes to 
herbal medicines have a long history and sti l l  influence choices for self-care, often 
reinforced by consultation with traditional healers, particularly in rural areas; even for 
i l lnesses such as infertil ity, impotence, obesity, epilepsy and psychomotor d isorders. 
The find ings in  this work that 2 1  % of respondents indicated a preference for herbal 
over Western medicine for treating cancer is of concern .  This may be an i l lustration 
of the prevalent trust in traditional medicines discussed above. As d iscussed above, 
the h igh prevalence of herbal medicine taking in the UAE is not an isolated 
occurrence with other Arab countries reporting similar rates. This has important 
health impl ications, as over-rel iance on ineffective herbal remedies could lead to 
deferral of more effective chemotherapy. 
As Azaizeh et al 40 point out, herbal remedies in this region are prescribed by 
'ethnopharmacologists', often based solely on signs and symptoms rather than with a 
ful l  understanding of the disease. Many herbalists are not trained in the field of herbal 
medicine beyond the knowledge passed down from their predecessors and they may 
miss important diagnoses because of this (see Chapter 1 ,  section 1 .9 .5. 1 ). 
The number of people taking herbal and Western medicines together was high . The 
potential for interactions with Western medicines is therefore high. U nfortunately, the 
documentation of herbal / Western medicine interactions is l imited and most 
interactions are based on pharmacological action rather than clinical case reports. 
Furthermore, many subjects were self-medicating with herbal medicines for the same 
problem being treated with Western medicine. If the findings of this study are taken 
as being a true picture of UAE citizen behaviour, then these issues need to be 
recognised by practitioners of Western medicine to ensure patients are not putting 
themselves in unnecessary danger. It could be argued that as Abu Dhabi is very 
prosperous, and in many ways westernised, that patients in  this area are more l ikely 
to use a mixture of traditional herbal medicine and Western medicine compared to 
the less developed rural parts of the UAE. As such, Abu Dhabi and other areas with 
similar population demographics such as Dubai, may present the greatest challenges 
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of prescribing Western medicine against a background of herbal medicine 
consumption. Certainly, Western medicine was generally preferred to herbal 
medicines when respondents were forced to choose between them. This was 
especial ly true for chronic d isease states, although this may reflect the nature of the 
sample as the Rawdha Cl inic suppl ies services are based on Western medicine. 
2.4.1 Study limitations 
This phase of the work did have its l imitations. Firstly, the sample did not reflect 
national statistics. However, this is in part due to the make-up of the UAE. Abu-Dhabi 
is one of seven geographical regions, and along with Dubai, is responsible for most 
of the country's wealth, when compared to some of the more remote regions such as 
Um Al Qiween and Ras Al khaimah. Abu Dhabi therefore attracts younger, better 
educated people with better employment prospects, which accounts for the 
demographic differences between our sample and national statistics. 
Secondly, the cl inic used also served as a mother and child centre which probably 
contributed to the higher number of women being sampled. The study suffered from 
a cultural phenomenon, in that the lead researcher was female and this had a 
negative influence on recruiting men to the study. A change in sampl ing technique 
failed to address the disparity adequately. It is recognised that the absence of a 
disproportionately high number of men might influence the prevalence rates for 
herbal medicine usage-both type and indication. Future studies in this and other 
countries in the region might avoid this problem by using a male interviewer. 
Chi ldren were excluded from the present study; however, it would be interesting to 
extend the investigation to include them. HM use is prevalent among pregnant and 
breastfeeding women too, and the effects of HMs on neonates, infants and chi ldren 
has not been studied extensively. 
This study was l imited to UAE citizens, which are actually a minority in the country 
due to high in-migration of foreign citizens, guest workers and nomadic peoples. 
These too would contribute to the overal l picture of herbal use in the UAE, but lay 
outside our study. 
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Although aimed primarily at determining herbal use prevalence, side effects were 
noted in this study. Respondents volunteered little specific detail but the severity 
prompted one respondent to seek medical attention. Herbal remedies are widely 
considered to be safe and inexpensive but this is often not the case. 
2.4.2 Conclusions 
The major findings from this study are summarised below. 
• 85% (n=279/329) of respondents said they were in good or excellent health; 
• 76% (n=250/330) of respondents had, at some time, taken HMs; 
• 38% (n=94/248) of respondents were currently taking HMs, with 65 different HMs 
being taken to treat 48 conditions; 
• 88% (n=1 98/225) of respondents stated the last HM taken was either effective or 
very effective; 
• 75% (n= 1 8 1 /240) of respondents took HMs on a when needed basis; 
• 78% (n=258/330) of respondents stated that they had at some time taken a HM 
and Western medicine concurrently yet only 37 respondents ( 1 1  %) stated they 
were currently taking HM and Western medicine together; 
• 1 1  % (n=27/240) reported suffering from an ADR; 
• family and friends were by far the greatest influence on respondents in respect to 
purchasing decisions and seeking advice from herbal practitioners; 
• respondents living in rural areas were more likely to use HM and visit a herbal 
practitioner than those from urban areas. 
• disclosure to a doctor about taking HM was uncommon. 
70 
• respondents had confidence in HMs and preferred them to Western medicine on 
the grounds of effectiveness and safety, yet when given a choice between the 
two for certain conditions then Western medicine was preferred. 
This chapter has shown that UAE citizens are very frequent users of herbal 
medicines. The lack of control on product quality, respondent faith in their usefulness, 
together with the wide prevalence of taking prescribed Western medicines whilst self 
medicating with herbal products, raises questions over patient safety. 
2.4.3 Further work 
Prevalence of HM taking within the study population has been established as being 
high. Safety concerns have been raised over their widespread use with little medical 
input or knowledge that people are taking such products. Chapter 3 describes a more 
focussed study of these issues in a secondary care setting. 
7 1  
Chapter Three: 
A study of potential ADRs to herbs in patients with renal disease, 
visiting a hospital nephrology clinic in Sheikh Khalifa Medical City 
(SKMC), Abu Dhabi. 
3 . 1  Introduction 
As mentioned in Chapter 1 ,  herbal medicines (HMs) are popular therapies across various 
communities. Coming from nature, people are still reluctant to l ink them with the risk of adverse 
effects. Many of these products do not require a prescription; thus their use and any potential 
risks may easily escape the physician's or pharmacist's attention. I ncreasing recognition that 
herbs can cause adverse effects or treatment fai lure ,  often through interaction with synthetic 
d rugs, has stimulated interest in herbal medicine safety. 1 14•1 1 5  
ADRs are a common cause of hospital admission and make a significant contribution to 
healthcare costs. 1 1 6 · 1 1 7 ADRs resulting from herb-drug interactions have been identified as 
significant factors responsible for patient morbid ity and mortality. 1 1 8  
With the exception of  the findings in Chapter 2 ,  information on the prevalence of subjectively 
experienced ADRs to HMs and their subsequent burden in the general population is mostly 
lacking in a Middle Eastern setting . In one Swedish study, a cross-sectional mail survey of self­
reported ADRs occurring during a 2-week period of using prescription, over-the-counter (OTC), 
or HMs in a random national sample aged 1 8-84 years was conducted. ADRs were reported by 
6.4% of the total study sample, 1 0.2% of the 2,851 users of prescription drugs, 1 .0% of the 
2 ,862 users of OTC drugs, and 0. 1 % of the 1 ,352 users of herbal drugs. 1 19 
A study conducting face-to-face interviews with 51 5 users of herbal remedies to determine the 
reporting of ADRs to HMs and conventional OTC medicines showed that H M  consumers would 
act differently with regard to reporting an ADR (serious or minor) to their GP depending on 
whether it  was associated with a HM or a conventional OTC medicine. 120 One hundred and fifty 
six (30.3%) respondents said they would consult their GP i rrespective of whether the ADR was 
associated with the use of a herbal remedy or conventional OTC medicine, whereas 221 
respondents (42 .9% ) would not consult their  G P  for a serious ADR associated with either type 
of preparation. One hundred and thirty-four respondents (26.0%) would consult their GP for a 
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serious ADR to a conventional OTC medicine, but not for a similar ADR to a herbal remedy. 
This study indicates that even when HMs cause problems, at least some patients may be 
reluctant to report them to their carers. 
3 . 1 . 1  Potential of HMs to cause serious harm 
Constituents of herbal medicines can be toxic and numerous examples of liver, kidney or other 
organ damage are on record. 1 21 All herbal medicines contain a range of pharmacologically 
active constituents, and users of herbal medicines often combine herbal medicines with 
prescribed drugs; thus herb-drug interactions are a real possibility.1 1 4·1 1 5· 1 1 8 While HMs under 
MoH control are firmly regulated, HMs and dietary supplements imported by the municipalities in 
their thousands, are not submitted to stringent regulation and control. Thus unreliable quality 
can be a problem. In particular, this poses a risk when herbal medicines are contaminated (e.g. 
with heavy metals) or adulterated ( e.g. with prescription drugs ). 121  
Cuzzolin et al 1 22 found that among 1 ,044 women interviewed during a 5-month period in the 
outpatient department of an urban university general hospital ,  491 (47%) reported taking at least 
one herbal compound in the last year; of these, 272 (55.4%) consumed only HMs while 219 
(44.6%) also took conventional drugs. Seventy three different herbal products were used. Forty 
seven of the 491 patients (9.6%) reported side-effects: 22 (4.5%) after taking only HMs and 25 
( 5.1 % ) in combination with conventional medicines. ADRs to HMs reported included 
gastrointestinal upset after dandelion, propolis or fennel ;  cardiovascular problems after liquorice, 
ginseng, and green tea; dermatological eruptions after propolis, thyme, arnica, and 
passionflower; and neurological disorders after guarana and liquorice. Drugs taken in 
association with the HM and potentially involved in adverse reactions were NSAIDs, antibiotics, 
benzodiazepines, antihypertensives and oral contraceptives. In 29 of 47 of cases (61.7%), the 
adverse reaction was not communicated to the doctor; however in five cases, side-effects were 
serious enough to cause hospital admission. 
The potential for serious interactions between conventional medicines and HMs is discussed 
elsewhere in this thesis (see Section 1 .1 3); however several cases resulting in hospitalisation 
are discussed below. 
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An increasing number of cancer patients are using complementary and alternative medicines 
(CAM) in combination with their conventional chemotherapy. A range of HMs has been 
reported to interact with anticancer drugs, including St. John's wort with irinotecan and 
imatinib.1 23 Induction of drug-metabolizing enzymes leading to therapeutic failure is a probable 
mechanism; although this might go unrecognised because treatment failure is common in 
cancer treatment. Wu et al 1 24 report the case of a 67 year-old woman who developed severe 
pancytopenia with initial presentations of vomiting, diarrhoea, oral ulcers and fever about one 
week after taking a 5-day course of Cantharanthus roseus. Bone marrow biopsy showed 
autolysis, which indicated massive necrosis of the haematopoietic cells. There was no 
malignant cell infiltration. The patient also had severe gastrointestinal disturbances, 
bacteraemia, urinary tract infection, and impaired renal and liver function. The authors imply that 
the effects were due to an interaction with the HM resulting in reduced clearance of vinca 
alkaloid chemotherapy . 
The use of herbal supplements by cancer patients in the perioperative period is common and 
consistent with the substantial increase in the use of alternative medical therapies. Different 
HMs or phytomedicine supplements are reported to possess antiplatelet activity , adversely 
interact with corticosteroids and central nervous system depressant drugs, have gastrointestinal 
manifestations, produce hepatotoxicity and nephrotoxicity, and produce additive effects when 
used with opioid analgesics.1 25 
An 87-year-old African-American patient with a history of stage IV-A follicular non-Hodgkin's 
lymphoma, atrial fibrillation, and hypertension and long-term drug therapy consisting of warfarin, 
felodopine, lisinopril-hydrochlorothiazide, controlled-release diltiazem, potassium chloride, and 
oxycodone presented at the accident and emergency department with haematuria and an 
international normalised ratio (INR) of 6.9. After ruling out poor patient compliance and dietary 
changes, the authors discovered that the patient had started taking royal jelly one week 
previously. They stated that the most probable explanation for the patient's elevated INR and 
subsequent bleeding was an interaction between royal jelly and warfarin. 1 26 
Seak and Lin 1 27 report a case of unintentional poisoning from Ruta graveolens, a HM used for 
'heart protection' in a 78-year-old woman in Taiwan. The patient developed bradycardia, acute 
renal failure with hyperkalaemia, and coagulopathy after three days of consuming a decoction 
made from the herb. She required haemodialysis in the emergency department; after which 
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symptoms gradually resolved. The authors suggested that Ruta caused multiple pathologies in 
their patient. 
Chang et al 1 28 assessed the prevalence of adrenal dysfunction and any relation to prior HM use 
in a Taiwanese hospital emergency department. Thirty adult patients with sepsis or acute 
myocardial infarction (AMI) were eligible for the study; 23 (77%) were suffering from severe 
sepsis and the other seven (23%) had an AMI. Thirteen of the 30 patients (43%) had serum 
cortisol levels of <15micrograms/dL, consistent with adrenal insufficiency: nine with severe 
sepsis and four with an AMI. Eight (62%) of the 13 patients with low cortisol levels reported 
using HMs, while only two ( 12%) of the 17 with normal cortisol levels reported taking them. Only 
two ( 15%) of the patients with low cortisol levels failed their corticotropin stimulation test, 
suggestive of true adrenocortical insufficiency. Both reported using herbal preparations. The 
authors concluded that while adrenal dysfunction was common among critically ill patients seen 
in the emergency department, the use of HMs was high in patients with low serum cortisol. 
HMs have been associated with serious end-organ damage resulting in hospitalisation; 1 29•133 
indeed, several traditional HMs, notably kava 1 29•1 34 are banned in most countries because of 
this. Never-the-less, new reports involving novel HMs keep emerging. Rifai et al 135 reported the 
case of a 58-year-old male patient who was admitted because of developing severe acute 
hepatitis caused by ingestion of a Che/idonium (celandine)-containing preparation, which was 
thought to be responsible for the hepatitis. This was corroborated by resolution of liver function 
tests upon de-challenge. Savvidou et al 1 36 reported two cases of Teucrium po/ium (golden 
remander)-induced hepatitis in two Greek female patients, who used the plant extract to control 
cholesterol levels. Both patients presented with very high aminotransferases after consuming 
tea made from the herb for two or three months. One patient also developed jaundice. 
Histological examination of liver biopsies showed hepatitis with moderate or severe necro­
inflammatory activity. Discontinuation of the herbal remedy resulted in normalisation of the liver 
enzymes in both patients. A similar reaction to this herb in a 70 year-old farmer using it as a 
hypoglycaemic aid, was also reported by Starakis et a/.137 
In summary, the use of HMs is not without risk. They can cause serious ADRs when used alone 
but also have considerable potential for important drug interactions. Most evidence is anecdotal 
and there is little pharmacoepidemiological information on the extent of the problem. Chapter 2 
has shown that UAE citizens routinely use HMs alongside modern medicine. There is no data at 
the present on the safety of such herbal medicines taken by the public irrespective of whether 
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they are patients or healthy individuals. Phase two of this research attempted to explore the 
extent of the perceived problem in the context of patients visiting a single clinic at the hospital 
where the author was employed as a researcher. 
3.1 .2 Research aim 
The aim of this research was to conduct a pilot study of adverse reactions to herbal medicines 
within the controlled environment of a tertiary clinic in the Abu Dhabi Emirate Sheikh Khalifa 
Medical City (SKMC). 
3.1 .3  Research objectives 
1. To provide qualitative and quantitative data on the safety of herbal medicines in SKMC 
patients and to determine the health risks involved with their use. 
2. To identify herbal ingredients, interactions, and outcomes of their use or misuse. 
3. 1 .4 Subsidiary Study Questions 
1 .  To describe the different types and causes of herbal ADRs 
2. To estimate the risks anticipated from taking herbal medicines with and without Western 
medicines. 
3. To identify risk factors which predispose an individual to herbal adverse reactions. 
4. To estimate the incidence rate and magnitude of health risk associated with herbal use 
in the study population. 
3.2 Methodology 
3.2.1 Introduction 
Several options were considered for this stage of the research; alternatives are discussed in 
Chapter 4 under 'Suggestions for future work'. The final choice of method was a pragmatic one, 
based on availability, proximity and what the author was permitted to do at the time of the study. 
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either on admission or visiting the outpatient departments might yield quality information on 
herbal use and potential risks, because the author would have access to full patient records and 
be in a position to develop her interviews, used in Phase 1 of the research, to question subjects 
in-depth about their use of and attitudes to HMs. 
An initial thought was to approach a private hospital, the New Medical Centre (NMC) in Abu 
Dhabi. The latter is one of the busiest private hospitals in Abu Dhabi. Choice was based on its 
size (seeing over 2,000 outpatients per day) and the fact that it employed over 100 physicians 
who might be recruited to assist with the study. In April 2006, a meeting was held between the 
author, the Head of Research and Medical Director of NMC to explore these possibilities. 
Unfortunately it was decided not to progress the research at NMC for the following reasons: 
1. NMC hospital did not have a computerised information system for medical records; 
2. there was no formalised system for reporting ADRs; and, 
3. most emergency cases were referred to public hospitals (such as SKMC which is the 
biggest public hospital in Abu Dhabi City). 
To circumvent most of the problems described above, the focus of the research then turned to 
the largest public hospital in Abu Dhabi : the Sheikh Khalifa Medical City. 
3.2.2 The Sheikh Khal ifa Medical City (SKMC) 
SKMC receives the highest number of public patients in Abu Dhabi City and provides a 
comprehensive network of health care facilities and services. The overall strategy of SKMC is to 
improve the current status of healthcare delivery by expanding its services and technology, 
upgrading and improving the physical condition of its existing facilities, combining its health care 
resources for a more efficient model of healthcare delivery, increasing its current bed capacity to 
accommodate the needs of its patients, and creating a system for health care professionals to 
work as one team within SKMC, under the guidance of the Abu Dhabi Health Authority. SKMC 
employs approximately 4,000 staff with an overall capacity of 520 beds. The centre was 
inaugurated officially in March 2,000 and identified as the most frequently used specialist centre 
in the country for major, complicated cases and critical emergencies. SKMC has a wide range of 
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specialist departments, including cardiology, renal and hepatic units and a busy accident and 
emergency department. 
3.2.3 Establ ish ing the project at SKMC 
In August 2006 , a letter outlining the research scope and objectives was sent to SKMC; 
subsequently, a meeting was held between the author, the SKMC Medical Director and Chair of 
the Medicine Department. Provisional support for the study was obtained, subject to the 
following conditions: 
1. The project would require ethics approval and scrutiny by the SKMC Institutional Review 
Board ( I RB). 
2. A co-investigator should be appointed who is a member of the consulting staff at SKMC; 
subsequently, the Head of the Nephrology Clinic was appointed as co-investigator for 
this study. 
3. Consent forms for the patient participation portion of the study should be vetted. 
4. The Department of Medicine would arrange the appropriate physician contacts. 
5. Access to medical records and research space in the Medical Records Department 
would be arranged. 
From the meeting with the Medical Director, it was emphasised that: 
• although prescribing HMs was not integrated in clinical practice at SKMC, patients would 
be questioned about their herbal use from other prescribers or self treatment and if they 
experienced any ADR to a HM. 
• patient files were not fully integrated electronically, and most of the patient information 
and case details were not available online; however patient files could be checked 
manually. Laboratory results were accessible electronically. 
• informed consent and confidentiality of patient data would be rigorously pursued. 
• it was recommended that the nephrology division might be a suitable environment for the 
study. 
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The fatter point was agreed between the author and her project supervisors and the Head of the 
Nephrology Division was approached by the author and the project proposal introduced, in May 
2007. This met with an enthusiastic response and a further meeting was arranged with other 
p hysicians in the Division to again, outline the project, including a summary of the results from 
Phase 1 (see Chapter 2). 
3.2 .3 . 1  The SKMC Nephrology Divis ion 
At the time of the study, the Nephrology Division at SKMC received approximately 500 
outpatient clinic visits per month in addition to regular visits from chronic dialysis patients (over 
200 patients on haemodialysis and 20 patients on peritoneal dialysis). The Nephrology 
outpatient clinic employed 3 nurses and usually 2-3 physicians in each shift (9am -12 noon and 
1 pm -5 pm) to see patients from Sunday to Wednesday each week. The Division was a busy 
but friendly environment in which to conduct the research ,  with ample opportunity to interview 
patients as well as access their records. 
3.2.3.2 Nurse recru itment 
The author met with the nurse in charge of the nephrology outpatient clinic and a group of 
nurses employed within the nephrology division, to discuss the project aims and methodology 
and seek their support in providing access to interview patients. The nursing staff helped by 
providing a visit schedule and a private, quiet room for conducting interviews. Recent patient 
attendance records were useful in determining the logistics for the investigation. The author also 
met with the nurse in charge of the dialysis unit where an estimate of patient numbers for the 
study was made. 
3.2.3.3 Interviewer assistant recruitment 
Due to the work involved, it was decided to recruit assistants to help with interviewing patients, 
medical review and data entry. Assistants were already employees at SKMC and were trained 
for two weeks prior to study entry to conduct the interviews and collect data to the same 
standard as the author. The author ensured that these assistants were aware of the aims, 
objectives, methodology and ethical issues of the project and were under her direct supervision. 
A total of six assistants were used: three qualified pharmacists and three final year pharmacy 
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3.2.4 Data capture form 
A data capture form was designed for the study and piloted in the first five subjects. The form 
contained an adapted version of the ADR form proposed for use, but not yet implemented by 
the UAE Ministry of Health for recording ADRs to conventional medicines. The data capture 
went through several iterations and formed part of the ethics application. A final version of the 
form, together with covering information and consent sheets, is included in Appendix 3.1. Space 
was provided for patient demographic detail and recording their primary diagnoses, 
conventional and herbal medicines taken and supporting laboratory data, if available. A data 
validation form was incorporated to complete when checking the patient's medical notes. 
3.2.5 Eth ical Issues 
The study was approved by SKMC institutional review board (IRB) on Feb. 28, 2007. The 
application included a full protocol for the study and a patient, informed consent form written in 
English and Arabic languages. This indicated that patients had the choice to participate in the 
survey and that they could withdraw at any time without prejudice. 
Patients were required to sign the informed consent form prior to interview and accessing their 
medical records. The consent form was to be retained by the author for at least six years from 
the end of the study. 
Confidentiality was assured by assigning a unique, anonymous study number to each patient, 
which was used to identify individual data sets. Data was stored securely either in a locked 
cabinet within a locked room or in the case of computerised data on a password protected 
desktop computer at the same location. Only the author and her supervisors had access to the 
coded data. 
3.2.6 Study Design 
A prospective, 3-month, cohort study followed all patients presenting at the SKMC nephrology 
department either as outpatients or for renal dialysis. 
Inclusion criteria were: 
1 .  UAE Nationals or residents, capable of understanding English or Arabic and responding 
to questioning; 
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2. patients aged 13 years or over. Younger patients attended a separate Paediatric Clinic. 
Exclusion criteria were : 
1. non-nationals/ non-residents who were on a short visit visa; 
2. persons incapable of understanding English or Arabic; 
3. children aged below 13 years. 
3.2.7 Detai ls of Methodology 
The principal investigator (the author) or one of her assistants approached all patients visiting 
the clinic to assess suitability for inclusion in the study (see above). Nurses in charge provided 
daily lists of patients attending the clinic and dialysis units to the author. The list included age, 
gender, nationality details and patients' SKMC record numbers. 
Included patients were approached for informed consent and once consented, were surveyed 
using a structured questionnaire described in Section 3.2.8.1 (see also Appendix 3.1 ). 
Interviews took place in a private room in the outpatient clinic; or by the patient's bed on the 
dialysis ward. The questionnaire was administered in Arabic or English according to preference. 
Specific questions were asked about whether the patient had experienced any ADRs and 
whether they felt they were related to the HM they were taking (if any). A list was compiled of 
the prescription medicines (PMs) and HMs that each patient was taking or had recently taken (in 
effect, a conventional drug history). 
If necessary, when an ADR (herbal or otherwise) was identified, the author contacted the 
medical team to facilitate completing an ADR report using the form shown in Appendix 3.1. 
3.2.7. 1 Assessing ADR causality 
Once a suspected ADR was detected, the author prepared a case study, including all the 
information on that particular patient, background published information on the pharmacological 
action(s) of each medicine taken (both PM and HM) and any previous reports of toxicity. 8 1  
An assessment of causality was through consensus of a panel, consisting of the author, a 
professor of pharmacology and therapeutics and a nephrologist teaching physician based in the 
Faculty of Medicines and Health Sciences, UAE University. 
Decisions were assisted by use of the algorithm developed by Naranjo et al. 1 38 This is widely 
used in research involving ADRs with conventional medicines, 139•145 and has been applied to the 
assessment of herb-drug interactions. 146 The elements of the original Naranjo and a modified 
version also used by the author are shown in Table 3.1. 
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Original Questions 
1 .  Are there previous conclusive reports on this reaction? 
Yes (+1) No (0) Do not know or not done (0) 
2.  Did the adverse event appear after the suspected drug 
was given? 
Yes (+2) No (- 1) Do not know or not done (0) 
*3. Did the adverse reaction improve when the drug was 
discontinued or a specific antagonist was given? 
Yes (+1) No (0) Do not know or not done (0) 
*4. Did the adverse reaction appear when the drug was re­
administered? 
Yes (+2) No (- 1) Do not know or not done (0) 
5. Are there alternative causes that could have caused the 
reaction? 
Yes (- 1) No (+2) Do not know or not done (0) 
*6. Did the reaction reappear when a placebo was given? 
Yes (-1) No (+1) Do not know or not done (0) 
*7. Was the drug detected in any body fluid in toxic 
concentrations? 
Yes (+1) No (0) Do not know or not done (0) 
*8. Was the reaction more severe when the dose was 
increased or less severe when the dose was decreased? 
Yes (+1) No (0) Do not know or not done (0) 
*9. Did the patient have a similar reaction to the same or 
similar drugs in any previous exposure? 
Yes (+1) No (0) Do not know or not done (0) 
• 9 = definite ADR: 5-8 = probable ADR; 1-4 = 
possible ADR; 0 = doubtful ADR 
Modified Questions 
1 .  Are there previous conclusive reports on 
this reaction? 
Yes (+ 1) No (0) Do not know or not done (0) 
2. Did the adverse event appear after the 
suspected drug was given? 
Yes (+2) No (- 1) Do not know or not done (0) 
3. Are there alternative causes that could have 
caused the reaction? 
Yes (- 1) No (+2) Do not know or not done (0) 
Modified score (suggested by researcher ) 
• 5 = definite ADR 
• 3-4 = probable ADR 
• 1-2 = possible ADR 
• 0 = doubtful ADR 
*These questions in the original Naranjo 
algorithm would all have scored zero in the 
present study due to its nature. They were 
therefore omitted from the modified scoring 
system used by the author. 
Table 3.1 Key elements of the Naranjo causality assessment algorithm and the modified 
algorithm used by the author. 
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3.2 .  7 .2  Pi lot study 
The author conducted a pilot study of 15 subjects (5 females and 10 males) in the outpatient 
nephrology clinic at the start of the main study, to ensure that the questions and method of 
surveying were appropriate and understandable and whether patient identification and follow-up 
were practical. The interview took approximately 10 minutes to administer with most patients 
although some took up to 20 minutes. With the exception of having to include more space on 
the data col lection form to record patient medicines, few problems were encountered with the 
methodology and these 15 patients were included in the main study. 
3.2.8 Main study methodology 
3 .2 .8 .1  Interview schedule 
Patients were recruited and interviewed over 13 weeks between June 17th and September 13th, 
2007. The strategy for the patient interviews is detailed below. 
1 .  The investigator checked the patients' schedule of visits with the nurses to find out how 
many patients were attending. 
2. The nurse or investigator invited the selected patient to the interview room. 
3. The investigator introduced herself and the project, then explained the focus on individual 
HM and PM use (if any). 
4. The investigator assured the patient that what they said would not affect their medical care 
treatment plan and that the project was general research into the topic. 
5. The investigator then asked for signed informed consent. 
6. Once consent was obtained, the investigator started by asking the patient about their herb 
use and whether they were currently taking any. Also whether they had used HMs before 
becoming i l l ,  how often and what for. Patients were also asked the same questions about 
any PMs they were taking. 
7. The investigator then asked if the patient had ever experienced any discomfort or adverse 
drug event during their use of HMs or PMs. If taking HMs, the patient was asked if they 
had told their doctor that they were taking them. 
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8. After the investigator had finished the interview, she thanked the patient for their time, and 
in her capacity as a pharmacist explained the importance of checking with their doctor and 
pharmacist before taking any non-prescribed medicines or herbal supplements. 
9. All data was recorded on the data collection form shown in Appendix 3. 1 .  
10. Patients were also asked for any herbal samples, e.g. empty bottles or packs, to record 
the preparation and ingredients from the label. This was important for data validation and 
assessment of ingredients and their quality. 
1 1 . As this was a longitudinal study, the investigator cross-checked the identity of each 
interviewee between the outpatient and dialysis unit patient lists to ensure that no patient 
was interviewed twice. 
3.2.8.2 Medical Review 
After the interview stage a review of the patient's medical records, drug charts and laboratory 
data was cond.ucted. All were traced using the patient's unique hospital record number. Medical 
review with the patient's attending doctor was conducted for every tenth record to validate the 
methodology. 
The following procedure was used by the investigator when reviewing medical records. 
1. The author gave the list of SKMC file numbers for review to the officer of the Medical 
Records Department. 
2. The patient survey list, medical file numbers, patient name and signed consent form were 
cross-checked for consistency. 
3. Details collected during the patient interview were validated and supplemented with that 
in the medical record including, where applicable, the patient's diagnosis(es), PMs and 
HMs taken ( if recorded). 
4. Results of laboratory tests were also recorded. 
5. All available information sources were cross-checked, including physicians' notes, and 
drug charts from nephrologists / other physicians, regardless of specialty. 
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6. Details of possible ADRs were noted. 
7. The author signed and dated the survey cover sheet and made a record of the numbers 
of all SKMC fi les reviewed. 
3.2.8.3 Data Entry and Analysis 
All data were coded as a series of variables matching the fields of the data collection form and 
manipulated and analysed using SPSS version 16. All data were validated by the author after 
entry and before analysis. 
Appropriate statistical analyses were conducted after advice from the author's local supervisor, 
Prof. Mohamed Bani Yas, Vice Dean of the Faculty of Medicine and Health Science (FMHS) at 
UAE University. The data were also discussed with Prof. Nico Nagelkerke, Professor of 
Statistics, also of FHMS. Various analyses were conducted using a variety of statistical tests, 
depending on the level and distribution of the data. Tests used are detailed in appropriate 
sections of the results. 
The strength of ADR causality was assessed by the Naranjo algorithm.1 38 
3.2.9 Quality Assessment of the Outputs 
Where a potential ADR to a HM was identified, corroboration was sought using systematic 
literature searches of standard world medical l iterature, including Medline, PubMed, and the 
WHO-EMRO database. Experts in the field were contacted from the UAE Ministry of Health, 
SKMC, and the Faculty of Medicine and Health Sciences (FMHS), UAE University. 
3.3 Results 
Five hundred and eight patients were interviewed in the outpatient clinic and 180 in the dialysis 
unit were included in the study (n=688). An additional 42 patients were excluded (15 
outpatients and 27 on dialysis) because they could not understand either English or Arabic, 
were very sick, unconscious, had mental il lness or were extremely confused. An additional 13 
patients declined to participate in the study ( 10 outpatients and 3 on dialysis). 
86 
3.3 .1  Demographics of Participants 
The demographic profile of participants is shown in Table 3.2. Subjects were grouped into male 
(58.9%, n=405/ 688) and female (41 . 1%, n=283/688). All age groups over 1 2  years old were 
represented with fewer by proportion, less than thirty or greater than 70 years old. Over half of 
patients were UAE nationals. 
The demographic profile of participants who said they were currently using herbs was similar to 
that of those who were not in terms of gender (Chi2=3.646, p=0.056) and age distribution 
(Chi2=4.057, p=0.669). However, there was a significant difference in terms of Nationality 
(Chi2= 1 8.9, p<0.001 )  where there were more Nationals in the herb-using sample. 
Parameter Total Sample Current herb users 
(n and % values) (n and % values) 
(n=688) (n=468) 
Gender 
Male 405 (58.9%) 264 (56.4%) 
Female 283 (4 1 . 1%) 204 (43.6%) 
Age Distribution (years) 
Less than 18 24 (3.5%) 1 8  (3.8%) 
1 9-29 69 ( 1 0%) 45 (9.6%) 
30-39 1 1 3 ( 1 6.4%) 80 ( 17. 1%) 
40-49 1 1 8 ( 1 7.2%) 75 ( 1 6%) 
50-59 195 (28.4%) 140 (30%) 
60-69 108 ( 1 5.7%) 7 1 (1 5.2%) 
Above 70 60 (8.7%) 39 (8.3%) 
No reply 1 (0. 1%) 
Nationalities 
UAE Nationals 402 (58.6%) 291 (62.2%) 
Arab Nationalities 1 82 (26.5%) 1 26 (26.9%) 
Asian Nationalities 95 (1 3.8%) 44 (9.4%) 
Western Nationalities 7 ( 1 .0%) 7 (1 .5%) 
No reply 2 (0.3%) 
I 
Table 3.2 Demographics of patients in the study. 
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3 .3 .2 HM - taking Practices of Participants 
The HM taking practices of patients are shown in Table 3.3. 
The sample could be divided into those who had taken herbs at some time (80.7%, n=555/688) 
and non-herb users ( 1 9.3%, n= 1 33/688). 
Four hundred and sixty-eight patients (68. 1 %, n=468/687) said they were currently taking herbal 
medicines; 499 from the total sample (72.6%, n=499/687) said they had used herbs before they 
became ill, while 439 patients currently taking herbs (93.8%, n=439/468) said they used them 
before they got sick. 
Three hundred and sixty-five (65.8%, n=365/555) patients exposed to herbs at any time had 
used HMs while taking prescription medicines, while 329 patients (70.3%, n=329/468) were 
currently using HMs while taking prescription medicines. 
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Total sample Current herb users 
Question (n and % values) (n and % values) 
I 
(n=688) (n=468) 
! Patient taking herbal medicines, 
I either now or in the past. 
Yes 555(80.7%) 468 (100%) No 133 (19.3%) 
Is the patient currently using herbs? 
Yes 468 (68.1%) 468 (100%) 
No 204 (29.7%) 
No answer 16 (2.3%) 
Did pat ients use herbs before they 
becam e  i l l? 
499 (72.6%) 439 (93.8%) 
Yes 171 (24.9%) 24 (5.1%) 
No 18 (2.6%) 5 (1.1%) 
No answer 
Patients using herbal medicines 
whilst taking prescription medicines 
Yes 365 (53.1%) 329 (70.3%) 
No 99 (14.4%) 66 (14.1%) 
Patients don't take H M 133 (19.3%) 0 (0%) 
No answer 91 (1 3.2%) 73 (15.6%) 
Table 3.3 Herb taking practices of participants. 
Over two thirds of patients who were either taking or had used HMs in the past (69%, 
n=383/555) said that they did not inform their doctor or pharmacist that they were using herbal 
medicines, while 66 patients (11.9%, n=66/555) claimed they did. Of those patients currently 
taking herbs, 327 (69.9%, n=327/468) said they had not informed their doctor or pharmacist 
while 57 patients (12.2%. n=57/468) claimed they did. 
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Of the total sample, 16.6% (n=114/688) said they had visited a herbal centre recently, while in 
the patients currently taking herbs, this rose to 20.3% (n=95/468). Also, in the total sample, 17% 
(n=117/688) said they had taken HMs with OTC medicines; which was mirrored In the cohort 
currently taking HMs ( 17.7%; n=83/468). 
Of the total sample, 62.6% (n=431/688) said they. were currently visiting hospitals other than 
SKMC, while 64. 1 % (n=300/468) of those currently taking HMs did the same. In addition, 27.1 % 
of the total sample ( n= 187 /688) said they were visiting clinics other than the nephrology clinic, 
within SKMC and receiving medicines from them. In comparison, 29.7% (n=139/468) of those 
currently taking HMs were visiting other clinics within SKMC. 
3.3.3 Diseases suffered by study participants. 
3.3 .3. 1  M ost common diseases other than renal .  
Table 3.4 summarises the most common conditions suffered by the total sample of patients 
(n=688) and in those currently taking herbs (n=468). 
Most common diseases In total sample (n=688)* In sample currently taking 
< 
herbs (n=468)* 
Hypertension 341 (49.6%) 283 (60.5%) 
Diabetes 217 (31 .5%) 179 (38.2%) 
Dyslipidemia 105 (1 5.3%) 93 (19.9%) 
Anaemia 47 (6.8%) 41 (8.8 %) 
Table 3.4 Most common diseases other than renal, suffered by patients in the study. 
*Totals add up to greater than n because some patients had more than one disease. 
3.3.3.2 M ost common renal diseases suffered 
The specific renal diseases suffered by patients who were currently taking herbs (n=468) is 
shown in Table 3.5. 
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Renal condition Current herb users (n=468) 
Renal transplant 121 (25.9%) 
Receiving dialysis 102 (21.8%) 
Other nephrological diagnoses 245 (52.4%)* 
Chronic kidney disease 81 (17.3%) 
End stage renal disease 71 ( 1 5.2%) 
Proteinuria 64 (28.2%) 
Nephropathy 37 (7.9%) 
Renal Failure 18 (3.8%) 
Microalbuminuria 17 (2.6%) 
Haematuria 12 (5.2%) 
Renal Impairment 8 (1.7%) 
Renal Stones 8 (1.7%) 
Urinary tract infection 6 ( 1 .3%) 
Nephrotic syndrome 5 (1.1%) 
Polycystic kidney disease 3 (0.6%) 
Systemic lupus erythematosus 3 (0.6%) 
Table 3.5 Renal diseases suffered by patients currently taking herbal medicines. 
*Other nephrological diseases total more than 245 because some patients had more than one condition. 
Patients suffered from a range of diseases (Table 3.4) in addition to their kidney-related 
diagnoses (Table 3.5 ). Some patients had multiple co-morbidities. The distribution of major 
morbidities did not change appreciably between those not currently taking herbs and those 
currently taking them (Chi2=2.616; p=0.455). No association between the diseases listed and 
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HM use is implied from this data, but it serves to illustrate that a wide range of herbs were being 
used in a wide range of conditions. Suspected ADRs to HMs are discussed in Section 3.3.6. 
3.3.4 Medicine taking characteristics of study patients. 
3.3.4. 1 Herbal medicines taken 
More than 100 different herbal preparations were mentioned by the study patients. A list of the 
most commonly cited by five or more subjects is shown in Table 3.6 for the 468 who were 
currently taking herbs and the 555 who were taking or who had taken HMs - referred to as the 
all-time herb user group. 
The first 16 herbs ranked the same between the two groups; there were minor differences in 
ranking thereafter. Some respondents said they were taking a 'mixture of herbs' and some 
patients were taking two 'mixtures of herbs' (52 in the all-time user groups and 4 in the current 
user group, making total numbers of herbal mixtures of 219 and 14 7 respectively). Fifty-nine of 
167 (35.3%) subjects from the all-time herb group and 50 of 143 (35%) subjects currently taking 
herbs could not identify any of the ingredients of these mixtures by name. The identifications 
that were possible are shown in Table 3.7. This shows the wide variety of herbs taken in mixture 
form and in over one third of cases, the subject's lack of knowledge about their exact content. 
Table 3.8 shows the varying numbers of herbal preparations taken by subjects. The mode was 
three preparations, but there was a wide range with 224 (47.9%) of those who said they were 
currently taking herbs, taking four or more preparations. 
When validating reported herb use against the patient medical records, just two patients had 
anything about herbs written by their doctors. Only one recorded the patient taking an OTC 
medication. There were no records of patients having visited a herbal centre or experienced any 
discomfort or reaction to a herbal preparation. 
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Herb Common herbs for all-time Herb Common herbs for 
herb users current herb users 
(n = 555)* (n = 468)* 
Ginger 270 (48.6%) Ginger 238 (50.9%) 
Thyme 207 (37.3%) Thyme 179 (38.2%) 
Peppermint 198 (35.7%) Peppermint 177 (37.8%) 
M ixture of 167 (30.1%) Mixture of herbs 143 (30.6%) 
herbs 
Fenugreek 161 (29.0%) Fenugreek 143 (30.6%) 
Black seeds 136 (24.5%) Black seeds 118 (25.2%) 
Senna 1 13 (20.4%) Senna 90 (19.2%) 
Cardamom 72 (13.0%) Cardamom 67(14.3%) 
Anise 56 (10.1%) Anise 52 (1 1.1 %) 
Sage 56 (1 0.1%) Sage 49 (10.5%) 
Chamomile 52 (9.4%) Chamomile 47 (10.0%) 
Karkadeeh 50 (9.0%) Karkadeeh 45 (9.6%) 
(Hibiscus) 
Herbal tea 46 (8.3%) Herbal tea 36 (7.7%) 
Cinnamon 31 (5.6%) Cinnamon 26 (5.6%) 
Teucrium 26 (4.7%) Teucrium 19 (4.1%) 
Asafetida 18 (3.2%) Asafetida 16 (3.4%) 
Red seeds 18 (3.2%) Parsley 15 (3.2%) 
Aloe 16 (2.9%) Red seeds 14 (3.0%) 
Cumin 16 (2.9%) Cumin 13 (2.8%) 
Parsley 16 (2.9%) Aloe 10 (2.1%) 
Myrrh 12 (2.2%) Myrrh 10 (2.1%) 
Arabic gum 10 (1 .8%) Saffron 10 (2.1%) 
Saffron 10 (1.8%) Arabic gum 8 (1.7%) 
Ayurvedic 8 (1.4%) Curcumin 6 (1.3%) 
Herbal 7 (1.3%) Fennel 6 (1.3%) 
medicine 
Fennel 6 (1.1%) Garlic 5 (1 .1%) 
Curcumin 5 (0.9%) 
Curry 5 (0.9%) 
Garlic 5 (0.9%) 
Moringa 5 (0.9%) 
paregrina 
Red pepper 5 (0.9%) 
Table 3.6 Herbs taken by five or more patients in the study. 
·Total citations are greater than the number of patients because many patients were taking several 
HMs .  
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All-time.herb users Current herb users 
Patient identification of main 
ingredients in 'mixtures of herbs' (n = 555) (n = 468) 
taken. 
From 219 total mixtures From 143 total mixtures 
Unidentified 59 (26.9%) 53 (37.1 %) 
Mixture of herbs containing black 
seed 26 (11.9%) 19 (13.3%) 
Mixture of herbs containing 21 (14.7%) 
fenugreek 26 (11.9%) 
Mixture of herbs containing ginger 18 (8.2%) 11 (7.7%) 
Mixture of herbs containing honey 14 (6.4%) 11 (7.7%) 
Mixture of herbs containing 7 (4.9%) 
peppermint 14 (6.4%) 
Mixture of herbs containing thyme 12 (5.5%) 8 (5.6%) 
Mixture of herbs containing senna 12 (5.5%) 10 (7.0%) 
Mixture of herbs containing anise 7 (3.2%) 3 (2.1%) 
Table 3. 7 Patient identification of main ingredients in 'mixtures of herbs' taken. 
Number of herbal All-time herb users Current herb users 
medicines taken by an 
(n = 555) (n= 468) individual 
1 herb 79 ( 14.2%) 60 ( 1 2.8%) 
2 herbs 95 ( 1 7. 1 %) 80 ( 1 7. 1 %) 
3 herbs 1 13 (20.4%) 99 (21 .2%) 
4 herbs 93 ( 1 6.8%) 76 ( 1 6.2%) 
5 herbs 74 ( 1 3.3%) 67 ( 14.3%) 
6 herbs 58 ( 1 0.5%) 52 ( 1 1 . 1 %) 
7 herbs 1 4  (2.5%) 1 3  (2.8%) 
8 herbs 1 5  (2.7%) 1 2  (2.6%) 
9 herbs 2 (0.4%) 2 (0.4%) 
1 0  herbs 0 (0%) 0 (0%) 
1 1  herbs 1 (0.2%) 1 (0.2%) 
12 herbs 1 (0.2%) 1 (0.2%) 
Not determined 1 0  ( 1 .8%) 5 ( 1 .0%) 
Table 3.8 Numbers of herbal medicines taken by individual patients. 
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3.3 .4.2 Prescription medicines taken. 
Patients were taking a wide range of PMs; the numbers of PMs taken by individual patients is 
summarised in Table 3.9. The mode was seven medicines, but there was a wide range, with 
153 (32.7%) patients currently taking herbs, taking more than seven PMs. 
Approximately half (52.5%, n=246/468) the current HM users could not remember the names of 
any of the PMs they were taking, but approximately one third (35%, n=164/468) could 
remember all their PM names. Thirty-nine (8.3%) could remember some of the names of their 
PMs. In contrast, almost all of the patients currently taking herbs could recall all the names of 
their individual HMs (95.1 %, n=445/468) with the remainder (4.9%, n=23/468) having partial 
recall. 
Number of prescription All-time herb users Current herb users 
medicines taken by an (n = 555) {n= 468) 
individual 
1 PM 34(6.1%) 28 (6.0%) 
2 PMs 49(8.8%) 45(9.6%) 
3 PMs 35(6.3%) 27(5.9%) 
4 PMs 35(6.3%) 31 (6.6%) 
5 PMs 48(8.6%) 45(9.5%) 
6 PMs 49(8.8%) 46(9.8%) 
7 PMs 61 (11 .0%) 51 (10.9%) 
8 PMs 47(8.5%) 42(9.0%) 
9 PMs 45(8.1%) 36(7.7%) 
10 PMs 35(6.3%) 30(6.4%) 
11 PMs 28(5.0%) 26(5.6%) 
12 PMs 10(1.8%) 7(1.5%) 
13 PMs 8(1.4%) 7(1 .5%) 
1 4  PMs 7(1.3%) 5(1 .1 %) 
Not determined 64 (11.5%) 42 (7.6%) 
Table 3.9 Numbers of prescription medicines taken by individual patients. 
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3.3.5 Biochemical measurements in patients taking HMs. 
It was of interest to characterise the biochemistry of patients currently taking HMs in the sample. 
This is  shown in Table 3.10, where patients are classified as having high, low or normal levels of 
the parameter in question. Normal ranges are quoted from the SKMC biochemistry laboratory 
manual, current at the time of the investigation. 
As expected for these patients, many showed signs of their kidney disease in terms of raised 
serum creatinine, urea, bilirubin and uric acid levels. Further evidence of kidney function 
deterioration was implied by reduced serum albumin and haemoglobin and decreased 
creatinine clearance. Markers for related diseases such as dislipidaemia (high cholesterol) and 
diabetes (raised fasting blood glucose) were also apparent. 
When comparing the glomerular filtration rates of patients, classified according to renal 
impairment stage, based on the National Kidney Foundation criteria, 1 47 some interesting 
differences between those taking herbs and those not taking herbs were observed (see Table 
3.11 ). 
Laboratory parameter Current herb users All-time herb users 
(n and % values) (n and % values) 
n=468 n=555 
Serum creatinine (n=429)* (n=512) 
Low 14 (3.3%) 1 7(3.3%) 
Normal ( 53- 106 µmol/J ) 1 2 1  (28 .2%) 1 36 (26.6%) 
H igh  294 (68.5%) 359 (70. 1 %) 
Creatin ine clearance (n=54) (n=62) 
Low 32 (59.2%) 37 (59 .7%)  
Normal (85-1 25 ml/min) 1 1  (20.4%) 14 (22.6%) 
H igh 1 1  (20.4%) 1 1  ( 1 7 .7%)  
Blood urea (n=431 ) (n=512) 
Low 1 1  (2.5%) 1 1  {2. 1 %) 
Normal (2.5-6 .5 mmol/I) 1 52 (35.3%) 1 72 (33.6%) 
H igh 268 (62.2%) 329 (64.3%) 
· Serum albumin (n=356) (n=427) 
Low 1 6 1  (45.2%) 205 (48%) 
Normal ( 35-50 g/I )  1 95 (54.8%) 222 (52%) 
High 0 (0%) 0 (0%) 
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Serum bi lirubin (n=308) (n=376) 
Low 0 (0%) 0 (0%) 
Normal (5-2 1  µmol/I) 287 (93.2%) 352 (93 .6%) 
H igh 2 1  (6.8%) 24 (6.4%) 
Haemoglobin (n=415) (n=492) 
Low 1 51 (36.4%) 1 90 (38.6%) 
Normal ( 1 1 5- 1 55 g/1) 244(58.8%) 281 (57. 1 %) 
High 20(4.8%) 21 (4 .3%) 
Cholesterol (n=31 1 )  (n=363) 
Low 33 ( 10.6%) 42 ( 1 1 . 6%)  
Normal (3- 5.2 mmol/I) 2 1 1 (67.8%) 249 (68.6%) 
H igh 67 (21 .5%) 72 ( 1 9 .8%) 
Glucose (fasting) (n=364) (n=421 )  
Low 7 ( 1 .9%) 7 ( 1 .3%)  
Normal (3.9-6 nmol/I) 1 92 (52.7%) 358 (85%) 
High 1 65 (45.4%) 60 ( 14.3%) 
Uric Acid (n=227) (n=257) 
Low 6 (2.6%) 7 (2.7%) 
Normal (200- 4 1 5  mmol/I )  142 (62.6%) 1 59 (61 .9%) 
High 79 (34.8%) 91 (35.4%) 
ALP (n=320) (n=390) 
Low 6 ( 1 .9%) 7 ( 1 . 8%) 
Normal (35-1 20 IU/I) 265 (82.8%) 3 1 8  (81 .5%) 
High 49 ( 1 5.3%) 65 ( 1 6 .7%) 
AST (n=316) (n=384) 
Low 38 ( 1 2%) 49 ( 1 2.8%) 
Normal ( 1 3-35 IU/I ) 248 (78.5%) 300 (78. 1 %) 
H igh 30 (9.5%) 35 (9. 1 %) 
ALT (n=319) (n=387) 
Low 5 ( 1 . 6%) 6 ( 1 . 5%) 
Normal (7-35 IU/1) 270 (84.6%) 327 (84.5%) 
High 44 ( 1 3.8%) 54 ( 1 4%) 
Table 3. 1 0  Biochemical values for patients currently taking HMs. 
* n= number of patients where data was available in their medical records; percentages are derived 
from these values. Values are point prevalence values taken from the patients' notes. 
ALP = alkaline phosphatase; AST = aspartate aminotransferase; ALT = alanine aminotransferase 
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G FR stage * Current herb All-time HM Non- herb 
takers takers taking group 
(n=468) ( n=555) (n= 1 33 ) 
Stage 1 68 (14.5%) 74 (13.3%) 11 (8.2%) 
(GFR = �90 ml/min) 
Stage 2 80 (17.1%) 90 (16.2%) 23 (17.3%) 
(GFR = 60-89) 
Stage 3 101(21.6%) 116 (20.9%) 26 (19.5%) 
(GFR = 30-59) 
Stage 4 41 (8.8%) 49 (8.8%) 13 (9.8%) 
(GFR = 15-29) 
i Stage 5 
I ( G FR = Less than 15) 
127(27.1%) 172 (31.0%) 51 (38.3%) 
i Data not available 51 (10.9%) 49 (8.8%) 9 (6.8%) 
Table 3 .11 Comparison of GFR stages between current herb, all-t ime herb and non­
herb taking patients. 
*GFR calculated using the Modification of Diet in Renal Disease (MORO) Study equation . 147 
The distribution of patients between the various glomerular filtration rate (GFR) stages was not 
statistically significantly different when comparing current herb users with non-herb users 
(chi2=7.42, df=4, p=0.115) or comparing all-time users with non-herb users (chi2=4.108, df=4, 
p=0.392). 
It was possible to calculate the mean GFR for patients at each renal disease stage. There was 
no statistically significant difference between the distribution of means for all-time herb users 
and non-herb users (p=0.12, Mann-Whitney, see Table 3.12); however, when current herb 
users were compared with non-herb users, a statistically significant difference emerged in 
favour of herb users (p=0.02, Mann-Whitney, see Table 3.13). 
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GFR stage All-time herb user N Mean Std. Deviation Std. Error Mean 
Yes 74 125.5 113.2 13.2 
GFR stage 1 
No 11 111.9 11.4 3.4 
GFR stage 2 Yes 90 72.4 8.4 0.9 
No 23 70.6 8.1 1.7 
Yes 116 45.1 9.2 0.9 
GFR stage 3 
No 26 44.7 8.6 1.7 
Yes 49 21.1 5.0 0.7 
GFR stage 4 
No 13 23.0 4.1 1.1 
Yes 172 6.6 3.0 0.2 
GFR stage 5 
No 51 6.9 3.2 0.4 
Table 3.12 Comparison of GFR means (ml/min) within stages between all-time herb and 
non-herb users. 
No significant difference; p=0. 1 2 ,  Mann-Whitney 
GFR stage Current herb user N Mean Std. Deviation Std. Error Mean 
Yes 68 109.4 17.9 2.2 
GFR stage 1 
No 11 111.9 11.4 3.4 
GFR stage 2 Yes 80 72.2 8 .4 0.9 
No 23 70.7 8.2 1.7 
Yes 101 45.2 9.1 0. 9 
GFR stage 3 
No 26 44.7 8.6 1.7 
Yes 41 21.0 4.8 0.7 
GFR stage 4 
No 13 23.0 4.1 1.1 
Yes 127 6.8 3.1 0.3 
GFR stage 5 
No 51 6.9 3.2 0.5 
: 
Table 3.13 Comparison of GFR means (ml/min) within stages between current and non­
herb users. (Significant difference; p=0.02, Mann-Whitney) 
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The apparent improved kidney function in those patients currently taking herbs compared with 
those who had not was supported by the differences found in other measures of kidney function. 
These are displayed in Table 3.14 and the results of the independent t-tests are shown in Table 
3. 15. 
Biochemical parameter Std. 
N* Mean Deviation Std. Error Mean 
Creatinine (µmol/I) Yes 429 338.1 364.1 17.6 
No 129 416.4 396.9 35.0 
Creatinine Clearance Yes 54 79.2 53.1 7.2 
(ml/min) No 23 52.8 50.4 10.5 
Tests of Urine Yes 14 1.9 0.7 0.2 
Collection for 24 hr (L) No 5 1.1 0.4 0.2 
Cholesterol (mmol/L) Yes 311 4.5 1.4 0.1 
No 93 4.0 1.1 0.1 
GFR (ml/min) Yes 419 46.6 37.5 1.8 
No 124 37.7 34.1 3.1 
Table 3.14 Comparison of mean values for selected biochemical measurements for 
current herb users and non-herb users. 
Yes=patients currently using herbs (n=468); No=patients not using herbs (n=1 33). 
*N = number of patients for which biochemical data could be retrieved. 
t-test for equality of means 
Lab Test Mean Std. 95% Confidence Interval 
t df Sig; (2- Differ Error of the Difference tailed) ence Differe nee Lower Upper 
Creatinine (µmol/I) -2.00 197.2 0.05* -78.3 39.1 -155.5 -1.2 
Creatinine Clearance 
(ml/min) 2.07 43.7 0.05 26.4 1 2.8 0.7 52. 1 
Tests of urine 
Collection for 24 hr 
(L) 3.2 13.4 0.02 0.8 0.3 0.3 1.4 
Cholesterol (mmol/L) 3.1 195.7 0.01 0.4 0.1 0.2 0.7 
GFR (ml/min) 2.5 218.6 0.02 9.0 3.6 1.9 16.0 
Table 3.15 Results of independent samples t-tests of means for biochemical 
measurements for current and non-herb using groups, reflecting some differences in 
renal function. 
'Non-equal variances were assumed in this analysis due to a significant p value (0.02) for Levene's test. 1 00 I I I I I I I I I I I I I I I I I i I I I I I I I I 
These analyses indicate that in the herb taking group, the mean serum creatinine was lower 
(borderline significance), but 24-hour urine collection and GFR were higher. The differences in 
serum creatinine and creatinine clearance was borderline significant. The only other statistically 
significant difference in means was serum cholesterol, which was higher in herb-taking patients 
than in non-herb taking patients. The herb-taking group would appear to have healthier renal 
function than non-herb users; however the reasons for this are obscure. I t  may be that these 
patients have healthier function by chance and that herbs play no part in this. It was not possible 
to associate any one herb (or herbal mixture) as being responsible due to wide variation in 
nature and numbers of herbs taken by the study sample. 
3.3.5.1 Other b iochemical findings of interest - correlations. 
Significant findings from cross-tabulation of biochemical variables and common herbs used by 
current-herb users using Pearson correlation gave the significant correlations shown in Table 
3. 16. No corroborating evidence for any of these associations could be found in the literature. 
Biochemical Herb df Pearson Chi-Square 
parameter value 
Thyme 40 0.035 
Potassium Anise 40 0.041 
Serum albumin Herbal Tea 38 0.011 
Bil irubin Chamomile 28 0.001 
Haemoglobin Thyme 92 0.045 
Herbal Tea 92 0.043 
Cholesterol Karkadeeh 58 0.028 
Peppermint 50 0.049 
AST 
Karkadeeh 50 0.025 
Table 3.16 Significant correlations between herb use and biochemical variables 
(total n=468). 
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AST = aspartate aminotransferase 
Common herbs and results of laboratory tests were analysed using the bivariate correlation 
method against the followings variables in SPSS: 
• demographic variables : gender , age , age group; 
• herbs: ginger, thyme, peppermint, mixture of herbs, fenugreek, black seeds, senna, 
cardamom, anise, sage, chamomile, karkadeeh, herbal tea; 
• renal disease classes and most common disease: transplant, dialysis, anaemia, 
hyperlipidemia, dyslipidemia + hyperlipidemia, dyslipidemia, diabetes, hypertension, end 
stage renal disease, chronic kidney disease, proteinuria; 
• most common medicines taken by patients: amlodipine, omeprazole, calcium, 
atorvastatin, prednisolone, acetylsalicylic acid, folic acid, vitamins, ciclosporin, atenofol, 
insulin , mycophenolate, iron, paracetamol , vitamin D, losartan, lisinopril, furosemide, 
irbesartan, gliclazide, candesartan; 
• renal function lab tests: creatinine, creatinine clearance, 24-hour urine collection, urea, 
sodium, calcium, magnesium, potassium, phosphate, uric acid, albumin, micro albumin, 
bilirubin, total protein, haemoglobin, cholesterol, glucose, ALP, AST, ALT, GFR, GFR 
stage; 
Significant correlations are shown in Table 3.17. 
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Biochemical Pearson corref ation Sig. 
parameter 
Herb 
coefficient (2-taifed) 
Thyme 
-0.1182 0.0143 
Serum n=159+ 
creatinine 
(n=429) Mixture of 
herbs -0.0980 0.0424 
n=103 
Anise 
0.0043 
Calcium n=39 +0.1513 
(n=354) 
Chamomile 
+0.1633 0.0021 
n=34 
Potassium Mixture of herbs +0.0971 0.0046 
(n=423) n=101 
Uric acid Mixture of herbs -0.1436 0.0306 
(n=227) n=59 
Ginger 
-0.2875 0.0124 
n=49 
Sage 
+0.2453 0.0339 
Microalbumin n=8 
(n=75) Herbal tea 
+0.4020 0.0004 
n=4 
Karkadeeh 
+0.2643 0.0219 
: n=8 
Haemoglobin Thyme 
-0.0988 0.0443 
(n=415) n=155 
I 
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Karkadeeh 
+0.1038 0.0346 
n=39 
Senna 
+0.1137 0.0361 
A lbumin n=72 
(n=356) Sage 
-0. 1310 0.0 157 
n=34 
Bi l irubin Black seeds 
-0.1211 0.0336 
(n=308) n=78 
A LT Karkadeeh 
+0.1444 0.0098 
(n=319) n=28 
Ginger 
+0.1078 0.0273 
n=217 
GFR Sage 
+0.1678 0.0006 
(n=419) n=46 
Chamomile 
+0. 1283 0.0085 
n=38 
Sage 
G FR stage* -0.1516 0.001 9 
n=46 
(n=419) 
Chamomile 
-0.1048 0.0320 
n=38 
Table 3.17 Significant correlations between individual herbs and biochemical variables 
for patients currently taking herbs, using bivariate correlation. 
= a negative correlation exists; + = a positive correlation exists. 
* a negative correlation here actually signifies a negative correlation with increasing stages of renal 
impairment. 
• n = the numbers of patients taking a particular herb for which data on the relevant biochemical 
variable was available. 
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The data in Table 3. 1 7  tell us that while these correlations are statistically significant, the 
strength of the correlation, as indicated by the Pearson correlation coefficient is weak, never 
exceeding 0.402 (for herbal tea and microalbumin). Such weak associations are probably a 
function of the diversity of herbs and numbers of preparations taken by this cohort. 
Relationships are discussed further in Section 3.4. 
3.3.6 Adverse reactions to herbal medicines. 
ADRs were reported by 42 patients in the group currently using herbs (9.0%, n=42/468); this 
figure rose to 49 patients (8.8%, n=49/555) when all those who had taken or were taking HMs 
were considered. Just three patients from the current HM user group (7. 1 %, n=3/42) said that 
they had mentioned the reaction to their carers; five from the total HM user group ( 10.2%, 
n=5/49) said they had informed their carers. 
On deeper investigation, 23 of the 49 patients were deemed by the expert panel to be 
unassessable or have a highly doubtful relationship to any medicine the patient was taking, due 
to lack of sufficient data on which to base a judgement. Key data for the remaining 26 patients 
(all taking herbs, with a total of 28 ADRs) appear in Table 3.18. Case detai ls are shown in 
Appendix 3.2. All subjects were presenting for routine outpatient appointments at the 
Nephrology Clinic. 
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Parameter Basic Description (n, % ) 
Gender (n=26) 
Females 1 2  (46.2%) 
Males 1 4  (53.8%) 
Age (n=26) 
Less than 1 8  years 1 (3.8%) 
1 9-29 years 1 (3 .8%) 
30-39 years 3 (1 1 .5%) 
40-49 years 6 (23. 1 %) 
50-59 years 1 0  (38.5%) 
60-69 years 4 (1 5.4%) 
70 years and above 1 (3 .8%) 
Type of Products involved in ADR (n= 28*) 
Herbs alone 7 cases (25.0%) 
Herbs / PM combination 21 cases (75.0%) 
Table 3.1 8  Key findings of herbal ADRs reported in the study. 
PM= prescription medicine 
*Two patients presented with two suspected ADRs each. 
3.3.6 . 1  Assessment of herbal ADR causal ity 
The scores allocated to each case using the author's modified Naranjo algorithm are shown in 
Table 3 . 1 9 . Each case was also rated using the original Naranjo algorithm. 1 38 
A comparison of the conclusions of the two methods is summarised in  Table 3.20; see Appendix 
3.2 for case details. 1 06 l i 
Case number· Are there 
previous 
conclusive 
reports on the 
reaction? 
2 
6 
8 
9 
1 0  
11  
1 3  
I (yes =+1; no=O; 
do not know or 
not recorded=O) 
1 
1 
1 
Are there 
alternative 
causes for the 
reaction? 
Did the adverse 
reaction appear 
after the 
suspected drug 
was given? 
(yes =-1; no=+2; 
(yes =+2; no=-1; do not know or 
do not know or not recorded=O) 
not recorded=O) 
2 -1 
2 -1 
2 2 
2 2 
2 2 
2 2 
2 2 
Total score 
(relationship) 
2 (possible) 
2 (possible) 
5 ( definitely) 
5 (definitely) 
5 (definitely) 
5 (definitely) 
5 (definitely) 
t-------+--------+----,--------i---------;--::::---c---c�--,------------j 
I 1 4  1 2 2 5 ( definitely) 
1 5  1 2 2 5 (definitely) 
1 5a 1 2 2 5 (definitely) 
1 6  1 0 2 3 (probable) 
1 7  1 1 -1 1 (possible) 
1 9  1 2 -1  2 (possible) 
21 1 2 -1 2 (possible) 
22 0 0 2 2 (possible) 
23 2 2 5 ( definitely) 
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1 
I I I 
I I I 
I I I 
1 
I I I 
I I I 
1 
I 
I I 
i 
I I I I I 
I I I 
I I I 
j 
I i 
I 1 
I I I 
l 
24 1 2 -1 2 (possible) 
24a 1 2 -1 2 (possible) 
25 I 1 2 2 5 (definitely) 
26 0 2 2 4 (probable) 
27 0 2 -1 1 (possible) 
31  0 2 -1 1 (possible) 
34 I 1 0 2 3 (probable) I 
35 1 2 -1  2 (possible) 
36 1 2 2 5 ( definitely) 
37 1 2 2 5 (definitely) 
40 1 2 2 5 ( definitely) 
48 1 1 0 2 (possible) 
Table 3. 1 9  Results of applying the author's modified causality algorithm to the ADR 
reports gathered in the study (n=28). 
* Case numbers represent the case number used in the original sample of 49 suspected ADRs and are 
used here to faci litate cross-reference to the original research records. Two cases ( 1 5  and 24) showed 
two ADRs each. 
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Strength of association Original Naranjo M odified Naranjo 
Scale Scale 
I 
(n=28) (n=28) 
I Defin ite 
I 
0 (0%) 13 (46.4%) 
i Probable 12 (42.9%) 3 (10.7%) 
C 
I Possib le 16 (57.1%) 12 (42.9%) 
Table 3.20 Summary of strength of causality assessments for the 28 A DR cases, applying 
the original Naranjo scale 138 and the author's modified scale. 
There was almost 100% agreement (with one exception, Case 37, see Appendix 3.2) between 
the outcome of applying the Naranjo algorithm and the panel consensus; whereas the author's 
modified Naranjo method overestimated the strength of association compared to the panel 
consensus in some cases (n=16). Therefore, the original Naranjo algorithm was taken as giving 
a more robust assessment of the true causality. There were no definite associations. This 
aspect is discussed further in the discussion section. 
The agents involved and the strength of the association are summarised in Table 3.21. Herbal 
medicines alone were possibly or probably implicated in 7 cases (25%); or in combination with 
prescribed medicines in the form of a drug interaction in another 21 (75%). 
Suspected Association (after consensus and using original 
agent (s) Naranjo algorithm) 
Possible Probable Total 
Herb 3 4 7 
Herb / 12 9 21 
prescription 
medicine 
Total 15 13 28 
Table 3.21 Strength of association with in agent groups after panel consensus and using 
the original Naranjo algorithm. 138 
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3.3.6.2 Specific herbal ADR associations 
Reported ADRs ranged in type and severity. The original case study reports are shown in 
Appendix 3.2. A summary is provided in Table 3.22. The reader will note that in over half the 
cases ( 1 7), it was not possible to say exactly which herb, from the range taken by the patient, 
contributed to the ADR. Results of a supplementary literature search after study completion are 
shown in Appendix 3.3. This revealed no striking associations between herb use and ADRs 
based on the published toxicities of these products. 
1 1 0 
Agent Nature of ADR (main herb involved) Case number* 
Herb (n=7) Malaise (ginger) 34 
Severe asthma (multiple) 35 
Colon inflammation (sage) 40 
Diarrhoea (senna) 2 
Stomach acidity and blood in the stools 8 
{multiple) 
I 
Itch (fenugreek) 10 
i Abortion (multiple) 23 
Herb / prescription medicine Renal failure (all multiple) 22,26,31 
interaction (n=21) Finger numbness (cardamom) 27 
Weakness (multiple) 36 
Tiredness (senna.senna) 14,24a 
Stomach pain (both multiple) 37,48 
Abdominal pain (multiple, multiple, 6, 1 6,24b 
multiple) 
Low blood pressure (multiple) 9 
Raised blood pressure (multiple) 1 7  
Dizziness (multiple) 1 3  
Stomach acidity (cinnamon, multiple) 1 1 , 15b 
Itch (fenugreek) 1 5a 
Nausea and vomiting (garlic, multiple, 1 9,21 ,25 
senna) 
Table 3.22 Nature of the A DRs seen in  this study. 
Full detai ls can be found in Appendix 3.2. 
Cases 1 5  and 24 exhibited two ADRs each. 
Multiple = the actual herb responsible could not be identified from the range taken by the patient. 
1 1 1  
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3.4 D iscussion 
Herbal medicines contain a myriad of pharmacologically active compounds that, when used by 
people with kidney disease, may be hazardous and harmful. Little information is available about 
herbs and dietary supplement use in the kidney disease population.148 Two examples shown to 
be of clinical significance in the dialysis population are noni juice, which should be avoided 
because of its high potassium content, and bulk-forming laxatives such as flaxseed which 
should be used with caution because of the need for increased fluid intake. 
3.4. 1 Evidence of harm to the kidney caused by herbal medicines. 
There are numerous reports of herbal medicines contributing to the development of renal 
disease. Chang et al 149 studied 1,537 patients receiving chronic haemodialysis and observed a 
high incidence of chronic tubule-interstitial nephritis related to the use of Chinese herbs or 
compound analgesics, which may contribute to transitional cell carcinomas (TCCs). The same 
team 1 50 noted a strong relationship between rapidly progressive interstitial renal fibrosis and the 
consumption of Chinese herbs. TCC is the predominant malignancy in Chinese renal transplant 
recipients. Female sex, the Chinese herb containing aristolochic acid and immunosuppression 
are markedly associated with the development of TCC.1 5 1  Aristolochia has been associated with 
progressive renal fibrosis, 1 52·1 53 tubular atrophy and interstitial fibrosis leading to severe renal 
functional impairment and end-stage renal failure, 1 52 urothelial carcinomas, 1 53 and Fanconi's 
syndrome. 1 54· 1 55 It is interesting to note that renal failure due to ingestion of Aristolochia was 
widely reported in China and other countries while no such toxicity was recorded in traditional 
Chinese herbal texts. 1 56 This illustrates an important point, relevant to the present research. Use 
of uncontrolled unlicensed herbal medicines and supplements may not be safe simply because 
no evidence of toxicity is written down. Absence of evidence is not evidence of absence as far 
as ADRs are concerned. More thorough study and documentation of suspected ADRs should 
help to ensure safer use of such traditional medicines. Aristolochia is now banned in most 
countries and no evidence of use of this herb was found in the present study. 
The American National Kidney Foundation has cautioned against the use of HMs and 
supplements by patients with chronic kidney disease (CKD) and has published a list of 
hazardous herbs (see Table 3.23). 1 57 Herbal supplements may be unsafe for CKD patients 1 1 2 
I 
simply because clearance is reduced allowing accumulation to toxic levels. Some herbs that 
have diuretic properties may also cause further damage to an already diseased kidney; these 
include bucha leaves and juniper berries. 1 57 
Category 1 : Herbs that may be toxic to the kidneys 
I Artemisia absinthium (wormwood plant) Periwinkle 
I Autumn crocus Sassafras 
\ Chuifong tuokuwan (Black Pearl) Tung shueh 
j Horse chestnut Vandelia cordifo/ia 
Category 2 :  Herbs that may be harmful in chronic kidney disease 
Alfalfa Buckthorn Ginger Nettle Vervain 
I Aloe Capsicum Ginseng Nani juice 
I Bayberry Cascara Horsetail Panax 
I 
Blue Cohosh Coltsfoot Licorice Rhubarb 
Broom Dandelion Mate Senna 
Table 3.23 List of herbs cited as being unsafe to use in chronic kidney disease by the 
American National Kidney Foundation. 1 57 
Table 3.6 and Appendix 3.2 show that some of the above were being used by patients in the 
present study, although no Category 1 herbs were being used. 
3.4.2 Herbal  medicine - prescription medicine i nteractions. 
Herb - prescription medicine interactions may also be clinical important.66• 158 · 1 59 Barone et al 1 60 
report how two renal transplant recipients started self-medicating with St. John's wart (SJW), 
resulting in subtherapeutic ciclosporin levels. One patient developed acute graft rejection as a 
result. Renal patients consuming herbal drugs are at risk from herb-drug interactions by various 
mechanisms. In transplant recipients, toxicity and underdosage of calcineurin inhibitor-based 
immunosuppression have been linked to phytochemically triggered activity changes of 
cytochrome P-450 isoenzyme CYP3A4 metabolism and drug transport proteins. This type of 
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interaction might be triggered by many other plant products besides SJW, less wel l-known for 
this risk ,  producing sign ificant interactions with antidiabetics, anticoagulants and 
antihypertensives. 1 6 1  
In an extensive review, Fugh-Berman 159 refers to studies that have shown possible interactions 
between specific herbal medicines (ginkgo, SJW, ginseng , garlic, echinacea , saw palmetto and 
kava) and prescribed drugs; 41 case reports or case series and 1 7  clin ical trials were identified. 
The resu lts indicated that SJW lowers blood concentrations of ciclosporin ,  amitriptyl ine, d igoxin, 
indinavir, warfarin ,  phenprocoumon and theophyll ine; furthermore it causes intermenstrual 
bleeding , delirium or mild serotonin syndrome, respectively, when used concomitantly with oral 
contraceptives ( eth inylestradiol/desogestrel), loperamide or selective serotonin-reuptake 
inhibitors (sertal ine, paroxetine). Ginkgo interactions include bleeding when combined with 
warfarin ,  raised blood pressure when combined with a thiazide diuretic and coma when 
combined with trazodone. Ginseng lowers blood concentrations of alcohol and warfarin ,  and 
induces mania if used concomitantly with phenelzine. Garlic changes pharmacokinetic variables 
of paracetamol, decreases b lood concentrations of warfarin and produces hypoglycaemia when 
taken with chlorpropamide. Kava increases 'off' periods in Parkinson patients taking levodopa 
and can cause a semicomatose state when given concomitantly with alprazolam. No 
interactions were found for echinacea or saw palmetto. 
Some herbs, including garlic, ginkgo, ginseng, and SJW, can have a significant influence on 
concurrently administered drugs. Herbal medicines may mimic, decrease, or  increase the action 
of prescribed drugs. Th is can be especially important for d rugs with narrow therapeutic windows 
and i n  sensitive patient populations such as older adu lts , the chronically i l l , including those with 
renal d isease, and those with compromised immune systems. 
Three q uarters of the ADRs identified in the present research were thought to involve 
pharmacodynamic interactions with concurrent conventional medicines. For example the 
gastroi ntestinal symptoms seen in Case 6, 1 5, 1 6 ,  1 9, 24 and 25 (see Appendix 3 .2) ;  a few were 
thought to have some interplay with the underlying renal d isease (e.g. cases 26 and 3 1  ) .  
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3 .4 .3  Non-d isclosure of herb use by patients. 
There have been calls for dialysis practitioners to include specific questions about herbs and 
dietary supplement use in medical and nutrition histories, and to increase their knowledge about 
these products in order to advise patients appropriately. 148 However, this study has revealed 
that there are significant barriers to them doing the former effectively. Not least of which is the 
lack of information offered by patients. 
Of those currently taking HMs in this study, approximately one fifth said they had visited a 
herbal centre recently and one fifth said they were taking OTC medicines as well. Almost 70% 
said they had not informed their doctor or pharmacist that they were taking HMs. A majority said 
they were also visiting other hospital departments for treatment. These data (see Section 3.3.2) 
i l lustrate the complex nature of care received by some of the subjects in this study. It is likely 
that in addition to obtaining herbal medicines from a herbal centre and OTC medicines from a 
pharmacy, some s ubjects would have received additional prescription medicines from other 
clinics they attended, either at other hospitals or within SKMC. What is clear is that even with 
obvious opportunities to do so, a minority of patients informed their carers that they were taking 
HMs. 
These observations are supported by the fact that when validating reported herb use against the 
patient medical records, j ust two patients had anything about herbs written by their doctors. 
Only one recorded the patient taking an OTC medication. There were no records of patients 
having visited a herbal centre or experienced any discomfort or reaction to a herbal preparation. 
This could lead to inappropriate prescribing of conventional medicines with the potential to 
interact adversely. The phenomenon of non-disclosure has been observed previously. Saw et al 
1 62 investigated potential drug-herb interactions with antiplatelet / anticoagulant drugs among 
250 patients attending medical wards; 106 (42.4%) were taking herbs with 76 of these (71.7%) 
having used herbs for the previous 1 2  months. Twenty-three patients were taking one or more 
of ginseng, garlic, and ginkgo which are thought to interact with antiplatelet or anticoagu lant 
therapy. More than 90% of herb-takers did not disclose the use of herbal medicine to their 
health professionals. 
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In the present study, many patients currently taking HMs were taking multiple herbal 
preparations, often in mixture form. In the case of the latter, over a third of patients could not 
name the ingredients in the compound herbal mixtures they were taking. 
In this sample, it appears that patients were better able to recall the names of their HMs than 
the names of the PMs they were taking. This may reflect a greater familiarity with HMs 
compared to PMs; perhaps because patients had been taking them for longer, perhaps because 
the names were more familiar and in everyday use, or perhaps because patients did not feel the 
need to remember the names of their PMs, trusting that the prescriber would prescribe what 
they required without expecting them to remember details for identification. 
3.4.4 H erbal medicines and biochemical measurements 
Use of herbal and alternative medicines may significantly alter biochemical test results. This 
may indicate the emergence of a disease caused by the herbal medicine, but may also lead to 
misinterpretation of biochemical or other results due simply to interference by the herb. Hence 
communication among pathologists, clinical laboratory scientists, pharmacists and physicians 
providing care to the patient is important in interpretation. In the context of the present research, 
interest is focussed on the emergence of abnormal laboratory results owing to altered 
pathophysiology. 
In this study, there appeared to be a slightly raised GFR associated with current herb use 
compared to no herb use at all, although this was variable within GFR stages. This is an 
interesting observation, but the picture is complicated; as shown earlier, herb-taking patients 
were consuming a wide variety and number of preparations; it was not possible to demonstrate 
that any single preparation was responsible for this difference. These comments also apply to 
the apparent decreased serum creatinine (but also raised serum cholesterol) observed in 
current compared to non-herb users and also to the rather weak correlations between use of 
herbs and some biochemical variables. 
One could for example postulate that there is a weak positive correlation between the use of 
ginger, sage and chamomile and GFR and that these herbs are actually promoting improved 
kidney function. This is further supported by a negative association between use of sage and 
chamomile and reducing GFR stage and the observation that in general, herb users had better 
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renal function than non-herb users; moreover, the most common herb used by current herb 
users was sage. Nothing could be found in the literature to support this however. 
The results of bivariate analysis shown in Table 3.17 revealed several interesting correlations 
between herbs taken by current herb users and laboratory measurements. It is stressed that 
while al l  the correlations were statistically significant, overall, they were weak and in many 
cases, the numbers of patients taking a particular herb were small . For example: 
1. microalbumin level showed a significant negative correlation with ginger and positive 
correlations with sage, herbal tea and karkadeeh; 
2. creatinine level showed significant negative correlations with thyme and mixtures of 
herbs; and 
3. haemoglobin level showed a negative correlation with thyme but a positive correlation 
with karkadeeh. 
Little supporting evidence for any of these observations could be found in the literature. Jadayil 
et al 1 63 studied the bioavailability of iron from local plants (black cumin seeds, milk thistle seeds, 
sesame seeds and thyme leaves) when incorporated into the diet of rats serum haemoglobin 
concentrations increased significantly (p<0.05) in the groups fed milk thistle seed and black 
cumin seed diets, but decreased for the group of rats fed thyme. 
In a study 1 64 conducted to evaluate the effects of Hibiscus sabdariffa L. (karkadeeh) calyx 
extract on some haematological parameters (haemoglobin, haematocrit, total white blood cells 
and differentials) in rats for 14 days, significant elevations were observed in haematocrit 
(p=0 .03) and haemoglobin (p=0.004) in the groups of animals given doses of 200 mg and 400 
mg per kg; however groups given high doses revealed significant reductions. 
3.4.5 Adverse effects to herbs seen in this study. 
As indicated earlier, consensus on all possible and probable reactions was reached using the 
original Naranjo algorithm rather than the author's modified technique. The latter produced 
several 'definite' associations which, in retrospect would not be reached in practice due to the 
absence of objective evidence. In some cases, the author was reliant on patient recall with little 
written evidence to aid the decision; so the original Naranjo algorithm 1 38 was adopted for further 
analysis. Even then, it is worth emphasising that in a study like the present one, key data that 
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would strengthen the association is missing. For example, no re-challenge was conducted, 
there was no measurement of active herbal principles in plasma and the patients were not 
studied for long enough to see if stopping the drug led to improvement in the adverse effect. 
I n  17 of the 28 ADRs noted, it was not possible to identify the actual herb responsible due to the 
range of HMs being taken by the patient. Twelve of the ADRs produced gastrointestinal effects, 
most of which were the results of interactions with other medicines the patient was taking (see 
Appendix 3.2). In many cases, it was not possible to match the effects seen with anything in the 
published literature (see also Appendix 3.3 where a more detailed literature search was 
conducted after completion of the study); however some corroborating evidence was found. 
Chamomile herbal tea has been used traditionally for medicinal purposes. Chamomile has 
moderate antioxidant and antimicrobial activities, and significant antiplatelet activity in vitro. 
Adverse reactions to chamomile, consumed as a beverage or applied topically, have been 
reported among subjects with allergies to other plants in the daisy family, i.e. Asteraceae or 
Compositae.165 This may have been a factor in case 15. 
Garlic is traditionally used for cardiovascular health and relief of cough, colds, and rhinitis. 
Adverse effects commonly include gastrointestinal disturbances, change in body odour through 
the sweat and breath, and rarely allergic reactions or hypoglycemia.166 Garlic may well have had 
a role in the severe nausea and vomiting experienced by the patient described in case 19. 
Venderperren et al 167  report the case of a 52-year-old woman who had ingested large amounts 
of senna herbal tea for more than 3 years. The patient developed severe hepatotoxicity and 
renal impairment requiring intensive care therapy. Renal impairment was consistent with 
proximal tubular acidosis, presenting with marked polyuria refractory to vasopressin 
administration. The chronic abuse of senna herbal tea may be associated with serious 
manifestations, including fluid and electrolyte loss, with chronic diarrhoea. Severe hepatotoxicity 
is unusual, but could be explained by the exposure of the liver to unusual amounts of toxic 
metabolites of anthraquinone glycosides (sennosides). An objective causality assessment 
suggested that hepatotoxicity was possibly related to senna laxative abuse. The finding of high 
urinary concentrations of cadmium suggested contamination of the herbal tea by metals. While 
the use of senna was associated with expected side effects such as diarrhoea and abdominal 
pain (e.g. cases 21 and 24), it was also being taken (along with other herbs) by one patient who 
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developed renal impairment (case 31 ). It is noteworthy that senna was the seventh most 
common herb taken by current herb users in this study, all of whom it should be remembered, 
were attending a nephrology clinic. 
3.4.6 Lack of physicians' knowledge on herbal medicines. 
Even assuming patients tell their doctors that they are taking herbal medicines, physicians often 
lack the knowledge base to effectively counsel patients regarding adverse effects and potential 
herb-drug interactions.168· 1 69 To prevent clinically important drug interactions it is important that 
the patient's carers have a thorough grasp of the pharmacocolgy of all the medicines the patient 
is taking and to realise the potential for significant interactions. It is recommended that on 
admission, a healthcare professional reviews all prescription, OTC and herbal medicines, and 
dietary supplements when taking a medication history. 1 70 
In addition, patient education about the potential interactions should be a routine component of 
preoperative assessment. The American Society of Anesthesiologists (ASA) recommends that 
all herbal medications should be discontinued 2-3 weeks prior to an elective surgical procedure. 
If the patient is not sure of the contents of the herbal medicine, he/she should be urged to bring 
the container so that an attempt can be made to review the contents of the preparation.1 71 In a 
similar vein, a study of psychiatrists in Australia and New Zealand who regularly managed 
patients taking SJW still reported an appreciable number of side-effects and drug interactions 
involving the herb, leading to the recommendation that psychiatrists should routinely enquire 
about their patients' use of alternative treatments, be mindful of possible side-effects and in 
particular be aware of the dangers of combining SJW with other psychotropics. 1 72 
Improving pharmacovigilance of herbal ADRs might help expand the knowledge base and 
provide more robust advice on drug / herb combinations to avoid or expand the list of diseases 
where the herb is judged to be unsafe to use. In a Canadian study, just 19% of a sample of 132 
community pharmacists surveyed, said they had previously reported an adverse event to Health 
Canada, the National pharmacovigilance scheme. When asked specifically about herbal 
medicine interactions, 47% of pharmacists stated that they had identified a potential interaction; 
however, only 2 of these reported it. The study showed that while pharmacists encounter 
reportable herbal-drug interactions, they rarely choose to report them. 1 73 The problem is by no 
means field-specific; Smith 1 74 observes that healthcare providers have little scientific evidence 
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on which to base recommendations about use of herbal supplements with chemotherapy. Lack 
of product standardisation and definitive knowledge about herb interaction with chemotherapy 
may expose patients with cancer to potentially serious side effects. 
The findings of a relatively low level of reporting of ADRs to herbal preparations in the present 
study was compared to other studies. Cuzzolin et al 122 interviewed 1,420 consumers about their 
herbal medicines use. Almost three quarters (71.8%) reported taking conventional medicines 
along with natural products; 3.9% referred to having experienced adverse effects to herbal 
remedies in the previous year. Herbal products were largely taken on a self-treatment basis by 
respondents; 73 different herbal products were used and 32 were consumed in association with 
traditional drugs. Forty-seven of 491 (9.6%) reported side-effects, 22 after taking only herbal 
medicines (8.1%) and 25 in combination with conventional drugs (11.4%). The observed 
adverse manifestations included the following: gastrointestinal after dandelion, propolis or 
fennel; cardiovascular after liquorice, ginseng, and green tea; dermatological after propolis, 
thyme, arnica, and passionflower; and neurological after guarana and liquorice. Conventional 
drugs taken in association and potentially involved in adverse reactions were NSAIDs, 
antibiotics, benzodiazepines, antihypertensives and oral contraceptives. In some cases (n=5), 
side-effects were serious enough to justify admission to the hospital. In 29 of the 47 ADRs 
(61 .7%), the adverse reaction was not communicated to the doctor. Bush et al 1 75 reported a 
study where 804 patients were surveyed, and 122 (15%) used herbal medicines. Eighty-five 
potential adverse herb-drug interactions were found in 49 patients (40% of herbal medicine 
users). Twelve possible adverse herb-drug interactions in 8 patients (7% of herbal medicine 
users) were observed. In all 12 cases, the severity scores were rated as mild, including 8 cases 
of hypoglycemia in diabetics taking nopal (prickly pear cactus). 
As the author's study revealed, nephrologists rarely recorded herbal drugs used by their 
patient's in the medical records. Other studies have also shown that the use of herbal medicines 
is seldom documented in medical records and that health professionals often overlook patients' 
use of them. One small study noted that eight out of 58 patients in Sahlgrenska University 
Hospital, Sweden used herbal drugs regularly before admission, six of whom used regular 
prescribed drugs simultaneously; just one patient had this use written in their clinical record.1 76 
Rivera et al 1 77 discovered that no record of herbal use was documented in a retrospective chart 
review of hospital inpatients; however, when an additional 60 patients were interviewed 
prospectively, 42% reported using herbal medicines for the treatment of asthma. Ten patients 
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reported taking a herbal medicine that could potentially exacerbate their asthma and 1 8  patients 
reported using a herbal medicine that could interact with other medications or cause other types 
of adverse events. The authors recommended that use of herbal medicines should be routinely 
explored when taking a medication history. 
3.4. 7 Chapter overview and conclusions 
The key findings from this study are listed below: 
The percentage of patients studied at the nephrology clinic who reported taking herbal 
medicines currently was higher (68%) than that found in the general population study described 
in Chapter 2 (38% ). 
HM use was widespread in this sample, even in those with multiple pathologies. 
Little published information was available to indicate that the most frequently taken herbs (see 
Table 3.6) were particularly toxic, although several had the potential to cause problems in 
individual cases (see Appendix 3.3). 
Few patients mentioned their use of herbal medicines to either a doctor or pharmacist in this 
secondary care setting. A large majority (70%) did not. 
Very few had the use of HMs documented in their medical records. 
A small percentage of patients currently taking herbs mentioned a suspected adverse reaction 
to HM, either alone or as an interaction with prescription medicine 9.0% (n=42/468). Of these, 
28 in 26 patients (5.6%), were deemed by consensus to be possibly or probably related to the 
HMs taken. 
The use of alternative remedies derived from plants and animals is increasing worldwide. Their 
source and composition varies depending on the prevalent local practices. The majority remain 
untested for efficacy and safety; often, their ingredients are unknown and the dosage and route 
of administration are not standardised. Potentially toxic chemicals may be added to them to 
increase their potency and mistaken identity has led to the use of toxic plants instead of the 1 2 1 
originally intended herb. Kidneys play a vital role in the metabolism and excretion of these 
substances and acute kidney injury is a common and important manifestation of their toxicity. 
The most usual renal lesions include acute tubular necrosis, cortical necrosis, and interstitial 
nephritis. Patients often present late to hospitals with multi-organ involvement. The diagnosis 
may be missed if the history is not sought specifically. These factors culminate in high mortality 
rates. Comprehensive study of this subject is difficult because of the remoteness of the rural 
areas, unfamiliarity with local cultures, and mystery and secrecy surrounding the natural 
medicines used. Physicians need to be aware of these factors to make a timely diagnosis and 
provide appropriate management. Public awareness and regulation of the use of these 
medicines are required to eradicate this entity from the community.1 78 
Interactions between herbal medicines and synthetic drugs exist and can have serious clinical 
consequences. Healthcare professionals should ask their patients about the use of herbal 
products and consider the possibility of herb-drug interactions. Interactions between herbal 
medicines and prescribed drugs can occur and may lead to serious clinical consequences. 
There are other theoretical interactions indicated by preclinical data. Both pharmacokinetic 
and/or pharmacodynamic mechanisms have been considered to play a role in these 
interactions, although the underlying mechanisms for the altered drug effects and/or 
concentrations by concomitant herbal medicines are yet to be determined. The clinical 
importance of herb-drug interactions depends on many factors associated with the particular 
herb, drug and patient. Herbs should be appropriately labelled to alert consumers to potential 
interactions when concomitantly used with drugs, and to recommend a consultation with their 
general practitioners and other medical carers. 
Many reports of herb-drug interactions are sketchy and lack laboratory analysis of suspect 
preparations. Healthcare practitioners should caution patients against mixing herbs and 
prescribed medicines. 
The finding, as in the present study, that a high proportion of subjects did not consult their GP or 
pharmacist following a herbal ADR is also of concern. 1 20 
Due to inherent toxicity, some herbal remedies should not be used under any circumstance. In 
addition, because nearly all herbal remedies contain multiple, biological ly active constituents, 
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interaction with conventional drugs is a concern. It is incumbent upon clinicians to be aware of 
those herbs that can cause intoxication, and to be cognisant of potential herb-drug interactions. 
Laboratory technology can help to evaluate potential drug interactions when drugs are 
prescribed concurrently. Increasing knowledge of inter-individual variation in drug breakdown 
capacity and recent findings concerning the influence of environment, diet, nutrients, and herbal 
products can be used to reduce ADRs and iatrogenic diseases.1 1 8  
Physicians, should have a detailed knowledge and understanding of the potential risks and 
purported benefits of herbal medicines and should thoroughly inquire about patient's use of 
herbal products. In addition, the education of each patient regarding the serious, potential drug­
herb interactions should be a routine component of preoperative assessment. The American 
Society of Anesthesiologists (ASA) suggests that all herbal medications should be discontinued 
2 to 3 weeks before an elective surgical procedure. 1 79 Dermatologists should be aware of herbal 
products likely to be used by their patients. Many of these products prescribed by alternative 
medicine physicians or purchased over the counter should be discontinued prior to dermatologic 
surgery to minimise the risk of surgical complications.180 With the increasing use of herbal 
supplements by cancer patients, surgical staffs need to screen patients pre-surgically for use of 
these supplements.1 25 
Potential herb-prescription drug interactions are not just limited to SJW. Inquiries regarding the 
usage of herbal supplements should be an integral component of a transplant recipient's 
medication history. Clinicians should be proactive and repeatedly provide education regarding 
the potential dangers of herbal medicines taken with conventional drugs. Interdisciplinary 
communication among medical herbalists, medical doctors,  pharmacists and dietetic experts 
needs to be improved and encouraged. 
If the patient is not sure of the contents of the herbal medicine, he or she should be urged to 
bring the container to the consultation so that the doctor or pharmacist can review its contents. 
Although this idea holds some promise in the outpatient clinic setting, care in emergency 
settings should be based on thorough drug history taking from the patient or a relative. 
So, before patients take any herbal supplement, they must be recommended: 123  
• to check with their physicians, dietician, pharmacist and/or product manufacturer 
regarding safety, dosage, duration of use and interactions with prescription drugs. 
• to use only standardised herbal extracts made by licensed and authenticated 
companies. 
• Not to take more than the recommended dosage, or for longer than recommended. 
• not to use herbal remedies for serious illness. 
• not to use herbs if considering pregnancy. 
Physicians should be made aware of the need to take a herbal as well as a drug history, and the 
clinical laboratory has a role in helping understanding of how herbal products may affect 
laboratory tests and in suggesting relevant lines of investigation in patients whose symptoms 
may be linked to the use of herbal products. 
Herbal medicines are not as safe as frequently claimed. Therefore, it can be harmful to take 
herbal medicines without being aware of their potential adverse effects. A comprehensive 
surveillance system for monitoring the adverse effects of herbal medicines is now essential. 
3.4.8 Study Limitations 
The study was of limited size and restricted to patients attending a single speciality within a 
single, albeit very large hospital in Abu Dhabi. Specific limitations are discussed below. 
Missed ADRs 
Other herbal ADRs or herb-drug interactions might have occurred during the study that were 
overlooked either by the patient (who in some circumstances was relying on recall) or the author 
and collaborators when analysing the case study data. Every effort was made to gather 
sufficient information to make an objective decision on the reported ADRs; but in some cases , 
cl inical notes were incomplete or patients did not provide answers to the interviewer's questions. 
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Sample size 
The sample of non-herbal users (control group) was much smaller than the current herb user 
group. This may have skewed some of the findings. Certainly, the numbers taking individual 
herbs were relatively small, hampering a robust co-relational analysis. 
Data retrieval from medical notes 
Details of the patients' disease profiles and laboratory findings were missing from some medical 
records; the illegible handwriting of some nephrologists also hampered data retrieval. 
Patient availability 
Some patients in the dialysis units could not participate in the study as they were unconscious, 
very sick or could not talk. Also, patients who were less than 13 years old and who could not 
speak English or Arabic languages were excluded from the study. In all these cases, valuable 
information on herb use might have been obtained through alternative approaches. 
3.4.9 Suggestions for future work 
Additional research strategies 
The National pharmacovigilance centres in many countries are responsible for monitoring 
pharmacovig ilance activities. At the outset of this research, this was not applicable to the UAE; 
accordingly, several alternatives were considered. 
Firstly, to approaching alternative medicine practitioners in Herbal Clinics to report herbal ADRs 
encountered in the course of their practice. This would involve surveying the herbal practitioners 
via emails, specifically herbal practitioners in herbal medical centres who are prescribing herbal 
medicine, whether in crude or processed form. This idea was not explored further, as many of 
these practitioners were unlicensed and would be difficult to identify. 
Secondly, approaching Health Food shops in shopping centres to survey customers about their 
experiences of HM use, including adverse effects. 
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Both strategies may have provided useful data, but the author would not have been able to 
corroborate what the subjects reported with their medical notes. 
Extending the methodology used in the author's renal clinic study to other specialities such as 
cardiovascular , rheumatology, dermatology, surgical and emergency departments would be 
feasible and would perhaps provide additional information on the safety (or otherwise) of HM 
use in patients with a range of underlying diseases. 
Establishing a pharmacovigi/ance centre in UAE Ministry of Health: 
The initial idea of surveying the safety of HMs in  the UAE, was through developing a national 
pharmacovigilance centre in the Drug Control Department (DCD) of the UAE MoH and 
extending its activities to cover HMs; however this was not feasible when the present research 
began, due to the acute shortage of human and financial resources, lack of technical assistance 
and lack of co-ordination between the MoH and other local healthcare authorities and 
municipalities. 
A National Pharmacovigilance Committee has formed at the end of 2008 between the MoH, 
local health authorities and the Medical Faculty of UAE University with the objective of 
establishing a national pharmacovigilance scheme. While this is still in its infancy, the author's 
involvement in gathering safety data through this scheme would be a logical extension to this 
research, perhaps using a modified version of the data capture form used in Stage 2 of the 
research. 
In addition Abu Dhabi's Health Authority (HAAD) has established its own local poison and drug 
information centre and produces a periodic news letter to educate practitioners to report ADRs. 
The author might have input to this and could study the effect of raised awareness of HM effects 
on frequency of reporting. 
Tighter regulation of HM use 
The MoH, local health authorities and municipalities have established a National Committee to 
regulate HMs and dietary supplements in the country, but this too is at an early stage of 
development. The MoH has also establ ished a medical advertisement department to control the 
advertisements of all medical products including HMs and dietary supplements. The author 
might make a contribution to both these in itiatives. 1 26 
Chapter 4 :  Overall Discussion and Conclusions 
4.1 Overall d iscussion 
Chapter 1 indicated that in common with many other countries in the region, herbal medicines 
(HMs) are an important part of self-treatment strategies in the UAE. The country is in an 
interesting position, where Western medicine is being more widely embraced against a 
background of traditional HM use, stretching back for centuries. This use is more prominent in 
rural areas where cultural beliefs and practices often lead to self-care, home remedies or 
consultation with traditional healers; however, as Chapter 2 shows, use in towns and cities such 
as Abu Dhabi is extremely common. 
Unlike conventional pharmaceutical products, many HMs are marketed without evaluation for 
quality, safety and efficacy and as a consequence, there is growing concern about the risk to 
patients from inappropriate use, inaccurate dosages, drug-herb and herb-herb interactions. 
Chapter 1 provided some stunning examples of the potential for deliberate or unintentional 
contamination of HMs discovered by the UAE MoH (see Table 1 .3). A brief review of published 
evidence of the potential for harm was also provided. The perception that herbal remedies are 
natural and therefore safe is widespread among users, but incorrect. 59 
Herbal remedies often contain highly active pharmacological compounds and are therapeutic at 
one dose and toxic at another. With increasing widespread use, it is important for public safety 
that HMs are examined and regulated as carefully as conventional medicines. The lack of 
pharmacological and clinical data on the majority of HMs is a major impediment to the 
integration of herbal medicines into conventional medical practices. 68 No-where is this more 
important than in the UAE. For valid integration, pharmacological and especially, clinical studies, 
must be conducted on those plants lacking such data. Adverse events, including drug-herb 
interactions must also be monitored to promote safe integration of efficacious HMs into 
conventional medical practice. In addition to the quality of the medicines themselves, other 
major concerns impinging on safety include herbal practitioner's licensure, scope of practice, 
and malpractice. Whilst the MoH regulates the quality, efficacy and safety of licensed herbal 
products and dietary supplements which are mainly available from pharmacies, control in local 
municipalities is less strict. Thousands of HM products are available from unlicensed, 
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uncontrolled sources such as health food and condimental shops in the UAE, which contributes 
to potential safety problems. 
At the time of conducting this research, there were no data relating to the usage of HMs in the 
UAE. The initial stage of the author's research attempted to quantify this and in addition, 
determine the attitudes and beliefs of users who were UAE Nationals. The results are discussed 
fully in Chapter 2. The Al Rowda Clinic was selected for the survey as it was considered the 
biggest PHC in Abu Dhabi and only provided services to UAE Nationals. Results confirmed the 
author's suspicions that the use of HMs was widespread - three quarters of the sample had 
experience of HM use - with a point�prevalence of current HM use of 38%. A wide range of 
herbs were used to treat a large number of disorders. Most herbal remedies were not Western 
'off the shelf' or proprietary herbal products, but herbs in the crude form , often used in mixtures, 
frequently obtained from unregulated sources, and most frequently recommended by a family 
member or a friend. In keeping with other studies,49 a large majority of users considered the 
HMs they were taking to be effective, natural and therefore safe; but an appreciable proportion 
(11%) cited adverse reactions which they thought were due to the HM(s) they were taking. 
In general, there was a disinclination by the patients to inform their GPs about HM use with less 
than a third of subjects doing so; those not informing their GPs had either not thought to 
mention it, thought their GP did not need to know or thought their GP did not believe in HM and 
that they would not be taken seriously. This has important implications for future 
pharmacovigilance of HMs. If GPs are to be encouraged to report them, patients must first be 
encouraged to inform their GPs of all the medicines they are taking. This is compounded by the 
fact that, as the research from Chapter 3 shows, patients appear not to be able or willing to 
report adverse drug reactions themselves. 
The objective of phase two of the research was to provide qualitative and quantitative data on 
the safety of HM use in a tighter group of patients where access to medical notes could be 
guaranteed. Chapter 3 explains that the choice of studying patients with renal disease, visiting a 
hospital nephrology clinic in Sheikh Khalifa Medical City Abu Dhabi, was based on reasons of 
access, etiquette and clinical relevance. Ways of extending the study are discussed below 
under 'suggestions for future work'. Despite these limitations, the study revealed some 
important new data. Patients in the sample, by definition, had moderate to serious kidney 
disease, yet concurrent use of HMs was approximately twice as high in this sample as it was in 
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the primary care sample studied in Phase 1 (68 vs 38%). Furthermore, a minority of patients 
mentioned their use of HMs to their attending Doctors; almost 70% said they had not informed 
their doctor or pharmacist that they were taking HMs. When validating reported herb use against 
the patient medical records, just two patients had anything about herbs written by their doctors. 
A smaller percentage in this sample reported an adverse reaction to the herbs they were taking 
(5 .6% vs 11 % ) but the phase two study allowed sufficient clinical detail to be obtained to assess 
causal ity and to some extent, severity. 
Over a third of patients taking compound herbal remedies could not identify the main active 
ingredient. Twenty-eight adverse reactions, described in 26 patients were deemed to be 
possibly or probably related to HM use but the actual herb involved could not be identified 
because the patient was taking multiple HMs in half the cases. Under such circumstances, there 
would be l ittle benefit in applying standard pharmacovigilance techniques to this data, as 
building up a picture of ADR incidence, and thus generating a safety signal, would be 
impossible without the name of the herb (mixture or otherwise) involved. 
There are potentially significant health risks posed by the concomitant use of HMs in patients 
taking conventional therapies. Phase 2 research showed that 7 (25%) of the adverse reactions 
involved HMs alone and 21 involved a HM / PM interaction. It is therefore important that if these 
are to be prevented, a fu l l  l ist of PMs and HMs taken should be available to the patient's 
attending healthcare professionals. 
4. 1 .1  Suggestions for improving ADR reporting to HMs 
The UAE is not unique in currently having little means of accessing, reporting and monitoring 
ADRs to conventional or any other types of medicines used by its citizens. The following are 
suggestions for some concrete steps that could lead to the support of a pharmacovigi lance 
system in the HM field. 
1. Generating a safety and efficacy database. 
HM products have evolved against widely different ethnological, cultural, climatic, geographical 
and even philosophical backgrounds; 181 nevertheless they face many reg ulatory challenges in 
ensuring their safety and efficacy. There are very few drug regulatory authority bodies that 
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evaluate the safety and efficacy of herbs on the basis of clinical trials. Current herbal reference 
texts do not contain sufficient information for the assessment and management of adverse 
health effects of many botanical therapies.182 
Large-scale clinical trials are needed to assess the public health potential of HMs and to 
establish indications and dosage recommendations. As a starting point, a searchable database 
could be constructed, containing licensed HM product details; this could then be expanded as 
new products, including crude herbal formulations imported through the municipalities and 
available through health food grocery and condimental shops, are investigated against 
established quality, efficacy and safety standards. 
2. Improving labelling and control of HMs 
It is clear from the results of this study that patients took a wide range of HMs about which little 
was known. Many were obtained from unlicensed suppliers and came in unlabelled containers, 
or with little indication of the main active ingredient, batch number or expiry date. There needs 
to be tighter legislation on the manufacture and supply of such products to protect patients from 
taking the same herb in two or more different forms and those overdosing themselves. Crude 
herbals are commonly formulated as a mixture, so that their ingredients may be ambiguous and 
even contain harmful contaminants; because nearly all herbal remedies contain multiple, 
biologically active constituents, interaction with conventional drugs is a concern. Thus there is a 
need for the MoH to insist on the licensing of all herbal products making a medicinal claim, 
especially those authorised for marketing by the municipalities, and the withdrawal from the 
market of clearly dubious HMs with no clear labelling or content. Source or manufacturer and 
batch number should also appear on the label , in addition to clear warnings against 
inappropriate use, for example during pregnancy. 
If resources could be found, municipalities might be encouraged to build their own quality 
control laboratories to test HMs approved locally and investigate reports of adulterated or mis­
labelled products. 
There is also a need for improved communication between the MoH, local health authorities, 
municipalities, approved manufacturers and customs to detect substandard or counterfeit HM 
products. 
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3. Licensing of HM manufacturers 
As with conventional Western medicines, manufacturers of HMs and dietary supplements 
approved by the municipalities should be subject to inspection against a minimum standard of 
good manufacturing practice and if successful, issued with a licence for production of specified 
HMs. Manufacturing processes should be subject to regular inspection and products produced 
under licence should be subject to quality control. Licences might be revoked if standards are 
not maintained. 
Consideration should also be given to licensing the facilities where HMs and dietary 
supplements are kept and in which they are transported, particularly in the municipalities. 
4. Licensing of HM practitioners 
Consideration needs to be given to effective regulation of HM practitioners, who should be 
governed by a professional code of practice and have agreed standards of training and 
competency. 
5. Promotion of HMs 
The promotion of HMs as natural safe alternatives neglects the possibility of adverse reactions. 
Legislation to improve public health protection and promote only fully substantiated marketing 
claims for HM products is required. Promotion and advertisements of these products in media 
and journals should be regulated and subject to regular scrutiny. While the UAE has such a 
system for conventional medicines, little is known about its effectiveness in controlling HM 
advertising, particularly that reaching the country from the surrounding area. 
6. Patient education 
Most herbal products do not require a prescription in the UAE. Thus, their use and any potential 
risks may easily escape the physician's and pharmacist's attention. One strategy to address this 
is for an information leaflet to accompany every HM at point of sale or supply, containing vital 
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information such as the names of the ingredients, indications and dosage, in addition to 
contraindications, warnings and precautions, interactions with other medicines and potential 
side effects. Patients should be encouraged though the leaflet, and by their attending healthcare 
professionals, to report untoward effects to their doctor or pharmacist and to seek advice on 
potential drug interactions for taking a HM. Bi-lingual presentation (at least Arabic and English) 
would also be an advantage. 
7. Healthcare professional education 
This study has shown that patients are at risk of adverse reactions or interactions involving 
HMs, yet most practicing physicians have little knowledge of herbal remedies or their effects. 
Most healthcare professionals are not adequately prepared educationally to meet patients' 
requests for information on herbal products and dietary supplements. Perhaps this is why so 
few bothered to mention HM use to their carers. In the UAE, physicians' and pharmacists' 
knowledge of both herbs and adverse event reporting is poor and they are unaware that such 
events, particularly serious ones, should be reported. 
To optimise patient care, healthcare professionals have a responsibility to educate themselves 
about herbal therapies in order to help patients, who clearly use HMs a lot, discern the facts 
from the fiction, avoid harm, and gain what benefits may be available. In order for this to 
happen, some requirement for training in this area might be injected into undergraduate and 
postgraduate curriculums, not just for doctors and pharmacists, but also for nurses. 
8. Healthcare provider - patient communication 
One outstanding finding from this study is the apparent reluctance of patients to involve their 
carers in the decision to use HMs. In addition to educating patients to disclose all the medicines 
they are taking it is essential that HCPs take a thorough drug history on first patient contact, be 
it in the GP surgery, the admissions ward of a hospital or in a speciality clinic, to ensure that the 
attending clinician is aware of all potentially harmful preparations taken by the patient. The 
history should include questions regarding the taking both herbal and over-the-counter 
medications. Furthermore, the history should be accurately transcribed into the patient's notes 
and updates with each visit. Recent studies have shown that suitably trained pharmacists are 
capable of taking accurate drug histories of high quality1 83 and that drug histories can help 
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prevent AD Rs. 1 84 This may be a role which UAE pharmacists could embrace when adopting a 
more clinical role. I f  so, the data collection tool developed by the author for phase 2 might well 
prove useful. 
9. Integration of patient data 
A recent MoH strategy to integrate patient information and share the patient's medical record 
through all UAE public healthcare settings will certainly facilitate the monitoring of HM use, but 
this will only be useful in this context if the patient tells the healthcare provider what they are 
taking and the provider enters the information in the patient's notes. Hospital and community 
pharmacies shou ld be included in this process. 
1 0. Encourage pharmacovigilance 
ADR reporting is the main method of monitoring the safety of medicines. Encouraging 
spontaneous reporting can contribute to improved awareness among health personnel and 
patients about the benefit-harm profile. Reporting of suspected ADRs associated with HMs, 
whether licensed or unlicensed , and including physicians and community pharmacists as 
recognised reporters, are steps in the right direction. Ultimately, patients themselves might be 
encouraged to report, although at the moment, they seem reluctant to do so. 
Such a pharmacovigilance scheme might also prove useful in detecting false claims and 
substandard medicines and devising risk management plans for suspect products. As 
mentioned previously, at time of writing, the UAE MoH, pharmacovigilance scheme is in its 
infancy; but there seems to the author to be no reason why this should not be expanded to 
HMs, with immediate effect and she strongly recommends this approach. 
4. 2 Conclusions and suggestions for future work 
Use of HMs for health maintenance, treatment or prevention of minor conditions, and also for 
serious ,  chronic illnesses is popular in UAE. 
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HM regulation seeks to protect the public health by ensuring the necessary guarantees of 
quality, safety and efficacy. Good communication between regulators, practitioners, patients and 
the public is necessary so that those who choose to take HMs can do so with acceptable safety. 
This research has provided the first evidence of the extent of HM use in primary care and has 
focussed on use in just one secondary care setting. Future research might take the following 
lines. 
1. Interview HCPs to gain their views on the use of HMs in their patients and what they 
would like their patients to tell them. 
2. Interview HCPs to obtain a better idea of their level of knowledge about HMs, the 
information sources they use to educate themselves . about HMs, and their training 
requirements. 
3. Evaluate the power of drug history taking to discover the extent of HM use in patients 
admitted to hospital and the potential for avoiding harm from ADRs or herb-drug 
interactions during their hospital stay. 
4. Apply the author's data collection form in the above and in other clinical settings where 
the potential for prescription of large numbers of PMs is high, for example the 
rheumatology, mental health, gastroenterology or cardiology clinics. 
5. Introduce pilot pharmacovigilance programmes in the above. Covering both HMs and 
PMs using a spontaneous reporting system similar to that used in the US and UK as 
described in Chapter 1. 
6. Review all HM product claims against the evidence base for safety and efficacy and 
produce a register of approved ingredients and their indications, and make inclusion on 
the list a pre-requisite for marketing and supply in the UAE. 
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Appendix 1 :  Names of common herbs and their main uses in the UAE 
Herb Arabic Synonyms Species (Family) Herbal Use 
Name 
Aloe � - ).,, • .a Aloe vera ( i )  Aloe barbadensis Recommended for the treatment of atonic 
(Liliaceae). constipation and suppressed 
( ii )  Aloe ferox and its menstruation. 
hybrids with Aloe africana 
and Aloe spicata. 
Anise -:,_,.....;1.,i Anise, Pimpine/la anisum L. Expectorant, antispasmodic, carminative 
Aniseed, Anisi (Apiaceael umbelliferae) and parasiticide. Traditionally, it has been 
Fructus, used for bronchial catarrh, pertussis, 
Anisum spasmodic cough,  flatulent colic; topical ly 
for pediculosis and scabies; its most 
specific use is for bronchitis, tracheitis 
with persistent cough, and as an aromatic 
adjuvant to prevent col ic following the use 
of cathartics. It has been used as an 
oestrogenic agent. It has been reputed to 
increase milk  secretion, promote 
menstruation, facil itate b irth, al leviate 
symptoms of the male cl imacteric and 
increase libido. 
Asafetida - �I Asafetida, (i) Ferula assafoetida L. Carminative, antispasmodic and 
�I Asant, Devil's (Feru/a rubricaulis Boiss) expectorant. It has been used for chronic 
Dung, Gum (ii) Ferula foetida bronchitis, pertussis, laryng ismus 
Asafetida (Apiaceael Umbelliferae) stridulus, hysteria and specifical ly for 
intestinal flatulent col ic. 
Black seed �I Nutmeg flower Nigel/a Sativa It is used internal ly for difficulty in 
- 1> IJ.,.._.JI urination, dysmenorrhoea, indigestion, 
�.;,JI � colds, asthma and for impotence. It has 
also been used as an antiflatulent and as 
an anthelmintic. 
And it is used externally for skin 
inflammations and for muscle and joint 
pain. 
I I I 
f-
I 
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Arabic 
Name 
� - J4-,,:, 
. 'Li ...,_,..... -
- �I 
�I 
�' 
- i,.\J_,....ll 
�_;,JI � 
Synonyms 
Aloe vera 
Anise, 
An iseed, Anisi 
Fructus, 
Anisum 
Asafetida, 
Asant, Devil's 
Dung, Gum 
Asafetida 
Nutmeg flower 
Species (Family) 
( i )  Aloe barbadensis 
(Liliaceae). 
( i i )  Aloe ferox and its 
hybrids with Aloe africana 
and Aloe spicata. 
Pimpinel/a anisum L.  
(Apiaceae/umbelliferae) 
( i) Ferula assafoetida L. 
(Feru/a rubricau/is Boiss) 
( i i )  Ferula foetida 
(Apiaceael Umbelliferae)  
Nigel/a Sativa 
Herbal Use 
Recommended for the treatment of atonic 
constipation and suppressed 
menstruation . 
Expectorant, antispasmodic, carminative 
and parasiticide. Traditionally, it has been 
used for bronch ial catarrh, pertussis, 
spasmodic cough,  flatu lent colic; topical ly 
for pediculosis and scabies; its most 
specific use is for bronchitis, tracheitis 
with persistent cough, and as an aromatic 
adjuvant to prevent colic following the use 
of cathartics. It has been used as an 
oestrogenic agent. It has been reputed to 
increase mi lk secretion, promote 
menstruation, facil itate birth , al leviate 
symptoms of the male climacteric and 
increase l ibido. 
Carminative, antispasmodic and 
expectorant. It has been used for chronic 
bronchitis, pertussis, laryngismus 
stridulus, hysteria and specifically for 
intestinal flatulent col ic. 
It is used internal ly for difficulty in 
urination, dysmenorrhoea, indigestion , 
colds, asthma and for impotence. It has 
also been used as an antiflatulent and as 
an anthelmintic. 
And it is used externally for skin 
inflammations and for muscle and joint 
pain .  
---
-
! 
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Chamomile . \., �.,: . Chamomil la Matricaria recutita L. Carminative, antispasmodic, m ild 
recutita ( L . )  (Asteraceael Compositae) sedative, anti-inflammatory, antiseptic and 
Rauschert, anticatarrha l .  It has been used for flatulent 
Hungarian nervous dyspepsia, travel sickness, nasal 
Chamomile, catarrh, nervous diarrhoea, restlessness 
Matricaria and specifical ly for gastrointestinal 
chamomilla L . ,  disturbance with associated nervous 
Matricaria irritabil ity in chi ldren.  It has been used 
Flowers, topically for haemorrhoids, mastitis and 
Sweet False leg ulcers . Also used for gastrointestina l  
Chamomile, spasms and inflammatory diseases of the 
Wild gastrointestinal tract and external ly for 
Chamomile skin and mucous membrane inflammation 
and bacterial skin diseases including oral 
cavity and gums. It is also approved for 
inflammation and irritation of the 
respiratory tract (by inhalation ) and ano-
gen ital inflammation (baths and irrigation). 
C innamon - .Uj (i) Ceylon (i) Cinnamomum Antispasmodic, carminative, 
0:1-).1 Cinnamon, zeylanicum BI .  (Lauraceae) antidiarrhoeal ,  antim icrobial , cool ing 
True (ii) Cinnamomum loureirii agent and anthelm intic. It has been used 
Cinnamon Nees for anorexia, intestinal colic, infantile 
( i i) Saigon (ii i )  Cinnamomum burmanii diarrhoea, common cold, influenza, and 
Cinnamon (Nees) BI .  specifical ly for flatulent colic, and 
( i ii) Batavia dyspepsia with nausea. Cinnamon bark is 
Cassia, also stated to be astringent, and 
Batavia cinnamon oil is reported to possess 
Cinnamon, carminative and antiseptic properties. 
Padang-
Cassia, 
Panang 
Cinnamon 
-
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Clove Ji.i) 
Fenugreek 
Ginger 
Caryophyllus 
aromaticus,  
Eugenia 
aromatica, 
Eugenia 
caryophyl lata, 
Eugenia 
caryophyl lus .  
Syzygium aromaticum 
(Myrtaceae) 
Carminative, anti-emetic, toothache 
remedy and counter-irritant. 
Bockshornsam Trigonelfa foenum-graecum Possess mucilaginous demulcent, 
e 
Zingiber 
L. 
( Leguminosae) 
Zingiber officinale Roscoe 
(Zingiberaceae) 
laxative, nutritive, expectorant and 
appetite stimulant properties, and has 
been used topical ly as an emollient. 
Traditionally, it has been used in the 
treatment of anorexia, dyspepsia, gastritis 
and convalescence, and topically for 
furunculosis, myalgia, lymphadenitis, 
gout, wounds and leg ulcers . 
Possess carminative , diaphoretic and 
antispasmodic properties. Traditionally, it 
has been used for colic, flatulent 
dyspepsia, and specifically for flatulent 
intestinal colic. Modern interest in ginger 
is focused on its use in the prevention of 
nausea and vomiting,  particularly motion 
sickness, as a digestive aid, and as an 
adjunctive treatment for inflammatory 
conditions , such as osteoarthritis and 
rheumatoid arthritis. 
- :-----L----1------k�---;-:--:-------t-;:P-,-la::n�t-:d:;:e:-::c::o:::c�t,· o;::;n:;-;-;is::-;-:u�se;;.d�fo;;-;r:--t�h;-;;e�t�re�a;it:;:;:m�e�n:tlt Harmal J..� Rhazya stricta 
I 
of diabetes mellitus, fever, stomach ulcers 
and as an anthelmintic. Inhalation of 
smoke from the leaves can be used for 
the treatment of nasal allergy. 
I '¼ 
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Myrrh _J-4 ( i )  African ( i )  Commiphora molmol Possess antimicrobial, astringent, 
Myrrh, ( Bursuraceae) carminative, expectorant, anticatarrhal 
Balsamodendr (ii) Commiphora abyssinica and antiseptic properties. Traditionally, it 
on Myrrha ,  (ii i ) Other Commiphora has been used for aphthous ulcers, 
Commiphora, species pharyngitis, respiratory catarrh, common 
Commiphora cold, furunculosis, wounds and abrasions ,  
myrrha (Nees) and specifically for mouth ulcers, gingivitis 
Engl . ,  Somali and pharyngitis. Also used topical ly for 
Myrrh mild inflammation of the oral and 
( i i )  Arabian pharyngeal mucosa.  
Myrrh, Yemen 
Myrrh 
Parsley �J.ii.,, Apium Petroselinum crispum Parsley is stated to possess carminative, 
petrosel inum (Apiaceae/ Umbelliferae) antispasmodic, diuretic, expectorant, 
L . ,  Carum antirheumatic and antimicrobial 
petrosel inum properties . Traditional ly, i t  has been used 
(L . )  Benth . ,  for flatulent dyspepsia, colic, cystitis, 
Petroselinum dysuria, bronchitic cough in the elderly, 
sativum Hoffm. dysmenorrhoea, functional amenorrhoea, 
myalgia and flatu lent dyspepsia with 
intestinal colic. 
Red seed �I Lepidium sativum Seeds and green leaves are used, which 
- �\�\ 
are rich in vitamins and minerals. Used as 
J\..1 )\ 
a tonic, appetizer and with other herbs, to 
enhance sexual performance. 
Indicated medically in the treatment of 
mouth and throat infections. 
In the UAE it is used for cleaning the 
womb and stomach after del ivery. 
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! 
Sage - '½,41),:.A Dalmatian Salvia officinalis L. Sage is stated to possess carminative , 
�I Sage, Garden (Labiatae) antispasmodic, antiseptic and astringent 
Sage, True properties. Traditionally, i t has been used 
Sage to treat flatulent dyspepsia, pharyngitis, 
Red Sage uvuitis, stomatitis, gingivit is, glossitis 
refers to Salvia ( internal ly or as a gargle/mouthwash), 
haematodes hyperhidrosis, and galactorrhoea. Also 
Wall . used internally for d yspeptic symptoms 
Greek Sage and excessive perspiration, and external ly 
refers to Salvia for inflammation of mucous membranes of 
tri loba mouth and throat. 
Spanish Sage 
refers to Salvia 
lavundaefol ia 
Seder J.i...JI Ziziphus Fruits are rich in nutrients and have a 
beneficial effect in respiratory tract 
diseases. 
I 
I Oecoction of the leaves is used for 
gastrointestinal d isturbances, diabetes 
mellitus, menstrual b leed ing, d iarrhoea, 
fever and toothache. It is also used as an 
anthelmintic 
� 
I 
I 
I 
I 
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I 
Senna - �w.....ll ( i )  Alexandrian ( i )  Cassia senna L. Senna is stated to possess cathartic 
J_;l:,..ll Senna, Cassia (ii) Cassia angustifolia properties (leaf greater than fruit) and has 
acutifol ia ( Leguminosae) been used traditionally for constipation. 
Del ite, Senna is also used in combination with 
Khartoum ispaghula for constipation. 
Senna The Committee on Proprietary Medicinal 
(ii) Indian Products (CPMP) has adopted core SPCs 
Senna, (Summary of Product Characteristics) for 
Tinnevelly senna leaf and senna fruit (C. angustifol ia 
Senna and C. acutifolia) with indications for 
short-term use in cases of occasional 
constipation .  
Terminalia - �  Terminalia chebula Used for constipation, dyspepsia, 
I � duodenal ulcer and hyperlipidaem ia. 
Teucrium ;.ia.:i,. Teucrium Sp. Plant decoction or emulsion is used as an 
appetizer, for the treatment of diabetes, 
intestinal problems, lymph problems, l iver 
malfunction, acute pneumonia, flu ,  
rheumatism, malaria, fever and also to 
ease menstrual symptoms. 
Thyme j&, j  Common Thymus vulgaris L., It is stated to possess carminative, 
Thyme, Thymus zygis L. (Labiatae) antispasmodic, antitussive, expectorant, 
French bactericidal , anthelmintic and astringent 
Thyme, properties . Traditional ly, it has been used 
Garden for dyspepsia, chronic gastritis, asthma, 
Thyme, diarrhoea in children, enuresis in children, 
Rubbed laryngitis, tonsill itis (as a gargle), and 
Thyme specifically for pertussis and bronchitis. 
i 
I 
I I I I I r I 
I 
I 
I 
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Only for UAE Nationals 
Dear Sir / Madam 
Attached is a survey which has been approved by the Ministry of Health to screen the UAE 
nationals in all districts, to study the safety of herbal medicines taken by patients, whether 
you are using herbs alone or along with prescribed medicines. 
We would like to know your opinions regarding herbal medicines or medicinal herbs, whether 
you are using them or not. In case you are using / were using any herb(s), we would like to 
know the names of those herbs which have been of benefit in treating your disease to 
recommend them to others, and to know the names of the herbs that harm you; in order to 
warn others not to use them. 
Also, we would like to inform you that taking some common herbs e.g .  thyme, chamomile, 
ginger, senna, mixture of herbs, black seed, aloe, myrrh, anise etc are considered herbal 
medicines, therefore kindly make sure to answer question (12) with "Yes " if you have ever 
been treated with herbs and complete the survey. 
We would like to assure you that the information given by you will be confidential and 
secured and wil l not be disclosed to others, and we promise to use your data to follow-up 
your condition and evaluate the healthcare services and medicines given to you. 
Here are some definitions of terms used in the survey: 
1 .  Prescription / Conventional medicines: Modern medicines of chemical nature 
prescribed in hospitals ,  clinics or pharmacies. 
2. Treatment with herbs: of 3 types: 
A. Medicinal plants/ crude herbs (not chemically processed): are dried plants, either 
mashed.complete or in powdered form , sold in condimental shops or herbs selling 
shops e.g. thyme ,ginger , mixture of herbs , aloe , myrrh , senna , fenugreek, black 
seed, Gum, fennel,  .. etc. 
Continued .......... . 
B. Compounded herbs / Mixtures of herbs: are crude herbs prepared by a herbal 
practitioner or traditional healers; they includes crude herbs or herbs mixed with 
honey, herbal oils, or herbs mixed with water or other l iquids; also creams or pastes 
prepared in herbal shops or homes. 
C. Herbal medicines (chemically processed): herbs or herbal medicines in 
pharmaceutical form (e.g. capsules, pil ls, l iquids or creams) which look like a 
conventional medicine in its finished pack. These can be obtained from pharmacies, 
health food shops or natural product shops, organic shops or alternative medicines 
centres. 
3. Herbal practitioner : a person who provides consultation or prescribes or dispenses 
herbs or treats with herbal medicines. 
4 .  Condimental shops: shops where herbs or medicinal plants are sold - popular in 
old souks or traditional shops. 
5. Hea lth food shops: shops or centres that sell manufactured or processed herbal 
medicinal or d ietary supplements; located mainly in modern shopping centres. 
Kindly complete the survey and return it back to the nurse in the clinic / or put it in its 
envelope (pre-paid post) and send it to the address displayed on the o utside of the 
envelope. 
If you have any questions, please call: 02-61 1 7421 or 02-6334958 or email :  
fabdallah@moh.gov.ae 
SECTION ONE: GENERAL INFO RMATION Post □ Interview D 
S.No H ealth card No.  ( 
Please  h e l p  u s  by  a n sweri n g  the  fol l ow i ng  q u est ions  on the i nformat ion about your  background :  
1 . Gender : 
a) Ma le  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D 
b) Female . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D 
2 . Age . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  years old .  
3 .  Where do you l ive? 
Em i rate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
C ity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . •  
Street o r  Area . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
4. Marital Statu s 
a) S ing l e  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D 
b) Marr ied . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D 
c) D ivorced / Wi dow . . . . . . . . . . . . . . . . . . . . . . . . .  D 
5 .  If  you  a re mar r i ed  female ,  then a re  you? 
a) Pregnant  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D 
b) B reastfeed i ng  m other  . . . . . . . . . . . . . . . . . . . . . . . . .  □ 
c) non of the above . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D 
6.  How many fam i ly m e m be rs are l ivi ng  with you 
i n  the  house? 
a) 1 - 3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  0 
b) 4 - 6  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  0 
c) 7-9  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  □ 
d) 1 0 - 1 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  o 
e) More than 1 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D 
7. What i s  you r  educat ion  l evel? 
a) Cannot read nor wr ite . . . . . . . . . . . . . . . . . . . . . . .  D 
b) Read a n d  write o n ly . . . . . . . . . . . . . . . . . . . . . . . . . . . .  □ 
c) Les s  than h i g h  schoo l  . . . . . . . . . . . . . . . . . . . . . . . . .  □ 
d) H i g h  s chool on ly  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  □ 
e) G raduate of Co l lege or  U n ivers ity . . . . . . . .  □ 
f) Postgradu ate (Maste r or  Doctorate) . . . . .  O 
8 .  Occu pat ion 
a) I n  fu l l  t ime  paid e mployment . . . . . . . . . . . . . . . . .  D 
b) Se lf-employed . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  0 
c) Unemp loyed . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  · · . .  ·D 
d)  House  wife . . . . . . . . . . . . . . . . . . . . . . . . . . . . · . . . . . .  · . .  · . .  ·D 
e) Reti red . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D 
f) F u l l  t ime student . . . . . . . . . . . . . . . . . .  • . .  • •  . .  • . .  ·D 
g) Oth er, p lease state . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
If you are i n  employment ;  what i s  you r  
occu pation? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
9 .  What i s  you r  total hous ehold monthly i n come 
( i n  D i rham)? 
a) Les s  than 5 , 000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D 
b) 5 ,0 0 0-9,999 . . . . . . . . . . . . . . . . .  · ·  · ·  · . .  · · · · · ·  · · ·D 
c) 1 0,000- 1 4 ,999 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  □ 
d) 1 5 ,000- 1 9 ,999 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  □ 
e) 2 0 ,000-24 ,999 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D 
f) 2 5 ,000 and above . . . . . . . . . . . . . . . . . . . . . . . . . . . □ 
1 O .  I n  genera l ,  how wou ld  you s ay you r  h ealth 
was over last month? 
a) Exce l lent . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D 
b) Good . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  □ 
c) Fa ir  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D 
d) Poor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D 
e) Very poor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  □ 
1 1  . Have you ever been to see a herba l  
pract it ioner? D Yes O No 
1 2 . Have you ever t r i ed  treatment u s i n g  herbs  
e .g .  thyme, b lack cumin ,  chamom i l e ,  
Aloe,  g inger, senna, or herbs to treat 
d iabetes, hypertens ion ,  stomach u lcer,  
red uce weig ht, cold and fl u ,  headache; 
etc.? O Yes D No 
If the answer to quest ion  ( 12) was No, p l ease turn to s ection  Five on page (5) to answer question (3 7), I f  
the answer was Yes, p lease  cont i n u e  with th is  questionna i re .  
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SECTION TWO: WHAT HERBAL MEDICINES YOU TAKE 
For th is section , we wou ld  l i ke to know what are the herbal medicine (s) you are taking o r  have take n .  On ly 
answer th is sectio n  if you have ever taken , or are currently taking any herbal medic ine .  
(For the fol lowi ng q u e st ions ,  t ick any that apply) 
1 3 . Which type of h e rbs h ave you u sed before o r  are us ing now? (Tick al/ that appl ies to you) .  
a) Medici nal  p lants o r  cru de  he rbs . . . . . . . 0 c) Herbal medicines ( In pharmaceutical form).  D b) Compou nded herbs . . . . . . . . . . . . . . . . . . . . . . . .  O d) Other,  Please state . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
1 4. Please l i st the  h erbal med ic ines  you are taking now, or have taken i n  the last few months ; p rovid ing  a br ief 
reason why ( if  you re m e m be r) e.g. Senna to relive constipation. 
Name of Herbal medicine 
2 
3 
4 
s 
1 5 . How effective was t h e  last herbal medici n e  you used? 
D Very effect ive O Effective D Not sure 
1 6 . How many h e rbal med ic ines  are you taking now? 
a) O . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  • • . .  • • • • • · · · · · · · · · · · D 
b) 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  0 
c) 2- 3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  • • . .  • . .  • • · · · · · .. D 
Reason for taking 
O Not effective D Made me fee l  worse 
d) 4- 5 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  0 
e) More than 5 . . . . . . . . . .  . .  . . . . . . . . . . . . . . . . . . . . . D 
1 7. How do you use  he rbal med ic i nes? (Tick al/ that appl ies to you). 
. 
a) Oral  so l i d ; (tablet ,  capsu le ,  powd er) . . . . . . .  D d) Topically appl ied 0� ski n_; (cream, D . . • D ointment, gel ,  solut ion,  o t ls ,  patches) . . .  b) Oral L1q u 1 d s ; (syru p ,  0 1 1) . . . . . . . . . . . . . . . . . .  • · · · · · 
c) Herbal teas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
1 8. Where do you store herbal med ic ines? 
a) I sto re the m i n  the c u pboard or  cabi net 
b) I store t h e m  at roo m  te m pe ratu re 
□ e) Other, please state . . . . . . . . . . . . . . . . . . . . . . . . . . . 
□ □ 
c) I store them in the fridge . . . . . . . . . . . . . . . . . . . .  D 
d) Other, please state . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
1 9 , Have you ex pe rienced any s ide  effect or adverse effect from us ing  herbal medic ine
? 0 Yes □ No 
th ympto ms of the  s ide effect? 20. If yes to the a bove q uest ion ,  then what were e s 
. . . . . . . . . . . . . . . . . . . .  . · · · · · · · · · · · · · · · · · · · · · · · · · · · ·  · · · · · · · · · · · · · · · · · · · ·  · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·  · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·  
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· · · ·  
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·  · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·  · · · · · · · · · · · · · · · · · · ·  · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·  
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·  
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·  
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·  
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·  · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·  
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·  · · · · · · · · · · · · · · · · · · ·  · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·  
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No. 
1 ___________ _ 
2 1 . When you exper ie n ced th i s  s i de effect, d id you : (  Please t ick al/ that appl i es  to you) .  
a) Cont i n u e  tak i ng  med ic i n e  and see i f  the D f) Consu l t  the sale person i n  the cond imental s hop  D symptoms  revo lved . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D g) Consu l t  your  herbal practitione r  . . . . . . . . . . . . . . . . . . . . . . .  D b) Stop tak i ng med ic i ne  i m med iate ly. . . . . . . . . . . . . . . . . D h) Go to the  hospital as an emergency case . . . . . . . . . .  D c) Consu lt you r  d octo r . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  i )  Admi t  t o  the hosp ital □ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . □ 
:� �:�:�:�  �;� ::1:
a
;�r::
i
�\�- �-��-��-�;�� -���� 
. .  
���PD 
j )  Other ,  Please State . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
2 2 .  Name a l l  med icat io n s  you were tak i ng when you experienced the s ide effect i nc lud ing  the convent ional  
med icatio n s .  
I SECTION THREE: WHY A N D  WHEN YOU TAKE HERBAL MEDICINES 
In th i s  sect i o n ,  we wou ld  l i ke to know why you take herbal med ic i nes  and when you are taking or have taken 
herbal med ic i n e s .  
23 .  Please state you r  reasons  fo r choos i ng t o  take herbal med ic i nes .  e .g .  I prefer t o  use  herbal med i c ines 
because they h ave been obtai ned from natural sou rces .  
l .  
2 .  
3 .  
24.  Approxi mate ly  h ow often d o  you take herbal med ic ines? 
d) I take them on ly when I need them D a) I take t h e m  every day . . . . . . . . . . . . . . . . . . . . .  D 
b) I take the m very often . . . . . . . . . . . . . . . . . . . . .  D 
c) I take them somet imes . . . . . . . . . . . . . . . . . . . .  D 
e) I rare fy take them . . . . . . . . . . . . . . . . . . . . . . . . .  D 
f) Other, Please state . . . . . . . . . . . . . . . . . . . . . .  . .  
2 5 .  Do you read i nfo rmat io n  o n  the pack o r  leaflet before tak i ng  herbal med ic i nes? D Yes D No 
SECTION FOUR: WHERE AND HOW YOU BUY HERBAL MEDICINES? ·. • 
I n  th is  section ,  we wou l d  l ike to know about where you buy you r  h erbal medic ines from and how you chose 
them .  Aga in ,  o n ly an swer th is sect io n  i f  you have ever taken ,  or are cu rrently taking any herbal  medic ines .  
26. From where d o  you normal ly o btai n  you r herbal medic ines? (P lease t ick al/ that appl ies to you). 
a. Health foo d  shop  . . . . . . . . . . . . . . . . . .  □ b. Herbal  med ical center . . . . . . . . .  □ 
c. Su permarket or g rocery . . . . . . . . .  □ d. Health Spa o r  gym c lub . . . . . . . . .  □ 
e. Pharmacy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  □ f. I nte rnet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  □ 
g.  Cond i  m ental shop . . . . . . . . . . . . . . . . . .  □ h. Othe r  (please state) . . . . . . . . . . . . . . . . . . . . . . . .  
2 7. When you buy you r herbal med ic ine ,  d o  you normal ly rece ive any advice from t h e  sal esperson 
on  how to take them? D Yes D No 
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28. Please state why you buy he rbal med ic ines  from the p laces you have chosen  i n  question 2 6  (Please t ick all 
that app l ies  to you) .  
a. The shop i s  c lose  to my home . . . . . . . . . . . . . . . . .  D 
b. The shop i s  t idy and e legant . . . . . . . . . . . . . . . . . .  D 
c. The shop i s  b ig  and has  variou s types of herbal 
med ic ines  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D 
d. The shop located i n  b ig  s hopping center/ food 
market . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D 
e. 
f. 
g. 
h. 
i .  
The sa le  person i n  the s hop  i s  k ind to me 
D 
The p rices are cheaper than other places D 
There i s  an  experienced herbal p ractit ioneO 
I get free herbal samples when I buy from the 
shop . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D 
Other,  p lease state . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . .  
2 9 .  How do you k now that herbal med ic ines  are u sefu l  for you r  cond it ions or ai lments? (Please t ick all that 
app l i es  to you)? 
a. From my exper ience i n  med ic ines or herbs 
(phys ic ian ,  pharmac is t ,  Medical  techn ic ian ,  and 
nurse ,  employee i n  t he  health care department ,  
cond imental shop,  or health food shop) . . . . . . . . .  . 
b. I have been recom mended to use he rbal 
med ic ines  by he rbal p ract it ioner . . . . . . . . . . . . . . . . . . .  . .  
E. I have been recommended to use herbal 
med ic i nes by fam i ly / friend . . . . . . . . . . . . . . . . . . . . . . . . .  . .  
□ 
□ 
□ 
d .  I have been recom m ended to use herbal 
med ic i nes  by a phys ic ian ,  dent ist ,  pharmac i s t  o r  
nurse  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D 
e. I have attended lectu re/workshop/conference that 
recommended us ing  herbal medic ines . . . . . . . . . . . .  D 
f. I have read a recom mendation to u se he rbal 
medic i nes in an art ic le of Magaz ine  / Jou rnal . . .  D 
g .  I saw/  l i stened t o  show o n  TV o r  Rad io which 
recommended us ing  herbal medic ines . . . . . . . . . . . .  D 
h .  I read recom mendation to  use he rbal med ic i nes  
on the i nternet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D 
i .  I read recommendat ion to  u se herbal med ic ines  
i n  Textbooks/  books & drug l eaflets / posters D 
j . Other ,  p lease state . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . .  
30 .  If there i s  more than one choice of herba l  medic ine to treat you r cond ition ,  how d o  you decide which 
one to choose? Pl ease t ick al l that appl i es to you 
a. The cheapes t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  0 
b. The most i n fo rmative label  . . . . . . . . . . . . . . . . . . . . . . . . . . . .  0 
c. The strongest  vers ion avai labl e . . . . . . . . . . . . . . . . . . . . .  O 
d .  The one you be l ieve to be the most effective . . . D 
e. The one ,  wh ich  comes i n  the largest quantity . . .  D 
f. The brand name ,  wh i ch  i nspi res the most 
confidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  O 
g .  The one ,  which requ ires l east number  of doses D 
per day . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . .  
h .  F lavor ( if th i s  i s  an option). . . . . . . . . . . . . . . . . . . . . . . . . . . .  D 
i .  The  product you have see n / heard of  the  most  0 
j . Recom mended by fami ly/fr iend . . . . . . . . . . . . . . . . . . . . .  D 
k. The most attractive label . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D 
I .  Recom mended by staff. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D 
m. Other  (please state) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
3 1 . Dur ing the las t l  2 months approx imate ly where and how many vis its d id you make to buy or  obtai n 
herbal med ic i ne  from the l i st below? 
Nu mber of vis its i n  last 1 2  months 
0 1 2 3 4 5 more than 5 
a) Herbal med ical center . . . . . . . . . . . . . . . . . . . . . . . . . . .  D □ □ □ □ □ □ 
b) Health food  s hops . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  □ □ □ □ □ □ □ 
c) Con d i  men tal shops . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D □ □ □ □ □ □ 
d) Pharmacy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D □ □ □ □ □ □ 
e) G roce ry or supermarket . .  . . . . . . . . . . . . . . . . . . . . . .  D □ □ □ □ □ □ 
f) Sport or  gym c lub  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D □ □ □ □ □ □ 
g) Othe r ,  p lease state . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  □ □ □ □ □ □ □ 
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3 2 .  Where d id  you r meet the  he rbal practit ioner? 
a) Neve r been to h erbal practitione r  . . . . . . . . . . .  · ·D 
b) Government  Hos pital . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  □ f) Herba l /  Health medica l  ce nter . . . . . . . . . . . . . . .  D 
c) Private Hos pita l /  p rivate c l i n i c  . . . . . . . . . . . . . . . . . .  □ g) H i s  home  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D 
d) Hea l th  food shop  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  □ h) Condi  mental shop . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  Q 
e) Pharmacy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  □ i )  You r  home . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D j) Other ,  p l ease state . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
3 3 .  D id  you see  a d octo r and a h e rbal  p ractition e r  at the same t ime fo r the same reason? D Yes D No 
34.  Do you consu l t  you r  doctor befo re taking any herbal medic ine? D Yes □ No 
3 5 . Please answer e i ther sect ion" a" o r  " b" ,  whichever appl ies to you :  
a .  I f  the answer to q uest ion (3 4) was yes, why d o  you consu lt them? (Please t ick a l l  that appl i es) .  
i .  I always d i scuss  any pos s i bl e  n ew medication with my doctor. . . . . . . . . . . . . . . . . . . . . . . . . . .  D 
i i .  I fee l  m y  doctor shou ld be  fu l ly aware about a l l  t h e  med ication I take. . . . . . . . . . . . . .  D 
i i i .  Any other  reason? 
b .  I f  the  answer to q uest ion  ( 3 4) was no, why don ' t  you consu l t  them? (P lease t ick a l l  that  appl ies) .  
i .  I don 't th ink  my docto r needs to know about any med ication I take u n less  
I t ' s  med icat ion that they prescribed for me . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D 
i i .  I d i d n ' t  t h i nk  to ment ion  i t  to t h e m  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D 
i i i .  I d id n ' t wan t  to  t roub le the  doctor; they're busy enough as i t  i s . . . . . . . . . . . . . . . . . . . . . . . . . . .  D 
iv. I don 't th i n k  my docto r be l i eves i n  herbal medic ines so wou ld n 't take me serious ly D 
v. Any othe r  reason? 
36 .  Do you th ink you wi l l  conti n u e  u s i n g  herba l  med ic i ne(s) as treatment  of you r  cho ice for you r cond i tion? 
Yes No 
SECTION FIVE: YOUR VIEWS ABOUT HERBAL AND CONVENTIONAL MEDICINES 
For th is  sect ion we wou l d  l i ke to know you r  views on herbal medicines and ,  if you chose to use  them .  Also 
your views about conventional medicines compared to herbal ones .  
3 7 . P lease t ick the  appropri ate box to show you r  op in ion on the fo l lowi ng s tatements :  
Stronqlv Agree No Disagree 
agree opinion 
a) I h ave more confidence i n  herbal med ic ines  than conve ntional ones □ □ □ □ 
b) Herbal med ic ines  are safe r than convent ional  medic ines . . . . . . . . . . . . . . . . . .  □ □ □ □ 
c) He rbal med ic i nes are m o re effective than convent ional medic i nes  . . . .  □ □ □ □ 
d) He rbal med ic ines  work as  q u ick ly as conventional medic ines to . . . . . . □ □ □ □ 
treat a prob lem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  □ □ □ □ 
e) There are no  p rob lems  taking h e rbal med ic ines  with conventional 
med ic ines  from a doctor or pharmacy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D □ □ □ 
f) He rbal med ic ines  have no  place i n  modern medic ine . . . . . . . . . . . . . . . . . . . . . . . .  D □ □ □ 
g) I Have exper ienced more usefu l  and benefit for a previous  ai l ment  
u s i ng he rbal med ici nes  than convent ional  o nes . . . . . . . . . . . . . . . . . . . . . .  □ □ □ □ 
h) Herbal med ic ines  treat the who le  body to make a person bette r, 
not j u st the prob lem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  • · · ·  . . . .  □ □ □ □ 
i) He rbal med ic ines  shou ld  contai n a l eaflet of s i m i lar  standard 
a n d  conten t  to conven t i o n al m e d ic i nes  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D D □ □ 
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Stronqlv 
disagree 
□ 
□ 
□ 
□ 
□ 
□ 
□ 
□ 
□ 
□ 
38 .  From t h e  l i st be low, p l e ase s tate you r  reasons  fo r choos ing  to take herbal and / or conve nt ional 
med ic i n e s .  (P lease t ick al/ th at app l i e s  to you). 
a. ls safe to u se? . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . .  
b. Processed c h e m ical man u factu r ing B B 
B B 
Herbal Conv 
f.Can i mprove & maintai n a person health . . .  O O 
c. Have n o  s ide  effects . . . . . . . . . . . . . . . . . . .  . .  
g .  l s  safe to be g iven to p regnant women  . . . . . . .  O O 
d. Can not get  add icted . . . . . . . . . . . . . . . . . . .  . .  
e.Can p reve n t  a person fro m g ett ing s i ck  D □ 
h . l s  safe to be g iven to b reastfeed ing  mothers□ D 
i. l s  safe to be g iven to ch i ldren below 1 2  years 
old . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  0 □ 
39 .  Have you ever  taken a conve nt iona l  med ic ine  to treat you r  condit io ns? D Yes D No 
40 .  If ye s to  the above qu e st ion , how e ffective was  the treatment  of you r  condit ions u s ing co nve ntional 
med ic i nes? 
D Ve ry effect ive D Effective D Not s u re D Not e ffective D Made me fee l  worse 
4 1 . Wh i l e  you we re tak ing  any of the he rbal medicines that you l isted ; were you also tak ing any 
conve nt ional med icat ions  e i ther  p re sc ribed or recommended by a doctor, dent ist ,  and pharmaci st? 
□ Yes D No 
If you chose  yes ,  p lease co nt i nue ;  if  you chose No p lease move to question  (42) .  
What cond i t ion (s )  was i t  treat ing? 
Can you n a m e  the  co nve nt iona l  med ication(s) 
42.  Fo r the fol lowi n g  cond i t ions ,  p lease state which wou ld be you r  fi rst  choice of med icat ion for treat ing 
co nd i t i o n :  
The condition Conventional The condition Herbal Convention. 
a. Bru ises  and / o r  I nj u ries .  D 
b. Back pai n and / o r  neck pa i n  . . . . . . . . .  D 
c. Anxiety and / o r  d e p ress ion  . . . . . . . . .  D d. ln
_
somn ia  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D e. Diabete s . . . . . . . . . . . . . . . . . . . . . . . . .  • •  . . . .  · ·  . . . . .  D f. Co ld and fl u . . . . . . . . . . . . . . . . . . . . . . . .  • . . . .  · . .  
g .  Asth ma and / o r  l u ng d i so rders . . . . . .  D 
h. Headache and / o r  m i g ra ine  . . . . . . . . .  D 
i .  Fatig u e  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . .  
j . Arthr i t is  / j o i n t  pa in  . . . . . . . . . . . . . . . . . . .  . .  
k. High b lood p re s s u re . . . . . . . . . . . . . . . . . . .  . .  
□ □ □ 
□ □ □ □ □ 
□ □ □ □ 
I. H i g h  choleste rol . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . .  D 
m. Sexual d i sorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D 
n. I n fe rt i l ity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D 
o .  Stomach and / or d igest ive d isorders.□ 
p. Sk in  d isord e rs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D 
q .  We ight  loss  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D 
r. We ight gai n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D 
s .  I m m u n ity and nutr ients d isorders . . . . . .  D 
t .  Cancer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D 
u. General  we l l  be ing for hea lth & body . .  
v. Oth er (s) p l ease state . . . . . . . . . . . . . . .  D 
43. Do you k n ow if any of you r  fam i ly m e m be rs use  he rbal m ed ic ines? D Yes D No 
□ □ □ □ □ □ □ □ □ □ 
b 7 · n u m be r  of ch i l d ren  n u mbe r  of  ad u lts . . . . . . . . .  . .  If ye s ,  how many female  mem ers . . . . . . . . . . . . . . . . . . . . . . . . . .  , . . . . . . . . . . .  . 
I b 7 · numbe r  of ch i ldren  . . . . . . . . . . . .  n u mber of adults . . . . . . . . .  . H ow many ma e m e m  e rs . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  , 
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SECTION SIX: YOU R VI EWS ABOUT HEALTH PROFESSIONALS 
In th i s  fi nal sect ion ,  we wou ld  l i ke to know about you r  views to different health care professionals an d  if  
you eve r  seek advice  from t h em  regard i ng you r  health or c l i n ical cond i t ion (s). 
44. Please t ick the  appropr iate box to s how your  opin ion on the fol l owing statemen ts :  
Strong/v Agree No Disagree Srronglv 
agree opinion disagree 
a. A vis i t  to herbal pract i t ioner is cheaper than doctor . . . . . . . . . . . . . . . . . . . . . . . . . D □ □ □ □ 
b. Herbal pract i t ioner shows more counse l l i ng ski l ls than doctor . . . . . . . . . . .  D □ □ □ □ 
c. Herbal pract i t ioner  offe rs many prom ises of cure for chron ic or 
med ical cond i t ion(s) than doctor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D □ □ □ □ 
d. Medici nes  g iven by h e rbal p ract i t ione r  is never out of s tock □ □ □ □ □ 
e. Medic i nes  g iven i n  the  health centre/ hospi tal i s  often out  of stock D □ □ □ □ 
f. You r  herbal pract i t ioner  d i scourage you from visit ing a doctor . . . . . . . . .  □ □ □ □ □ 
g. Your  doctor d i scourages you from vi s it ing herbal practitioner . . . . . . . . . . .  D □ □ □ □ 
h. You r  doctor d i scourages you from taking any herbal medicine (s) . . .  □ □ □ □ □ 
i .  You r herbal pract i t ioner d i scou rage you from taking any 
convent ional med ic ine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  □ □ □ □ □ 
45 .  From the c las s if ied hea l th  care p rofess ional s and others l i sted i n  the fol lowing tab le ,  (please t ick (✓) a l l  
that appl i e s  to  you ) :  
Statement 
A- Have suggested 
to you the use of 
herbal medic ines? 
B-Have ever 
suggested to you to 
see the herbal 
ractitioner? 
C- Have Prescribed 
to you an herbal 
medicine? 
D- Have advised you 
on what, when, how 
to use herbal 
medicine before you 
Purchased your last 
herbal medicine? 
2 
Phys i cian Pharmacist 
3 4 5 6 
Dentist Nurse Herbal Sale person i n  
Practitioner condimental 
sho s 
46. Wou ld you l i ke to l eave you r  phone  n u m be r  to cal l you if i
t 's n eces sary? D Yes 
The contact n u m ber --- ----------- -
------------------------ ----
Remarks ( if you wou l d  l i ke to add anyth ing  to th is Interview
). 
7 8 
Sale person Other, 
in Health Please 
food sho s state 
□ No 
-- ------------------------------------------------------- ---------------------------- -----------------------------------
---- ------- - -- :;;;;;���-;;;;;;��-;our t
ime and being constructive and beneficial" 
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Appendix 3.1  
Patient information and consent sheets, and data capture form 
used in Phase 2 of the research. 
149 
Information Sheet 
This survey has been approved by 
SKMC for investigating the safety of 
herbs used by patients taking them with 
or without medicines prescribed by 
their Doctor. 
It is very important for us to know the 
herbs that cause adverse events or 
reactions, as this will help to warn 
others as well. 
Before we start, we would like you to 
read the informed consent information 
below. 
• Participation in this survey is voluntary 
for individuals who would like to take 
part in this study.The survey will be 
completely anonymous and voluntary. We 
will not give your personal details to 
others. 
• This survey will help us to detennine the 
safety of your medicines and herbs you 
have taken or plan to take in the future. 
If you have any questions please ask the 
investigator before you proceed. 
Informed Consent 
1 .  You must be o f  1 3  years or older to 
participate in this survey. 
2.  There are no risks involved in 
completing the survey. 
3. This survey is used to collect 
infom1ation on your health, medicines, 
and it will not interfere with your 
medical treatment. 
4. The survey may take about 15-30 
minutes to complete. 
5. Participation is entirely voluntary; you 
may at any time withdraw from 
participation. 
6. All data obtained from this survey will 
be strictly co11fitle11tia/. Data will be 
kept anonymously and will not be shared 
with any other parties under any 
circumstance. 
7. This study and survey have been 
approved by the SKMC and your 
physician. 
After reading the consent items, please 
proceed to the questionnaire on the next 
page to get started with the survey. 
You may leave the survey at any time with 
nurse or at reception. 
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Sheikh Khalifa Medical City (SKMC) 
Patient Code # ---------
Name of Subject: 
File Number: 
Consent Form 
Title of Project: Safety of Herbal 
Medici11es i11 the UAE 
Name of Researcher: Fatima A. Abdulla 
Telephone # . ........................................... . 
• I confirn1 that I have read and understood 
the infonnation sheet for the above study. 
• I have had the opportunity to consider 
the infonnation, ask questions and have 
had these answered satisfactorily. 
• I understand that my participation is 
voluntary and that I am free to 
withdraw at any time, without giving 
any reason, and that this will not affect 
my medical care or legal rights. 
• I understand that relevant sections of 
any of my medical notes and data 
collected during the study may be 
looked at by the responsible 
investigators where it is relevant to my 
taking part in this research. I give 
pem1ission for these investigators to 
have access to my records. 
• I agree to take part in the above research 
study. 
► Signature of Person . . . . . . . . . . . . . . . . . . . . . . . .  . 
Date . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . .  
Time . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
► Signature of Investigator 
Date . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Time . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
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Patient History Notes 
Patient's First Name . . . . . . . . . . . . . . . . . .  Gender:O M O F  Age . . . . . . . . .  SKMC File No: . . . . . . . .  . 
Patient History 
1 .  What is your current health status "diseases"? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . .  
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·  
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·  
2. When did your health status "diseases" start, diseases history? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 
Other history details . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  .
0 • • 0 • • o • 0 o O • 0 0 • • • • 0 • • 0 • • • • I O • 0 0 • 0 • 0 • o O o O O • 0 • • 0 o • 0 • 0 • • 0 o • 0 0 0 0 0 0 • 0 0 0 0 • 0 o O O o O o O O O • 0 • • I • o • 0 0 • 0 o • o o • • • o • o O o • 0 0 0 • 0 • 0 • • o o O o • 
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·  
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·  
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·  
Herbal Medicines (HM): 
l .  Have you used herbs in the past? □Yes D No , if yes, then fill the table 
2. Are you using any herbs right now? □Yes □ No , if yes, then fill the table 
3. Have you used herbs before got your current health condition "disease"? □Yes 
. f  th fill th bl 1 yes, en 1 e ta e □ No, 
No. What Why did How What How Where When Prescribed 
were you take did you form often did was last 
they it take it? you did you time you 
use it? you obtain had / 
use it? it? takin2 it? 
I 2 
3 
4 
s 
6 
4. Have you used any herbs while taking prescription medicines? □Yes, 
5. Patient claim that he I she did not used herb's" while they have used? □Yes, 
6. Have you informed your physician or pharmacist about using / taking herbs? 
□Yes, D No 
7. Have you experienced any discomfort or ADR during herb intake?□Yes, □ No, 
if yes, then fill the ADR form. 
8. Have you informed your physician or pharmacist about this ADR?□Yes, □ No 
9. Patients have visited a herbal center? □Yes, D No, 
if ves then name of Herbal Center . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
and fill in the previous table the HM's that patient had, What for and how long? 
Conventional Medicines (CM) 
by? 
□ No 
□ No 
No. Name of Strength Dosage Dosage How long Indications Prescribed 
CM form? regimen? have you & reason by? 
used it? for use 1 2 3 I I I I I I I 
I : I I I I I I 
Statements on CM Yes or No If yes then, what What for? 
were/are they? 
1 .  Are you taking any OTC □Yes, □ No 
medications? 
2. Are you visiting other clinic or □Yes, □ No 
hospital? 
3. Are you taking other □Yes, □ No 
medicines prescribed outside the 
nephrology clinic? 
S.N . . . . . . . . . . . .  . SUSPECTED HERBAL ADVERSE DRUG REACTIONS (Confidential) 
If you are suspicious that an adverse reaction may be related to a Herb (s) or combination of herb-drugs 
please complete this fonn. 
Report suspected adverse reactions for: 
Medically significant case, Patient discomfort and irrritabi lity , Fatal , Life threatening , Involves or 
prolongs inpatient hospitalisation, Involves persistent or significant disability or incapacity, Congenital 
abnormality, Other improtant reactions. PATIENT DETAILS: Reaction 
Type SUSPECTE D Herb (S) Give the Brand name Suspected Reaction (s) Please describe the reaction(s) and any treatment given: Was the reaction serious? Patient's First name(optional) : Sex: M /  F Weight i f  known (kg): Age (at time of reaction): . . . . . . . . . . Hospital or Health centre: . . . . . . . . . . . . . . F i le  Number: Marital status . . . . . . . . . . . . . . . . . . .  Pregnant / Lactating (if woman) YesD If pregnant woman consuming the herb(s)), the trimester is : 1 / 2 / 3 If person consuming the herb(s) is an infant, the substance administered: Directly D or Breast Feeding Mother D No 0 Herbal Product (s) D Herb -Drug D Herb-Nutrients □Herb-Food 0 Others Brand Active Form Route Dose Date Date Source Prescribed Name Ingredient drug drug for started stoooed P lease describe the reaction (s} , symptoms and any Outcome (Tick) treatment given : Recovered □ Recovering O Hospitalized 0 Continuing D Day (s) . . . . . .  Other□ Date started: I If stopped, give date: Yes D No □ ff yes, please indicate why the reaction is considered to be serious (please tick all that apply): Patient died due to reaction □ Congenital abnonnal ity □ Involved □ persistent or Life threatening □ Caused involved or 
□ 
signi ficant prolonged inpatient disability or hospitalisation incapacity Medical l y  signi ficant D Please give detai ls: I I 
OTHER Did the patient take any other drugs in the last 3 months prior to the reaction? YesO No U 
HERBS / If yes: 
DRUGS / Item (Brand name if Route Dose Date Date Prescribed 
Ingredients possible) started stoooed for: 
(including 
self-
medication & 
herbal 
remedies) 
Medical Other Medical Problems: e.g. Medical history, test results, known al lergies, rechallenge (i f 
History and performed) suspected drug interactions. For congenital abnormalities please state all other 
Additional herbs /drugs taken during pregnancy and the last menstrual period. 
relevant · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 
information · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·  
· · · · · · · · ·  
Other Health Factors: D Obesity D Smoking OOthers 
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · • · " · · · · · · " · · · · · · · " • ' • •"" '' ' ' ' " ' ' ' '" ' ' ' ' ' '" ' '" ' ' '" '" ' '  
Lab Tests/Liver Function/Other Blood Tests? 
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 
Significant Recent Stresses or Life Changes? 
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·  
Was the Drug information service/Physisian consulted about the reaction or  before the drug(s) 
used? YesO No □ 
Details of Name ( optional) Profession Department: Date 
Reporter Dr □ Parmacist 0 Nurse D Patient □ 
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Return Kindly return the form after filling nesessary information to Dr. Fatima Ali on : 
Form Fax :02-63 13  742 or call 02-6334958 (Day Timing) 
or send an email to col lect forms on: Albraiki2@yahoo.com 
I 
� I I I 
, 
I survey No . . . . . . . . . . . . . . .  I Data Validationand Clinical_Ass_essment 
Patient First Name . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . SKMC File No . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
Describe General Patient Details 
Describe Patient Renal Diseases 
Patient is : D General (Unspecified) D Renal transplanted History note Nephrologis 
D on D ialysis D Other , to specify . . . . . . . . . . . . . . .  Patient's file t's Note 1 .  Has patient used herbs in the past? □Yes □ No □Yes □ No 
2. Has patient taken any herbs in the present? □Yes □ No □Yes □ No 
3. Has patient infonned the physician about taking herbs? □Yes □ No □Yes □ No 
4. Patient claim in interview that he / she Taking herb (s) ? □Yes □ No □Yes □ No 
5. Patient claim in interview that he / she Not Taking any herb? □Yes □ No □Yes □ No 
6. Has the Patient experienced any discomfort or ADR during □Yes □ No □Yes □ No 
herb intake, i[l!_es, then il,ll the ADR [orm. 
7. Has patient had an adverse reaction to a herb, then takes it □Yes D No □Yes □ No 
again and has the same reaction again? D unknown 0 unknown 
8. Patients has visited a herbal center? , if yes then name of □Yes □ No □Yes □ No 
Herbal Center . . . . . . . . . . . . . . . . . . . . . . . .  & fill in the previous 
table the HM's that patient had 
9. Patient has been admitted for emergency reason? if yes then □Yes □ No □Yes □ No 
what for? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
10.  Patient has been seen in unscheduled appointment? if yes □Yes □ No □Yes □ No 
then what for? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 1 .  Has patient had an adverse reaction to a herb, then takes i t  □Yes □ No □Yes □ No 
again and has the same reaction again? i(ves, then fill the 
ADR {prm. 
........................................................................................................................... 
_ ,  __ - I 
12. Patient taking OTC medications? If yes then what □Yes □ No □Yes □ No 
medicines? . . . . . . . . . . . . . . . . . . . . .  What for? . . . . . . . . . . . . . . . . . . . . .  
13.  Patient visiting other clinic or hospital? If yes then what □Yes □ No □Yes □ No 
clinic . . . . . . . . . . . . . . . . What for . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
14. Patient visiting other clinic in SKMC? If yes then what □Yes □ No □Yes □ No 
clinic . . . . . . . . . . . . . . . . . .  What for . . . . . . . . . . . . . . . . . . . . . . 
Remarks 1 · · · . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . · · · · · · · · · · · . . . . . . . . . . . . . . . . . . . . I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·  · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·  
Herbs taken by Patient (If different than Information given during Interview) 
No. What Why How What How Where When Prescribed History N ephrologist' s 
were did did form often did pt was by? note Note 
they pt pt pt pt obtain last Patient's 
take take use use it? time file 
it it? it? it? pt 
had 
it? 
I □Yes □Yes □ No 
□ No 
2 □Yes □Yes □ No 
□ No 
J □Yes □Yes □ No 
□ No 
4 □Yes □Yes O No 
□ No 
5 □Yes □Yes □ No 
□ No 
6 □Yes □Yes □ No 
□ No 
Conventional Medicines taken by Patient & Prescribed by Nephrologists 
No. Name of CM Strength Form Dosage Duration of Indications Prescribed 
regimen Use by 2 
J 
I 
I I 
I 
I 
I 
I I 
I 
I 
4 
5 
6 
7 
8 
Naranjo causality scale for ADR 
Question/ Scoring Yes/Noillo not know or unavailable Yes No Do not 
know or 
unavailable 
l. Are there previous conclusive reports on this reaction? l 0 0 
2. Did the adverse event appear after the suspected drug was given? 2 - 1  0 
3. Did the adverse reaction improve when the drug was discontinued or a 1 0 0 
specific antagonist was given? 
4. Did the adverse reaction appear when the drug was re-administered? 2 -1 0 
5. Are there alternative causes that could have caused the reaction? -1 2 0 
6. Did the reaction reappear when a placebo was given? -1 1 0 
7. Was the drug detected in any body fluid in toxic concentrations? 1 0 0 
8. Was the reaction more severe when the dose was increased/increasing or 1 0 0 
less severe when the dose was decreased? 
9. Did the patient have a similar reaction to the same or similar drugs in any 1 0 0 
previous exposure? 
Total 
Scoring: 9 = Definite ADR, (5-8) =Probable ADR, (1-4) =Possible ADR, 0 =Doubtful ADR 
I 
Survey ID: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . SKMC # . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
Name of Patient: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  Age . . . . . . . . . . . . . . . . .  Nationality . . . . . . . . . . . . . . .  
S.N Test Result Report date / Remarks 
1 Creatinine 
2 Creatinine Level 
3 Cr. Clearance 
4 er.Cl. Level 
5 GFR 
6 Urine 24 hr 
7 Urea 
8 Urea level 
9 Na 
1 0  Ca 
1 1  Mq 
1 2  K 
1 3  P04 
1 4  Uric acid 
1 5  Albumin 
1 6  Albumin Level 
1 7  Total Albumin 
1 8  Mic. Albumin 
1 9  Bil lirubin 
20 Billirubin Level 
21 Total Protein 
22 Protein 
23 Protein Level 
24 Hb 
25 Hb Level 
26 Cholesterol 
27 Cholesterol Level 
28 Glucose 
29 Glucose Level 
30 Tacrolimus 
31 Tacrolimus Level 
32 Enzymes 
33 Enzymes Level 
34 Correlated.CCT 
I 
l 
I I I 
I 
I 
I 
I I 
I I 
Appendix 3.2 
Case studies of patients reporting ADRs to herbal medicines in the 
Phase 2 study. 
150 
Summary of ADR Cases 
Case numbers represent the case number used in the original sample of 49 suspected ADRs. 
The 26 cases assigned possibly or probably related to herbs are presented here. 
Case number 2 
Reporter details Patient v Patient's doctor Other 
Patient details Age (years) Gender Reason for Attendance at 
SKMC 
15 Female ,,.., Follow up visit at ,, 
Nephroloqy Clinic 
Case Type Retrospective v Prospective 
Sign and symptoms 
Diarrhoea 
Lab tests ( N :Normal , L:  Low , H ;  High) 
Description of creatinine (N), urea (N) ,Na (N), Mg (N), K (N) ,  P04 ( N),uric acid 
. Suspected ADR (N),albumin (N),bilirubin (N),total protein (N) ,HB (N),cholesterol 6 
(H).glucose (N),ALP (N),AST(N), AL T(N),GFR 68 (L) 
Other 
Severe diarrhoea after senna intake 
Type Herbal ADR 
List of Herbal anise, thyme, senna, cinnamon 
Medicines taken 
List of Conventional Niferex, alendronate, vit D, Ca, paracetamol , 
Medicines taken 
Sources of data Patient notes j Conversation with j Patient's doctor ✓ patient ✓ 
Possible cause(s) Senna 
Justification - brief summary 
Niferex (multivitamins and iron) has diarrhoea 1 as a side effect, 
Author's conclusion alendronate side effect is diarrhoea, senna causes diarrhoea2 and 
possibly enhances this side effect of the PMs taken. 
i Naranjo score I modified Naranjo score 
1 (possible) / 1 ( possible) 
Consensus This relationship is possible. 
1 conclusion Most of the drugs listed are associated with diarrhoea. 
I 
1 http://www.drugs.com/sfx/n iferex-side-effects.html (accessed 9/07 /09) 2 http://www.drugs.com/mtm/senna.html (accessed 9/07 /09) I I I I I I I I I I I I 
i 
i Case number 6 
/ Reporter detai ls Patient v Patient's doctor Other 
i 
/ Patient detai ls Age (years) Gender Reason for Attendance at 
55 Female SKMC 
► Follow up visit at 
Nephroloav Clinic 
Case Type Retrospective v Prospective 
Sign and symptoms 
Abdominal pain 
Lab tests ( N :Normal , L :  Low , H; High) 
Description of creatinine 104 (N),urea 8 (H),Na134 (L),Mg 1 (N), K 4 (L),PO4 2 
Suspected ADR (H).uric acid 428 (H).albumin 37 (N),bilirubin 15 (N),total protein 66 
(N), HB 121 (N),cholesterol 6 (H),glucose 6 (N) ,ALP 70 (N),AST 15 
(N),AL T 17 (N), CCT 97 (N),GFR 71 (L) 
Other 
Abdominal pain when patient had senna or thyme. 
Type Herb- Drug Interaction resu lting in ADR 
List of Herbal senna, thyme, karkadeh, ginger, fenugreek 
Medicines taken 
emla cream (lidocaine), lactulose, aspirin, losartan ,  amlodipine, folic 
List of Conventional acid, 'renal' multivitamin supplement, omeprazole, moxonidine, 
Medicines taken atorvastatin, ea-acetate, sevelamer (for hyperphosphatemia), 
gabapentin 
Sources of data Patient notes I Conversation with I 
Patient's doctor 
✓ patient ✓ 
Possible cause(s) Senna, thyme and lactulose 
Justification - brief summary 
Author's conclusion 
Interactions between senna herbs & lactulose, atorvastatin side 
effect is stomach pain3. Senna may cause mild abdominal 
discomfort such as colic or cramps.3 Toxic symptoms of volatile oil 
of thyme (thvmol) documented for causing gastric pain3 
Naranjo score I modified Naranjo score 
2 (possible) / 2 ( possible) 
Consensus This case is a possible ADR 
conclusion 
3Herbal Medicine: A Guide for Health Care Professionals by J oanne Barnes, Linda A. Anderson, J . David 
Phi l l ipson, and Joanne Barnes, 2002. Pharmaceutical Press. 
I 
I 
I 
I 
I 
i 
! 
f Case number 8 
: Reporter details Patient v Patient's doctor Other 
I 
I 
/ Patient details Age (years) Gender Reason for Attendance at 
SKMC 
59 Male ► Follow up visit at 
Nephrology Clinic 
Case Type Retrospective v Prospective 
Sign and symptoms 
Increase stomach acidity and presence of blood in stool after herbs 
intake 
Lab tests ( N:Normal , L: Low , H; H igh) 
Description of 
Suspected ADR creatinine (N),urea (N), Na (N) ,Mg (N), K (N), P04 (N),uric acid 
(N),albumin (N),bilirubin (N),total protein (N),cholesterol (N),ALP 
(N),AST (N),AL T (N),GFR =73 (L) 
Other 
Tvpe Herbal ADR 
List of Herbal Peppermint, ginger, Arabic gum, thyme, fenugreek 
Medicines taken 
List of Conventional amlodipine, paracetamol , al lopurinol , ca�supplements, diclofenac 
I Medicines taken sodium qel, multivitamins, hydroxyzine 
[ Sources of data Patient notes I 
Conversation with 
I 
Patient's doctor 
✓ patient ✓ I 
I Possible cause(s) Patient had increase in acidity after ginger intake , and blood in 
I stool after thyme intake 
Justification - brief summary 
Author's (Fatima's) 
Side effect of paracetamol is occasionally b leeding4, rarely blood 
disorders (e.g thrombocytopenia , leucopenia , neutropenia)5• 
conclusion Ginger has inhibition of platelet activity 6 , toxic symptoms of volatile 
oil of thyme (thymol) documented for causing gastric pain, nausea, 
vomiting6 • 
Naranjo score I modified Naranjo score 
5 (probable ) /  5 (Definite) 
This case has a strong association. 
One or more herbs (thyme and/ or ginger) may have been 
Consensus associated with the patient's complaint. Diclofenac is an NSAID 
conclusion commonly associated with increased GI discomfort and sometimes 
b lood in the stools, but in this case, in gel form so the risk will be a 
lot lower than with the oral form. 
4 http://www.drugs .com/cons/tylenol-drops.html (accessed 9/07/09) 5 British National Formulary ( BNF) edition No.56 -September 2008 
6 
Herbal Medicine: A Guide for Health Care Professionals by Joanne Barnes, Linda A. Anderson, J. David 
Phi l l ipson, and Joanne Barnes, 2002. Pharmaceutica l Press. 
: 
I 
Case number 9 
Reporter detai ls Patient '\/ Patient's doctor Other 
1 Patient details Age (years) Gender Reason for Attendance at 
70 SKMC 
Female ► Follow up visit at 
Nephroloqy Clinic 
Case Type Retrospective Prospective '\/ 
Sign and symptoms 
Patient complained of low blood pressure after herbs intake. 
Lab tests ( N:Normal , L :  Low , H; High) 
Description of creatinine 108 (H).urea 9 (H) ,Na 138 (N) ,Mg 1 (N), K 4 (N),PO4 1 
Suspected ADR (N),uric acid 190 (L),albumin 34 (L),bilirubin 12 (N) ,total protein 74 
(N), HB 1 1 1  (L),glucose 1 0  (H),ALP 88 (N),AST 21  (N),ALT 29 
(N),GFR 65 (L) 
Other 
Type Herb- Drug Interaction resulting in ADR 
List of Herbal senna, thyme, fenugreek, black seed, cardamom 
Medicines taken 
List of Conventional  Ca-acetate, aspirin, atorvastatin, omeprazole,  isosorbide 
Medicines taken mononitrate, cetirizine 
Sources of data Patient notes j Conversation with j Patient's doctor ✓ patient ✓ 
Possible cause(s) Thyme, fenugreek, black seeds 
Justification - brief summary 
Nitrate drugs (lmdur) may interact with thyme7 and fenugreek7which 
Author's conclusion also have hypotensive activity. 
Black seeds have hypotensive effect7 
Naranjo score / modified Naranjo score 
5 (probable) / 5 ( definite) 
Consensus 
conclusion This case has strong (probable) interaction. 
7 Herba l Medicine: A Guide for Health Care Professionals by Joanne Barnes, Linda A. Anderson, J. David 
Ph i l l ipson, and Joanne Barnes, 2002. Pharmaceutical Press. 
I 
I_ 
I 
I 
I 1 
i ! 
J 
I 
I 
I 
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I Case number 10 
I Reporter details 
I 
Patient " Patient's doctor Other 
Patient details 
Case Type 
Description of 
Suspected ADR 
Type 
List of Herbal 
Medicines taken 
List of Conventional 
Medicines taken 
Sources of data 
Possible cause(s) 
Author's conclusion 
Consensus 
conclusion 
Age (years) Gender Reason for Attendance at 
SKMC 
63 Male ·-. Follow up visit at ,, 
Nephrology Clinic 
Retrospective '\/ Prospective 
Sign and symptoms 
Patient complained of itching after herb intake. 
Lab tests ( N :Normal , L: Low , H ;  High) 
creatinine 55 (N),urea 4 (N),Na 137 (N),Mg 1 (N), K 4 (N), PO4 1 
(N),uric acid 180 (L),bilirubin 36 (H),HB 110 (L) ,cholesterol 4 
(N),glucose 7 (H),GFR 107 (N) 
Other 
Itching after fenugreek intake 
Herbal ADR 
fenugreek 
amlodipine, Ca-acetate, folic acid, 'renal' vitamin supplement, 
lactulose, Na docusate, omeprazole, hydralazine, metoprolol 
Patient notes I Conversation with I Patient's doctor ✓ patient ✓ 
Fenuqreek 
Justification - brief summary 
Documented signs of an allergic reaction due to fenugreek are: an 
unexplained rash, hives, itching, unexplained swelling, wheezing, 
difficulty breathing or swallowing 8·9· 10·1 1  
Naranjo score I modified Naranjo score 
5 (probable) /  5 ( definite) 
This case has strong or high probability. 
3 http ://nccam.n ih .gov/health/fenugreek/#cautions (accessed 9/07 /09) 
9 http://nccam.n ih .gov/health/fenugreek/index.htm (accessed 9/07 /09) 
10i:,ttp://www.ncbi . n lm .n ih .gov/pubmed/18930518?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed .Pub 
med Resu ltsPanel . Pubmed DiscoveryPanel .Pubmed D iscovery RA&l inkpos=l&log$=relatedarticles&logdbfro 
m=pubmed (accessed 9/07/09) 
11http://www.ncbi .n lm.n ih .gov/pubmed/9087156?ord ina lpos-3&itool-EntrezSystem2 . PEntrez.Pubmed .Pubm 
ed Resu ltsPane l .Pubmed Defau ltReportPanel .Pubmed RVDocSum (accessed 9/07 /09) 
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Case number 
Reporter details 
Patient detai ls 
Case Type 
Description of 
Suspected ADR 
Type 
List of Herbal 
Medicines taken 
List of Conventional 
Medicines taken 
Sources of data 
Possi ble cause(s) 
Author's (Fat ima's) 
conclusion 
Consensus 
conclusion 
1 1  
Patient "' Patient's doctor Other 
Age (years) Gender Reason for Attendance at 
SKMC 
42 Female ► Follow up visit at 
Neohroloav Clinic 
Retrospective Prospective 'V 
S ign and symptoms 
Acidity of stomach 
lab tests ( N :Normal , l: low , H; High) 
creatinine 338 (H).urea 39 (H*),Na 131 (L), K 6 (H), P04 2 
(H).albumin 30 (L),bilirubin 7 (N),total protein 79 (N) ,HB 108 
(L),cholesterol 2 (L),glucose 12 (H).ALP 107 (N),AST 12 (L),AL T 8 (N), GFR 12 (L) 
Other 
Herb- Drug Interaction resulting in ADR 
ginger, cinnamon, cardamom, red chilli 
losartan, atorvastatin, allopurinol, aspirin 
Patient notes I Conversation with I Patient's doctor 
✓ pat ient 
Cinnamon and possibly other herbs 
Justification - brief summary 
Cinnamon is an irritant to mucous membranes 1 2, aspirin 1 3· 1 4  and 
atorvastatin 1 5  • 1 6side effects include stomach pain and heartburn. 
Naranjo score I modified Naranjo score 
5 (probable) / 5 ( definite) 
This case is of high probability. 
G I  symptoms may also be associated with diabetic nephropathy and 
chronic renal failure. 
1� Herbal Medicine: A Gu ide for Health Care Professionals by Joanne Barnes, Linda A. Anderson, J. David 
Ph i l l i pson, and Joanne Barnes, 2002. Pharmaceutical Press 
13 http://www.drugs.com/cdi/aspirin.html (accessed 9/07/09) 
14 http://www.drugs.com/sfx/aspirin-side-effects .html (accessed 9/07 /09) 
'5 http://www.drugs.com/lipitor.html (accessed 9/07/09) 
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Case number 
Reporter detai ls 
; Patient details 
Case Type 
Description of 
Suspected ADR 
Type 
List of Herbal 
Medicines taken 
1 List of Conventional 
I Medicines taken 
' 
: Sources of data 
: 
i Possible cause(s) 
! 
13 
Patient "\I 
Age 
(years) 
51 
Patient's doctor Other 
Gender Reason for Attendance at SKMC 
► Follow up visit at Nephrology 
Female Clinic 
Retrospective "\I Prospective 
Sign and symptoms 
Dizziness (and d iarrhoea) 
Lab tests ( N :Normal , L: Low , H; High) 
creatinine 186 (H).urea 10 (H),Na 140 (N), Mg 1 (N), K 5 (N), PO4 1 
(N),mic albumin 5 (N),HB 133 (N),cholesterol 4 (N),glucose 7 (H),GFR 
35 (L) 
Other 
herbs caused d iarrhoea and dizziness 
Herb- Drug Interaction resulting in ADR 
mix (black seed, fenugreek, anise, oat), ginger, thyme 
insulin, ASA, mycophenolate mofetil, Ca, atorvastatin, losartan, 
prednisolone,ciclosporin, amlodipine, metoprolol , moxonidine 
Patient notes j Conversation with j Patient's doctor ✓ patient ✓ 
Herbal mixture, ginger, thyme and PMs 
Justification - brief summary 
1 
Author's conclusion 
i 
Dizziness: insulin interacts with herbal ingredients with hypoglycaemic 
activity (fenugreek 1 7 + ginger1 7) ,  leading to dizziness . Calcium channel 
blocking drugs (amlodipine) interact with herbal ingredients with hypotensive 
activity (ginger+ fenugreek+ thyme) 17, amlodipine drug side effect is 
dizziness. 18  Antihypertensive drugs (losartan) interact with herbal ingredients 
with hypotensive activity (ginger+ fenugreek+ thyme) to cause potentiation 1 7 . 
Mycophenolate mofetil side effect is diarhoea 18 , omeprazole side effect is 
d iarrhoea and dizziness 18 , atorvastatin side effect is diarrhoea and 
dizziness 19, ASA side effects is dizziness and diarrhoea. 19 Losartan drug side 
effects is diarrhoea and dizziness. 20 Toxic srmptoms of volatile oi l  of thyme 
(thymol ) documented for causing dizziness 1 
Diarrhoea: none of the herbs listed are associated with diarrhoea. 
Naranjo score / modified Naranjo score 
5 (probable) / 5 ( definite) 
1 Consensus conclusion 
High possibility (probability) of herb - PM interactions l inked to 
d izziness. 
17 Herbal Medicine :  A Gu ide for Health Care Professionals by Joanne Barnes, Linda A. Anderson, J. David 
Ph i l l ipson, and Joanne Barnes, 2002. Pharmaceutical Press 
18 British National Formu lary ( BNF)  edition No.56 -September 2008. 
19 http://www.drugs.com/sfx/aspirin-side-effects .html (accessed 9/07 /09 )  
20 British National Formulary (BNF)  edition No.56 -September 2008. 
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! Case number 14  
! Reporter details Patient " Patient's doctor Other 
i Patient detai ls Age (years) Gender Reason for Attendance at 
I 
SKMC 
34 Male ► Follow up visit at 
Nephroloav Clinic 
Case Type Retrospective " Prospective 
Sign and symptoms 
tiredness. 
Lab tests ( N:Normal , L: Low , H; High) 
Description of creatinine 144 (H).urea 10 (H) ,Na 141 (N), Mg 1 (N), K 5 (N), PO4 1 
Suspected ADR (N), uric acid 441 (H).albumin 38 (N),mic albumin 109 (H*),bilirubin 
10 (N),total protein 65 (N) ,HB 134 (N),cholesterol 4 (N),glucose 9 
(H) ,ALP 82 (N),AST 24 (N) ,AL T 32 (N),GFR 49 (L) 
Other 
senna causes tiredness 
Type Herb- Drug Interaction resulting in ADR 
List of Herbal senna, Phytoshape slimming brand 
Medicines taken 
List of Conventional lisinopril 
Medicines taken 
Sources of data Patient notes 
J 
Conversation with j Patient's doctor 
✓ patient ✓ 
Possible cause(s) 
Justification - brief summary 
Author's conclusion 
Lisinopril l isted drug side effect is fatigue and malaise21 Phytoshape 
contains counterfeit sibutramine, which has weakness and fatigue21  
as side effects. 
Naranjo score I modified Naranjo score 
5 (probable) / 5 ( definite) 
Consensus This case is of high possibility. 
conclusion High probability of druq interaction between drugs and herbs. 
21 British National Formulary (BNF) edition No.56 -September 2008 
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/ Case number 1 5  
, Reporter details Patient " Patient's doctor Other 
Patient detai ls  Age (years) Gender Reason for Attendance at 
SKMC 
39 Female ► Follow up  visit at Nephrology 
Clinic 
Case Type Retrospective " Prospective 
Sign and symptoms 
1 Itching, 2: vomiting, stomach acidity 
Lab tests ( N :Normal , L: Low , H; High) 
creatinine 475 (H).urea 23 (H) .Na 1 44 (N), Mg 1 (N}, K 5 (N) ,  P04 2 
Description of (H) .al bumin 34 (L),b ilirubin 1 1  (N) ,  total protein 63 (N) ,HB 1 1 7 
Suspected ADR (N),cholesterol 4 (N),glucose 5 (N},ALP 57 (N),AST 6 (L),AL T 9 (N) ,  GFR 
10 (L) 
Other 
fenugreek caused itching , mixtures of herbs caused vomiting and 
heartburn 
Type Herb- Drug Interaction resulting in ADR 
List of Herbal Medicines mixture of herbs, fenugreek, arabic gum, chamomile, thyme, peppermint, 
taken senna. sage 
List of Conventional Methyldopa 
Medicines taken 
Sources of data Patient notes j Conversation with I Patient's doctor ✓ patient ✓ 
Possible cause(s) Herbs with methydopa 
Justification - brief summary 
Itching: methyldopa side effect is allergic (hypersensitivity) reaction22; 
signs  of an allergic reaction due to fenugreek are: unexplained rash, h ives, 
itching ,  unexplained swelling, wheezing ,  difficulty breathing or 
Author's conclusion swal lowing23• Chamomile can cause al lergic skin reactions24 . 
Vomiting and stomach acidity: herbal ingredients with local GI irritant 
activity include sage. 25 Toxic symptoms of volatile oil of thyme (thymol)  
documented for causing gastric pain, nausea, vomiting26• 
Naranjo score I modified Naranjo score 
5 (probable) / 5 ( definite) 
Consensus conclusion 
This association is of h igh possibility. High probability of interaction 
between drugs and herbs especial ly in this case of end stage kidney 
disease. 22 British National Formulary (BNF )  edition No.56 -September 2008 23 
http://diabetes.ernedtv.com/fenugreek/fenugreek-side-effects.html (accessed 9/07 /09) 
24 
Herbal Medic ine: A Gu ide for Health Care Professionals by Joanne Barnes, Linda A. Anderson, J .  David 
Ph il l ipson ,  a nd Joanne Barnes, 2002. Pharmaceutical Press. 
· ,5 
• http://www.drugs.com/npp/sage.html (accessed 9/07/09) 
26 http://www.druginfosys.com/Drug.aspx?drugCode=1254&drugName= Thymol&type=7 ( accessed 9/07 /09) 
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Case number 16 
Reporter detai ls Patient " Patient's doctor Other 
Patient details A ge (years) Gender Reason for Attendance at 
SKMC 
59 Male ► Follow up visit at 
Nephrology Clinic 
i Case Type Retrospective Prospective " 
Sign and symptoms 
Abdominal pain 
Lab tests ( N :Normal , L: Low , H; High) 
Description of creatinine 117 (H),urea 5 (N),Na138 (N) ,Mg 1 (N), K 4 (N),PO4 1 
Suspected ADR (N),uric acid 305 (N),albumin 39 (N),bilirubin 1 4  (N),total protein 67 
(N),cholesterol 4 (N),glucose 5 (N),ALP 1 27 (H).AST 1 7  (N),ALT 1 8  
(N),GFR 64 (L) 
Other 
abdominal pain when patient took herbs for constipation 
Type Herb- Drug Interaction resulting in ADR 
List of Herbal Mixture of herbs, thyme 
Medicines taken  
List of Conventional sildenafil, paracetamol, diclofenac gel, amlodipine, gliclazide, 
J 
Medici nes taken losartan, aspirin, atorvastatin, ranitidine, docusate sodium. 
! Sources of data Patient notes j Conversation with j Patient's doctor ✓ patient ✓ 
Possib le cause(s) Mixture of ingredients may have contributed to the ADR 
Justification - brief summary 
Author 's conclusion 
Laxative herbs e.g. senna can cause abdominal spasms and pain27 ; 
amlodipine drug side effect is nausea, stomach pain28; gliclazide 
side effect is stomach pain29. Toxic symptoms of volatile oil of thyme 
(thymol} include gastric pain. 27 
Naranjo score I modified Naranjo score 
3 (possible ) / 3 (probable) 
Consensus Possible association. 
conclusion Diabetic nephropathy may also contribute. 
27 Herbal Medicine :  A Guide for Health Care Professionals by Joanne Barnes, Linda A. Anderson, J. David 
Ph i l l i pson, and Joanne Barnes, 2002. Pharmaceutical Press. 
23 http://www. mayocli n ic .com/health/drug-information/DR60295 7 /DSECTION=side-effects ( accessed 9/07 /09) 
29 http://www.medicinenet.com/gliclazide-oral tablet/art ic le.htm (accessed 9/07 /09) 
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! Case number 1 7  
' Reporter detai ls Pat ie nt -v Patient's doctor Other 
Patient details Age (years) Gender Reason for Attendance at 
54 SKMC 
Male ► Follow up visit at 
Nephroloqy Cl inic 
Case Tvpe Retrospective v Prospective 
Sign and symptoms 
Raised blood pressure. 
Lab tests ( N :Normal , L: Low , H; High) 
Description of creatinine 1 87 (H) .urea 1 0  (H) ,Na141 (N) ,Mg 1 (N) ,  K 3 (L),P04 2 
Suspected ADR (H) .albumin 34 (N) ,mic albumin 1 8  (N) ,total protein  72 (N) ,HB 83 
(L),cholesterol 4 (N),glucose 5 (N),ALP 93 (N),AST 1 7  N ),AL T 1 3  
(N) ,Correlated CCT 1 1  (N) 
Other 
ginseng may cause increased blood pressure. 
Type Herb- Drug Interaction result ing in ADR 
List of Herbal ginseng,  thyme, fenugreek, g inger, herbal vitamin supplementation 
Medicines taken 
List of Conventional darbepoetin ,  allopurinol, multivitamins with i ron; sevelamer (for 
Medicines taken hyperphosphatemia)· losartan, vitamin D ,  NaHC03 , tamsulosin hydrochloride 
Sources of data Patient notes I Conversation with 
J 
Patient's doctor 
✓ patient ✓ 
. Possible cause(s) Ginger and ginseng plus PM 
Justification - brief summary 
Author's conclusion 
Tamsulosin may cause irregular heartbeat (tachycardia) and 
palpitations30. Animal studies have reported that g inger and g inseng 
have hypertensive activity31 . 
Naranjo score I modified Naranjo score 
1 (possible) / 1 ( possible) 
ADR l inked to a possible drug interaction (antagonistic) with one or 
Consensus more PMs. 
conclusion 
Hypertension associated with renal impairment may have been a 
feature in this patient. 
30 
British National Formu la ry ( BNF) edition No.56 -September 2008 
31 Herba l Medic ine: A Guide for Health Care Professionals by Joanne Barnes, Linda A. Anderson, J .  David 
Phi l l ipson, and Joanne Barnes, 2002. Pharmaceutical Press. 
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ase number C 
R eporter details 
• ·  
p atient details 
C 
D 
s 
-- --
ase_Ty� _ __ 
escription of 
uspected ADR 
- . .  
-··19 · 
�·- ------· 
-· -
- -
Patient , 
Age (years) 
1 9  
--
Retrospective , 
Patient's doctor 
Gender 
Female 
I Other 
I 
I Reason for Attendance at 
1 sKMC 
i -, Fol low up visit at Nephrology 
i Cl in ic 
I Prospective 
- . -· - - -- Sign and symptoms 
Severe nausea & vomiting  
Lab tests ( N : Normal , L:  Low , H;  High) 
creat,n ine 984 (H*) , urea  1 6  (H ) .Na  1 35 (N) ,  Mg 1 (N) ,  K 5 (N) ,  P04 2 
(H ) .a lbumin 35  (N ) ,b i l l irubin 1 3  (N ),total prote in 65 (N) ,HB 1 1 7 (N), ALP 6 5  
( N ) .AST 1 5  (N ),AL T 1 1  ( N ) , G F R  4 (L)  
· Other 
herbs caused n ausea a n d  vomitinQ --- -
�  -- · --
---!:f�rb- Drug Interaction resulting in AOR 
ist of Herbal Medicines I Garlic 
T 
L 
t 
L 
M 
aken . 
· r istof Conventional·----:-Omeprazole, N iferex (polysaccharide complex), darbepo1e In ,  
s 
p 
edicines taken -··- -- ---- •-
ources of data 
-- ----- - ---.-�-- - ---�-·· ·---
oi.;sib!e cause.t!L ___ 
mycophenolate I Conversation with I Patient's doctor Patient notes .J patient ✓ 
Herb / PM / underlyin g  d isease interaction 
Justification - brief summary 
omeprazole interacts with irritant  herbal ingredients (garl ic) to cause 
Author's conclusion 
exacerbation of side-effects of omeprazole32, omeprazole side effects 
include nausea and  vom itin g33 , N iferex ( iron supplements) side effects are 
stomach upset, vom it ing & nausea,34 darbepoet in  side effects include 
vomiting ,  nausea and  stomach pa in35 , mycophenolic acid side effects 
include severe nausea a n d  vomiting .36 
Naranjo score / modified Naranjo score 
2 (possible) / 2 ( possib le) 
Possible causal association due to h erb / PM interaction . May be associated with existing chron ic uraemia inducing severe nausea 
Consensus conclusion and vom iting in th is end  stage kidney fai lure p atient. Any additional herbs and drugs may exacerbate the symptoms. This is a very possible interaction .  
, ;  Herbal Medicine :  A Guide for Health Care P rofessionals by Joa 8 L' d A A d J D ·d nne a rnes, in a . n erson, . avI Phillipson, and Joanne Barnes. 2002. Pha rmaceut ica l  P ress. 
www.ma ochn1c .con, ·health d ru - informat ion DR601471 DSECTION=s ide-effects (accessed 9/07 /09) 
- ,,t t  www.ma ocl inic .com 'health dru - inf  ormat1on DR602285 DSECTION=side-effects (accessed 9/07 /09) 
'6 htt 
www.ma oclinic .com hea lth dru - informat ion D R601793 DSECTION=side-effects (accessed 9/07 /09) 
www.ma oclinic .com hea lth dru - informat ion DR601823  DSECTION=side-effects (accessed 9/07 /09) 
' l>tf 
'5 http:lj y L / g L I 
Case number 21 
Reporter details Patient v Patient's doctor Other 
Patient details Age (years) Gender Reason for Attendance at 
SKMC 
64 Female > Follow up visit at 
Nephrology Cl in ic 
Case Type Retrospective v Prospective 
Sign and symptoms 
Abdominal pain , vomitinci 
Description of Lab tests ( N :Normal , L :  Low , H;  High) 
Suspected ADR 
No abnormal lab tests in the patient's record 
Other 
Senna and / or thyme caused abdominal pain and vomiting 
Type Herb- Drug Interaction resulting in ADR 
List of Herbal cumin, senna, fenugreek, ginger, thyme, sage 
Medicines taken 
List of Conventional meloxicam, omeprazole 
Medicines taken 
Sources of data Patient notes / Conversation with / Patient's doctor 
✓ patient ✓ 
Possible cause(s) Herbs interacting with PM 
Justification - brief summary 
Omeprazole interacts with irritant herbal ingredients (sage+ thyme) 
to cause exacerbation of side-effects37 , omeprazole side effects 
Author's conclusion include abdominal pain38 , meloxicam side effects include heartburn ,  
nausea, stomach upset and severe vomiting38 
Toxic symptoms of volatile oil of thyme (thymol) documented for 
causing qastric pain, nausea, vomitinq.37 
Naranjo score / modified Naranjo score 
2 (possible) /  2 ( possible) 
Consensus Possible Interaction of the herbs with the drugs used. conclusion 
37 Herbal Medicine :  A Guide for Health Care Professionals by Joanne Barnes, Linda A. Anderson, J .  David 
Ph i l l ipson, and Joanne Barnes, 2002. Pharmaceutical Press 
38 British Nat ional Formulary ( BNF) edition No.56 -September 2008 
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Case number 22 
I Reporter details Patient -v Patient's doctor Other 
Patient details Age (years) Gender Reason for Attendance at 
43 SKMC 
Male .,. Follow up visit at 
Nephroloqy Clinic 
Case Type Retrospective -v Prospective 
Sign and symptoms 
Patient suspected herbs caused renal failure 
Description of Lab tests ( N :Normal , L :  Low , H; High) 
Suspected ADR creatinine 11 1 (H},GFR 52 (L) 
Other 
herbs caused renal failure 
Type Herb- Drug Interaction resulting in ADR 
List of Herbal mixture of herbs, thyme 
Medicines taken 
List of Conventional amoxicillin/clavulanate, paracetamol, orphenadrine 
Medicines taken 
Sources of data Patient notes I Conversation with / Patient's doctor ✓ patient ✓ 
Possible cause(s) Herbs interactinq with orphenadrine. 
Justification - brief summary 
Orphenadrine should be used with caution in hypertension and renal 
Author's conclusion impairment39 .Orphenadrine may be interacting with herbal 
preparations to exacerbate kidney disease. 
Naranjo score I modified Naranjo score 
2 (possible} /  2 ( possible) 
Possible Interaction. 
Consensus Orphenadrine does in itself exacerbate renal failure in somebody conclusion who already has kidney insufficiency. It is possible that these herbs 
worsen the renal situation. 
39 Brit ish National Formulary (BNF)  edition No.56 -September 2008. 
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Case number 23 
Reporter details Patient " Patient's doctor Other 
Patient detai ls Age (years) Gender Reason for Attendance at 
SKMC 
43 Female ,. Follow u p  visit at Nephrology 
Cl inic 
Case Type Retrospective \J Prospective 
Sign and symptoms 
Patient complained that herbs caused her abortion in 2nd trimester.  
Lab tests ( N :Normal , L: Low , H;  High) 
creatinine 1 91 (H),urea 7 (H),Na 1 35 (N) ,  Mg 1 (N), K 5 (N ), PO4 1 (N ),uric Description of 
J Suspected ADR acid 432 (H).albumin 26 (L) ,bilirubin 9 (N) ,  total protein 58 (L} ,HB 99 
(L) ,glucose 5 (N) ,ALP 70 (N),AST 1 6  (N),ALT 1 0  (N) ,  GFR 27 (L)  ! 
Other 
peppermint oil, fenugreek, chamomile or sage caused abortion 
Type Herbal ADR 
List of Herbal Medicines fenugreek, anise, chamomile, cumin, fennel, ginger, black seed, red seed, 
taken peppermint oi l .  
List of Conventional atenolol, indapamide 
Medicines taken 
Sources of data Patient notes I Conversation with I Patient's doctor ✓ patient ✓ 
Possible cause(s) 
Justification - brief summary 
Chamomile40 .41 is known to be uterotonic (excessive use of chamomile 
during pregnancy and lactation shou ld be avoided)41 . Sage is contra-
indicated during pregnancy. Traditionally, it is reputed to be an 
abortifacient and to affect the menstrual cycle. The volatile oil contains a 
high proportion of a- and P-thujones, which are known to be abortifacient 
Author's conclusion and emmenagogic
41
. 
Peppermint oil should be avoided during pregnancy due to insufficient 
safety information and a potential for toxicity.42 Fenugreek is reputed to be 
oxytocic and in-vitro has uterine stimulant activity has been documented41 . 
Use of fenugreek during pregnancy and lactation in doses greatly 
exceeding those normally encountered is not advisable. Sage is 
contraindicated during pregnancy and is reputed to be an abortificient. 
Chamomile is reputed to be abortificient43 
Naranjo score I modified Naranjo score 
5 (probable) / 5 ( definite) 
Consensus conclusion High probability of herb-induced abortion .  
40 http://www.nlm . n ih .gov/medl ineplus/druginfo/natural/pat ient-chamomile .html (accessed 9/07/09) 
•11 Herbal Medicine: A Gu ide for Health Care Professionals by Joanne Barnes, Linda A. Anderson, J .  David 
Ph i l l ipson, and Joanne Barnes, 2002. Pharmaceutical Press. 
42 http://www.n lm .n ih .gov/med l i neplus/druginfo/natural/patient-peppermint.html (accessed 9/07 /09) 
43 Herbal Medic ine: A Guide for Health Care Professionals by Joanne Barnes, Linda A. Anderson, J .  David 
Ph i l l i pson, and Joanne Barnes, 2002. Pharmaceutical press. 
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Case number 24 
Reporter details Patient " Patient's doctor Other 
Patient details Age (years) Gender Reason for Attendance at 
52 Female SKMC 
► Follow up visit at 
Nephroloav Clinic 
Case Type Retrospective " Prospective 
Sign and symptoms 
1 :  tiredness 2: nausea, abdominal pain 
Description of Lab tests ( N:Normal , L: Low , H; High) 
Suspected ADR No abnormal lab tests in patient's record 
Other 
senna caused nausea and abdominal pain, mixture of herbs caused 
stomach pain and tiredness 
Type Herb- Drug Interaction resulting in ADR 
List of Herbal mix (black seeds, garl ic, herbs), ginger, senna, fenugreek, senna, 
Medicines taken mixture of herbs 
List of Conventional irbesartan 
Medicines taken 
Sources of data Patient notes j Conversation with j Patient's doctor ✓ patient ✓ 
Possible cause(s) Interaction between ginger, fenugreek and i rbesartan. Interaction between senna and irbesartan. 
Justification - brief summary 
Tiredness: antihypertensive drugs (irbesartan) interact with herbal 
ingredients with hypotensive effect (ginger, fenugreek). 
Author's conclusion 
Nausea and abdominal pain: irbesartan side effects are nausea 
and stomach pain (dyspepsia and chest pain)44 , senna may cause 
mild abdominal discomfort such as colic or cramps. Prolonged use 
or overdosage can result in diarrhoea with excessive loss of 
potassium, albuminuria and haematuria45 
Naranjo score I modified Naranjo score 
2 (possible) / 2 ( possible) 
Consensus Very possible interaction. conclusion 
44 British National Formu la ry ( BNF) edition No.56 -September 2008. 
45 Herbal Medicine :  A Guide for Health Care Professionals by Joanne Barnes, Linda A. Anderson, J. David 
Ph i l l ipson, and Joanne Barnes, 2002. Pharmaceutical Press. 
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Case number 25 
Reporter details Patient " Patient's doctor Other 
Patient details Age (years) Gender Reason for Attendance at 
48 Female SKMC 
► Follow up visit at Nephrology 
Cl in ic 
Case Type Retrospective " Prospective 
Sign and symptoms 
Nausea (and dizziness) 
Lab tests ( N:Normal , L: Low , H; High) 
Description of 
creatinine 660 (H).urea 1 3  (H).Na 1 32 (L), Mg 1 (N}, K 5 (N),  PO4 1 
Suspected ADR (N),albumin 29 (L),bil irubin 1 1  (N) ,total protein 69 (N) ,HB 1 05 (L},glucose 
7 (H).ALP 54 (N),AST 1 7 (N) ,  ALT 9 (N),GFR 7 (L} 
Other 
senna caused nausea (and dizziness) 
Type Herb- Drug Interaction resulting in ADR 
List of Herbal Medicines mix (fenugreek, aloe), senna, aloe, stinkweed, myrrh 
taken 
List of Conventional valganciclovir, predn isolone, sirol imus, omeprazole, co-trimoxazole, 
Medicines taken amlodipine, ASA, atorvastatin, tacrol imus, trimetazidine 
Sources of data Patient notes I Conversation with I Patient's doctor ✓ patient ✓ 
Possible cause(s) Herbs interacting with PMs to produce nausea and possibly d izziness due to hypoqlycaemia. 
Justification - brief summary 
Sirol imus side effects include nausea, vomiting and dizziness,46 
prednisolone side effects include nausea and vom iting)47 and stomach 
Author's conclusion pain48 . Omeprazole s ide effects include stomach pain, nausea, vomiting 
and dizziness49; amlod ipine s ide effects include nausea, dizziness and 
stomach pain 5°, ASA side effects include heartburn, nausea and stomach 
upset51 , atorvastatin side effects include stomach upset52; senna is known 
to cause nausea53. 
Naranjo score / modified Naranjo score 
5 (probable) / 5 ( defin ite) 
Strong possibility (probable). 
Consensus conclusion Probable kidney graft failure (GFR = 7). Herbal drugs are highly likely to interact with 
immunosuppressive and anti hypertensive drugs in view of virtually no renal excretion. 
46 http://www. mayocl i n  ic.com/hea lth/d rug-i nformation/DR601827 /DSECTION=side-effects( accessed 9/07 /09) 
47 http://www. mayocli n ic.com/health/ drug-i nformation/D R602329/DSECTION=side-effects ( accessed 9/07 /09) 
48 Brit ish National Formulary (BNF)  edition No.56 -September 2008 
49 http://www.mayocl i n ic.com/health/drug-information/DR601471/DSECTION=side-effects (accessed 9/07 /09) 
so http://www.mayoc l in ic.com/health/drug-information/DR602957 /DSECTION=side-effects (accessed 9/07 /09) 
51 http://www.drugs.com/sfx/aspirin-side-effects.html (accessed 9/07 /09) 
52 http://www.mayocl in ic. com/health/drug-information/DR601517 /DSECTION=side-effects (accessed 9/07 /09) 
53 http://www.n lm .n ih .gov/medl ineplus/druginfo/meds/a601112.html (accessed 9/07 /09) 
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I Case number 26 
Reporter details Patient " Patient's doctor Other 
Patient detai ls Age (years) Gender Reason for Attendance at 
49 SKMC 
Male ► Follow up visit at 
Nephroloqy Clinic 
Case Type Retrospective " Prospective 
Sign and symptoms 
Renal fai lure 
Description of Lab tests ( N :Normal , L: Low , H;  High) 
Suspected ADR 
No available data 
Other 
patient took mixture of herbs to improve sex drive but it caused 
kidney fai lure 
Type Herb- Drug Interaction resulting in ADR 
List of Herbal mixture of herbs (identity unknown) 
Medicines taken 
List of Conventional calcitriol, ramipril, candesartan, amlodipine, fol ic 
Medicines taken acid, NaHCO3 ,darbepoetin 
Sources of data Patient notes I Conversation with I Patient's doctor ✓ patient ✓ 
Possible cause(s) I nteraction between herbal mixture and PMs 
Justification - brief summary 
.. 
Candesartan interacts with herbal preparations and dietary 
Author's conclusion supplements54, drug should be used with caution in  renal artery 
stenosis55. Darbepoetin interacts with herbal preparations.56 
Naranjo score I modified Naranjo score 
4 (possible) / 4 ( probable) 
Consensus Possible interaction. conclusion 
54 http://www.umm.edu/altmed/drugs/candesartan-020625.htm (accessed 9/07 /09) 
55 British National Formulary ( BNF) edition No.56 -September 2008 
56 http://www.drugs.com/cdi/darbepoetin-alfa-a lbumin . html (accessed 9/07 /09) 
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Case number 
Reporter detai ls 
Patient detai ls 
Case Type 
Description of 
Suspected ADR 
Type 
List of Herbal Medicines 
taken 
List of Conventional 
Medicines taken 
Sources of data 
Possible cause(s) 
Author's conclusion 
Consensus conclusion 
27 
Patient " Patient's doctor Other 
Age (years) Gender Reason for Attendance at 
45 SKMC 
Male ► Follow u p  visit at N ephrology 
Clinic 
Retrospective " Prospective 
Sign and symptoms 
Finger numbness 
Lab tests ( N :Normal , L: Low , H; High) 
creatinine 1 34 (H).urea 7 (H),Na 1 40 (N), Mg 1 (N), K 5 (N), PO4 1 ( N) ,uric 
acid 349 (N),albumin 40 (N) ,  total protein 67 (N) ,HB 1 62 (H) .g lucose 9 
(H),GFR 50 (L) 
Other 
cardamom caused numbness in finqers 
Herb- Drug Interaction resu lting in ADR 
cardamom 
prednisolone, ciclosporin, mycophenolate, losartan, amlodipine, carvedi lol , 
atorvastatin, clonidine, insulin 
Patient notes I Conversation with 
I 
Patient's doctor 
✓ patient ✓ 
Interaction of cardamom with PMs 
Justification - brief summary 
Ciclosporin57 '58' pednisolone57, amlodipine57 , carvedilol57 '59 '60 interact with 
herbal preparations. Carvedilol side effect is numbness or t ingl ing of hands 
or feet.61 This reaction could be an interaction of cardamom and 
conventional medicines taken by patient e.g .  ciclosporin 62 
Naranjo score / modified Naranjo score 
1 (possible) / 1 (possible) 
Very weak possibi l ity. 
Evidence for drug - drug interaction is strong. Whereas drug herb 
interaction in th is patient with probable renal transplant insufficiency is very 
weak. 
57 Herbal  Medicine :  A Guide for Health Care Professionals by Joanne Barnes, Linda A. Anderson, J .  David 
Ph i l l ipson, and Joanne Barnes, 2002. Pharmaceutical Press 
58 http://www.drugs.com/pro/cyclosporine-capsu les.html (accessed 9/07 /09) 
59 http://www.drugs.com/pro/carvedi lo l .html (accessed 9/07 /09) 
60 http://www.herbs2000.com/medica/carvedi lol .htm (accessed 9/07/09) 
61 http://www.mayocl in ic .com/health/drug-information/DR601665/DSECTION=side-effects (accessed 9/07 /09) 
62 http://www.health l ine.com/natstandardcontent/cardamom/2#H8 (accessed 9/07 /09) 
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Case number 31  
Reporter detai ls Patient "\/ Patient's doctor Other 
Patient details Age (years) Gender Reason for Attendance at 
SKMC 
38 Male ► Follow up visit at 
Nephrology Clinic 
Case Type Retrospective "\/ Prospective 
Sign and symptoms 
Patient suspected herbs causes renal failure 
Lab tests ( N :Normal , L :  Low , H;  High) 
Description of 
Suspected ADR creatinine 115 (H).urea 7 (H),Na 140 (N), Mg 1 (N), K 6 (H), PO4 1 
(N),uric acid 432 (H), albumin 41 (N),bilirubin 12 (N), total protein 69 
(N) ,HB 108 (L),cholesterol 4 (N),glucose 5 (N) ,  GFR 71 (L) 
Other 
Type Herb- Drug Interaction resulting in ADR 
List of Herbal Mixture(containing black seeds, cinnamon, moringa, paregrina, 
Medicines taken myrrh), senna, qinqer, thyme, fenuqreek 
List of Conventional pioglitazone, gliclazide, ASA, ciclosporin, mycophenolate, 
Medicines taken prednfsolone, lisinopril, amlodipine, omeprazole, atorvastatin 
Sources of data Patient notes j Conversation with j Patient's doctor ✓ patient ✓ 
Possible cause(s) Herbs may interact with PMs used 
Justification - brief summary 
Ciclosporin interacts with prednisolone63; patients may not be able 
to use ciclosporin if they have kidney disease; ciclosporin may 
Author's conclusion cause high BP or kidney problems, the risk is increased with high 
dose or prolonged use. 64 
Ciclosporin may interact with herbal preparations. 
Naranjo score / modified Naranjo score 
1 (possible) / 1 ( possible) 
Very weak possibility for interaction of the herbs with the drugs. The 
Consensus immunosuppressant drugs in themselves could be nephrotoxic if 
conclusion their blood levels are not correct in a renal transplant patient such as this. 
63 http://www.drugs.com/drug-interactions/predn isone d00350 cyclosporine d00079.html (accessed 
9/07 /09) 
64 http://www.drugs.com/cdi/cyclosoorine-caosules.html (accessed 9/07 /09) 
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Case number 34 
Reporter details Patient " Patient's doctor Other 
Patient details Age (years) Gender Reason for Attendance at 
53 SKMC 
Male ► Follow up visit at 
Nephrology Clinic 
Case Type Retrospective " Prospective 
Sign and symptoms 
patient complained of loss of activity, malaise 
Lab tests ( N: Normal , L: Low , H; High) 
Description of 
Suspected ADR creatinine 413 (H).urea 21 (H),Na132 (L),Mg 1 (N) ,  K 5 (N), PO4 1 
(N),albumin 37 (N),billirubin 11 (N) ,total protein 76 (N),HB 1 44 
(N),glucose 4 (N),ALP 107 (N),AST 10 (L),AL T 24 ( N),GFR 1 4  (L) 
Other 
loss of activity and malaise 
Type Herbal ADR 
List of Herbal senna, ginger, fenugreek, black seeds, chamomile, green tea 
Medicines taken 
List of Conventional prednisolone, ciclosporin, allopurinol, amlodipine 
Medicines taken 
Sources of data Patient notes I Conversation with I Patient's doctor ✓ patient ✓ 
Possible cause(s) 
Justification - brief summary 
Author's conclusion 
Ginger side effect is unusual drowsiness, 65 
All medici nes of amlodipine66'a l lopurinol67, ciclosporin68, prednisolone 69, 
side effects are to cause unusual tiredness or weakness; but the main  
effect appears to be a inaer. 
Naranjo score / modified Naranjo score 
3 ( possible) / 3 ( probable) 
Possible interaction. 
Consensus 
conclusion In addition to the effect of the possible transplant rejection in this 
patient which itself can cause malaise and generalized fatigue there 
might be a possible contribution to this situation by the herbs. 
65 http://www.drugs.com/cdi/ginger.html (accessed 9/07 /09) 
66 
http://www.mayocl in ic .com/hea lth/drug-information/DR600107 /DSECTION=side-effects (accessed 9/07 /09) 
67 
http://www.mayocl in ic .com/hea lth/drug-information/DR601763/DSECTION=side-effects (accessed 9/07 /09) 
68 
http://www. m ayocli n ic.com/hea Ith/ drug-i nformation/DR601591/DSECTION=side-effects ( accessed 9/07 /09) 
69 http://www.mayocl in ic.com/hea lth/drug-information/DR602333/DSECTION=side-effects (accessed 9/07/09) 
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Case number 35 
Reporter details Patient v Patient's doctor Other 
Patient details Age (years) Gender Reason for Attendance at 
SKMC 
62 Male ► Follow up visit at 
Nephroloav Clinic 
Case Type Retrospective v Prospective 
S ign and symptoms 
severe asthma attack 
Lab tests ( N :Normal , L: Low , H; H igh) 
Descr iption of creatinine 424 (H).urea 26 (H),Na 137 (N),Mg 1 (N), K 3 (L),PO4 2 
Suspected ADR 
(H) .uric acid 400 (N),albumin 37 (N),total protein 7 1  (N), HB 89 
(L),cholesterol 5 (N),glucose 6 (N) 
Other 
ginger and mixture of herbs worsen the respiratory system and had 
severe asthma attack 
Type Herbal ADR 
List of Herbal Mixture of herbs, thyme, ginger, senna, sweet basil 
Medicines taken 
List of Conventional valsartan, amlodipine, prednisolone, omeprazole, candesartan, 
Medicines taken budesonide with formoterol, salbutamol, tiotropium, azithromvcin 
Sources of data Patient notes j Conversation with I Patient's doctor ✓ patient ✓ 
Possible cause(s) Herbs used worsen respiratory function 
Justification - brief summary 
Ginger and mixture of herbs may worsen the respiratory function in 
Author's (Fat ima's) this asthmatic patient. There is good temporal association but no 
conclusion supportive evidence from the literature. 
Naranjo score / modified Naranjo score 
2 (possible) / 2 ( possible) 
Consensus Weak possibility. conclus ion 
i 
i I 
I I 
I I 
I I 
I I 
! 
Case number 36 
Reporter details Patient " Patient's doctor Other 
Patient details Age (years) Gender Reason for Attendance at 
SKMC 
57 Male ► Follow up visit at 
Nephrology Clinic 
Case Type Retrospective " Prospective 
Sign and symptoms 
weakness 
Lab tests ( N :Normal , L: Low , H; High) 
Description of 
Suspected ADR creatinine 355 (H).urea 11  (H),Na1 34 (L),Mg 1 (N), K 4 (N),PO4 1 
(N),uric acid 269 (N),albumin 20 (L),bilirubin 9 (N),total protein 49 
(L) ,HB 92 (L),cholesterol 3 (N),glucose 1 6  (H).ALP 1 1 3  (N),AST 23 
(N),AL T 20 (N),GFR 1 7  (L) 
Other 
Type Herb- Drug Interaction resulting in ADR 
List of Herbal mix of herbs (myrrh, stinkweed), ginger, fenugreek, red seeds 
Medicines taken 
List of Conventional valganciclovir, prednisolone, ciclosporin, sirolimus, co-trimoxazole, 
Medicines taken omeprazole, valsartan, atorvastatin, amlodipine, gliclazide, Mg, phosphate, lactulose, insulin. 
Sources of data Patient notes \ Conversation with \ Patient's doctor 
✓ patient ✓ 
Possible cause(s) 
Justification - brief summary 
Author's (Fatima's) Valganciclovir side effects include weakness or tiredness
70
, 
amlodipine can cause weakness71 ; atorvastatin side effects include 
conclusion weakness, muscle pain and tenderness72, antidiabetic drugs 
(gliclazide) interact with herbal ingredients with hypoglycemic effect 
(qinqer, fenuqreek and rnyrrh)73 
Naranjo score I modified Naranjo score 
5 ( probable) / 5 ( definite) 
Consensus Possible interaction. conclusion 
70 http://www.mayoclinic.com/health/drug-information/DR601413/DSECTION=side-effects (accessed 9/07/09) 
71 http://www.mayocl in ic .com/health/drug-information/DR600l07 /DSECTION=side-effects (accessed 9/07 /09) 
72 http://www.mayocl i n ic.com/health/drug-information/DR601517 /DSECTION=side-effects (accessed 9/07 /09) 
73 Herbal Medicine :  A Guide for Hea lth Care Professionals by Joanne Barnes, Linda A. Anderson, J. David 
Ph i l l i pson, and Joanne Barnes, 2002. Pharmaceutical Press. 
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Case number 37 
! Reporter details Patient v Patient's doctor Other 
Patient details Age (years) Gender Reason for Attendance at SKMC 
68 Male ,, Follow up visit at Nephrology Clinic 
Case Type Retrospective Prospectivev 
Sign and symptoms 
stomach pain (peptic ulcer) 
Lab tests ( N:Normal , L: Low , H; High) 
creatinine 91 (N),urea 4 (N),Na 1 42 (N),Mg 2 (H), K 4 (N),P04 1 (N),uric acid 3 15  (N),mic 
Description of albumin 22 (H),HB 1 65 (H).cholesterol 4 (N),gfucose 6 (N),GFR 78 (L) 
Suspected ADR 
Other 
ainaer caused stomach pain and acidity 
Type Herb- Drug Interaction resulting in ADR 
List of Herbal Medicines taken thvme, ginger, senna 
List of Conventional Medicines diclofenac sodium gel, paracetamol, amlodipine, insulin glargine, hydrochlorothiazide, 
taken lisinooril, ASA, atorvastatin, gliclazide, ezetimibe, rosiqlitazone, sildenafil 
Sources of data Patient notes I Conversation with patient " I Patient's doctor ✓ 
Justification - brief summary Paracetamol side effects include nausea, stomach pain and 
ulcer74, amlodipine side effects include stomach pain75, rosiglitazone side effects include 
stomach pain and nausea76, hydrochlorothiazide side effects include severe nausea or 
stomach pain77, lisinopril side effects include nausea and stomach pain76 , ASA side effects 
Author's conclusion include heartburn, nausea, upset stomach, severe stomach pain79, atorvastatin side effects 
include severe stomach pain,60 sildenafil side effects include stomach upset and discomfort61 . 
Toxic symptoms of volatile oil of thyme (thymol) documented to cause gastric pain62 . Senna 
may cause mild abdominal discomfort such as colic or cramps.63 
Naranjo score / modified Naranjo score 
5 (probable) / 5 ( definite) 
High possibility (probable). In addition to the different drugs which have stomach pain as side 
Consensus conclusion effect, the herbs might contribute to the situation. 
74 http://www. m ayocli n ic .com/hea Ith/ drug-i nformation/DR601885/DSECTION=side-effects (accessed 9/07 /09) 
75 http://www.mayocl in ic. com/health/drug-information/DR602957 /DSECTION=side-effects (accessed 9/07 /09) 
76 
http://www. m ayocl in ic .com/hea Ith/ d rug-information/DR602003/DSECTION=side-effects ( accessed 9/07 /09) 
77 http://www.mayocl in ic .com/hea lth/drug-information/DR602673/DSECTION=side-effects (accessed 9/07 /09) 
78 http://www.mayocl in ic .com/hea lth/drug-information/DR602023/DSECTION=side-effects (accessed 9/07 /09) 
79 http://www.drugs.com/sfx/aspir in-side-effects.html (accessed 9/07 /09) 
so http://www.mayoclinic.com/hea1th/drug-information/DR601517 /DSECTION=side-effects (accessed 9/07 /09) 
31 
http://www. mayocl in ic.com/health/ drug-i nformation/DR601513/DSECTION=side-effects (accessed 9/07 /09) 
32 
Herbal Medicine :  A Gu ide for H ealth Care Professionals by Joanne Barnes, Linda A. Anderson, J .  David 
Phi l l ipson, and Joanne Barnes, 2002. Pharmaceutica l  p ress 
83 
Herbal Medicine :  A Gu ide for Health Care Professionals by Joanne Barnes, Linda A. Anderson, J. David 
Phi l l ipson, and Joanne Barnes, 2002. Pharmaceutical press. 
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Case num ber 40 
Reporter details Patient '../ Patient's doctor Other 
Patient details Age (years) Gender Reason for Attendance at 
58 SKMC 
Female ► Follow up visit at 
Nephrology Clinic 
Case Type Retrospective '../ Prospective 
Sign and symptoms 
Colon inflammation 
Lab tests ( N :Normal , L: Low , H ;  High) 
Description of creatinine 90 (N),urea 4 (N),Na140 (N),Mg 1 (N), K 4 (N), PO4 1 
Suspected ADR (N),albumin 40 (N),bilirubin 12 (N),total protein 68 (N),HB 133 
(N),cholesterol 4 (N),ALP 113 (N),AST 37 (H).ALT 62 (H),GFR 91 
(L) 
Other 
saqe caused colon inflammation 
Type Herbal ADR 
list of Herbal sage, parsley, ginger 
Medicines taken 
list of Conventional None recorded in patient's medical file. 
Medicines taken 
Sources of data Patient notes I Conversation with / Patient's doctor ✓ patient ✓ 
Possible cause(s) 
Justification - brief summary 
Author's conclusion sage and parsley are considered to be irritant herbal ingredients. 
Naranjo score I modified Naranjo score 
5 (probable} / 5 ( definite) 
Consensus High possibility (probable). conclusion 
I 
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Case number 48 
Reporter details Patient -v Patient's doctor Other 
Patient detai ls Age (years) Gender Reason for Attendance at 
53 Male SKMC 
► Follow up visit at 
Nephrologv Clinic 
Case Type Retrospective -v Prospective 
Sign and symptoms 
Stomach pain 
Lab tests ( N:Normal , L :  Low , H ;  High) 
Description of creatinine 73 (N),urea 7 (H) .Na 142 (N), K 4 (N),albumin 38 (N),mic 
Suspected A DR albumin 57 (H),billirubin 1 2  (N) ,total protein 64 (N), HB 1 12 
(L),cholesterol 4 (N),glucose 5 (N),ALP 53 (N),AST 21 (N),AL T 22 
(N),GFR 74 (L) 
Other 
Chinese herbs caused stomach pain 
Type Herb- Drug Interaction resu lting in ADR 
List of Herbal Chinese herbs 
Medicines taken 
List of Conventional aspirin, omeprazole 
Medicines taken 
Sources of data Patient notes I Conversation with I Patient's doctor ✓ patient ✓ 
Possible cause(s) 
Justification - brief summary 
Aspirin side effects include upset stomach, severe or persistent 
A uthor's conclusion stomach pain84, omeprazole drug side effects include stomach 
pain85 ; but Chinese herbs were also strongly suspected in this case. 
Naranjo score I modified Naranjo score 
2 (possible) / 2 ( possible) 
Consensus Highly possible. conclusion 
84 http://www.drugs.com/sfx/aspi rin-side-effects.html (accessed 9/07 /09) 
85 http://www.mayocl in ic.com/hea1th/drug-information/DR601471/DSECTION=side-effects (accessed 9/07 /09) 
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Appendix 3.3 
Supplementary information on toxicity of herbs identified in 
Phase 2 of the research. 
151 
In both phases of the research, HM taking by subjects was widespread. In  an attempt to 
gauge the potential harm of such use, a literature search was conducted to retrieve any 
relevant published reports of harm. 
Method 
The following sources were of particular interest: 
Medline, and the journals: Phytochemistry; the Journal of Ethnopharmacology; and the 
Journal of Pharmacology and Toxicology. In addition, the reference textbook by Barnes et 
al. 1 was consulted. 
The search terms used were: toxicity, side effects, adverse event, adverse reaction, adverse 
drug reaction , toxicology, linked to the name of herb (see below), from 1/1/1999 to the 
28/1 2/09. Searches were carried out through the medical library of the Faculty of Medicine 
and Health Sciences in UAE University library. Other journals were also investigated where 
secondary references pointed to potentially relevant information. 
Searches were conducted using the top ten herb names listed in Table 3.6, page 93 
( 'mixture of herbs' could not be identified further) and identified as being implicated in the 
adverse reactions described in Table 3.22, Page 111. 
Findings are discussed below, both in the contexts of the presence of the herb in Table 3.6 
and of the ADRs described in Table 3.22. Only relevant pharmacology and toxicology are 
discussed. 
Results and discussion 
With reference to Table 3.6 (Herbs taken by five or more patients in the study.) , no links to 
ADRs with cardamom and anise were discovered, implicating that these herbs were unlikely 
to have caused problems in the 14.3% and 11.1% respectively of patients taking them. 
Indeed, very few reports of actual harm in humans were found for any of the herbs studied. 
In  Middle Eastern societies, many of the herbs might have a dual purpose of a medicine in 
one context but a foodstuff in another. As foodstuffs, one would not expect to see excessive 
toxicity or if it occurred, that it would be identified as such by the user. However, all the herbs 
listed by the research subjects were identified as being taken by them for a medicinal 
purpose, which may have heightened their awareness of potential adverse effects. The 
following comments apply to the eight remaining herbs in the top 10 in Table 3.6, in 
descending order. Supporting references are listed at the end of this Appendix. 
Ginger {used by 50.9% of patients in  Phase 2) 
Pharmacology 
According to Barnes et al. 1 , ginger has been shown to have both hyper- and hypotensive, 
hypocholesterolaemic, anti-inflammatory and hypoglycaemic properties in viva. An 
anticoagulant activity, through inhibition of platelet activity, has also been observed in vitro. 
Ginger is reputed to be an abortifacient and uterotonic activity has been documented for a 
related species. 'The clinical significance of these findings, if any, is unclear'. 1 Ginger may 
also help with motion sickness through a local action on the gastrointestinal tract and clinical 
studies have focused mainly on the effects of ginger in the prevention of nausea and 
vomiting. 
Toxicity 
Antiplatelet activity may have contributed to GI bleeding, leading to blood in the stools seen 
in Case 8, although other herbs were also implicated (hence the designation 'multiple'). 
Hypoglycaemic activity may have contributed to dizziness in Case 1 3, 'tiredness' in Case 24 
and ·weakness' in Case 36, although other herbs were also implicated. Doses of ginger that 
greatly exceed the amounts used in foods should not be taken during pregnancy or lactation; 
but i t  was taken, along with eight other herbs by the patient in Case 23 and could have 
contributed to abortion. No relevant primary references for these toxicities were discovered. 
Thyme {used by 38.2% of patients in  Phase 2) 
Pharmacology 
Thyme is reported to have hypotensive, respiratory stimulant and antispasmodic effects in 
vivo. 1 In vitro antispasmodic activity of thyme and related Thymus species has been 
associated with the phenolic components of the volatile oil and with the flavonoid 
constituents; their mode of action is thought to involve calcium-channel blockage. 1 
Toxicity 
Toxic symptoms documented for thymol include nausea, vomiting, gastric pain, headache 
and dizziness (as perhaps seen in Case 1 3). 1 Thymol is irritant to the gastrointestinal tract 
and may have contributed to the gastrointestinal symptoms seen in Cases 6, 8, 1 5, 1 6, 2 1  
and 37; although all of these were described as having 'multiple' origins. No relevant primary 
references for these toxicities were discovered. 
Peppermint (used by 37.8% of patients in Phase 2) 
Pharmacology 
Peppermint oil contains a range of aromatic compounds (e.g. menthol, menthone, cineole 
and menthofuran) which are reported to relax gastrointestinal smooth muscle, thus relieving 
flatulence and cholic. 2 
Toxicity 
Peppermint is traditionally associated with a carminative action. However two reports of 
adverse gastrointestinal effects were located: one of heartburn and perianal irritation,3 and 
one of abdominal distension and increased flatulence. 4 Peppermint use might have 
contributed to the symptoms described in Cases 8 and 15, but both were described as 
having 'multiple' causes. 
Fenugreek (used by 30.6% of patients in Phase 2) 
Pharmacology 
Hypocholesterolaemic and hypoglycaemic actions have been documented for fenugreek in 
both laboratory animals and humans; this is of potential relevance to Case 1 3. 1 
Hypoglycaemic activity in healthy individuals has been reported for whole seed extracts, with 
slightly lesser activity exhibited by gum isolate, extracted seeds and cooked seeds. 
Proposed theories of action include a reduction in carbohydrate absorption by the 
mucilaginous fibre. 
A stimulant action on the isolated guinea pig uterus, especially during late pregnancy, has 
been noted for both aqueous and alcoholic extracts. 1 This is of potential relevance to Case 
23. 
Toxicity 
There is l imited evidence from preclinical and preliminary clinical studies that fenugreek has 
hypoglycaemic activity and may therefore have contributed to the 'tiredness' mentioned in 
Case 24. The absorption of drugs taken concomitantly with fenugreek may be affected due 
to its high mucilaginous fibre content; but this was not thought to be a contributory interaction 
in the cases in this research. 
Fenugreek is reputed to be oxytocic and in vitro uterine stimulant activity has been 
documented. 1 Fenugreek was taken by the patient in Case 23 and may have contributed to 
her abortion. As Barnes et al. observe: ' The use of fenugreek during pregnancy and lactation 
in doses greatly exceeding those normally encountered in foods is not advisable. '1 
Two primary references provided evidence for the involvement of fenugreek in other cases. 
Izzo et al. 5 noted the potential for fenugreek to cause G I  symptoms (relevant to Cases 6, 8, 
13, 15, 2 1 ,  24 and 25). Faeste et al. 6 observed that fenugreek seed powder contains 
several potential al lergens and an allergic response to ingestion was observed in human 
subjects ( of possible relevance to Cases 1 O and 15). 
Black seeds (Nigel/a sativa) (used by 25.2% of patients in Phase 2) 
Pharmacology 
Little is known of the pharmacology of black seed compounds. Traditional internal uses 
include urination difficu lty, dysmenorrhoea, indigestion, asthma and impotence. 
Toxicity 
Four separate reports of the in vivo (animal) hypotensive and diuretic effects of black seed 
ingredients were located. 7•10 This hypotensive effect may be relevant to Case 9 a lthough the 
contribution to the drug interaction is described as 'multiple'. No reports were located of such 
effects in man. 
Senna (used by 19.2% of patients in Phase 2) 
Pharmacology 
The cathartic action of hydroxyanthracene, one of the constituents of senna, is well 
recognised and senna praparations have been used as laxatives for many years.1 It is 
thought that hydroxyanthracene glycosides are absorbed from the gastrointestinal tract, the 
aglycones liberated during metabolism and excreted into the colon resulting in stimulation 
and an increase in peristalsis. However, it has also been suggested that the purgative action 
of senna is due to the action of intestinal bacteria. Using human intestinal flora, it was found 
that sennoside A is reduced to 8-glucosyl rheinanthrone, hydrolysed to rheinanthrone and 
oxidised to sennidin A. The active principle causing peristaltic movements of the large 
intestine was thought to be rheinanthrone. 1 
Toxicity 
Senna may cause mild abdominal discomfort such as colic or cramps as seen in Cases 6 ,  
21 and 24; although nausea was associated with sen na use in  Case 25. Prolonged use or 
overdosage can result in diarrhoea with excessive loss of potassium, albuminuria and 
haematuria, and dehydration. 1 Diarrhoea was noted in Case 2.  No recent published case 
studies were found, perhaps because these affects are so well known. Potassium deficiency 
may lead to disorders of the heart and muscular weakness; 'tiredness' was noted as a 
symptom in Cases 14 and 24 and both subjects were senna users. Again, no corroborating 
case studies were found in the literature search. 
Cardamom (used by 14.3% of patients in Phase 2) 
No reports of toxicity were located. 
Anise ( used by 11 .1  % of patients in Phase 2) 
No reports of toxicity were located. 
Sage (used by 10.5% of patients in Phase 2) 
Pharmacology 
Sage is stated to possess carminative, antispasmodic, antiseptic and astringent properties. 1 
Traditionally, it has been used to treat flatulent dyspepsia, pharyngitis, uvulitis, stomatitis, 
gingivitis , glossitis (internally or as a gargle/mouthwash), hyperhidrosis, and galactorrhoea. 1 
A spasmogenic action exhibited by low doses of sage oil has been attributed to the pinene 
content. Antispasmodic activity in vivo (in guinea-pigs) has been reported for sage oil 
administered intravenously, which relieved contraction of Oddi's sphincter induced by 
intravenous morphine. 1 
Toxicity 
A case of human poisoning has been documented following ingestion of sage oil for acne. 
Convulsant activity in humans (and animals) has been documented for sage oil. Sage oil is 
reported to be a moderate skin irritant. Barnes et al. 1 warn that sage oil is toxic (due to the 
thujone content) and should not be ingested in large amounts. The irritant effects might have 
contributed to the symptoms of Case 40. 
Sage is widely contraindicated during pregnancy. The volatile oil contains a h igh proportion 
of a- and b-thujones, which are known to be abortifacient. 1 The herb was used by Case 23 
who experienced an abortion, although the subject was taking a range of herbs at the time. 
Chamomile (used by 10.0% of patients in Phase 2) 
Pharmacology 
The allergenic properties documented for chamomile have been attributed to anthecotulid, a 
sesquiterpene lactone present in low concentrations, and to matricarin, a proazulene which 
has produced positive patch tests in patients with an existing sesquiterpene lactone 
hypersensitivity.1 
Toxicity 
Reports of allergic reactions to chamomile are common, although in the majority of cases the 
plant species is not specified.1 Patients with an existing hypersensitivity to chamomile have 
demonstrated cross-sensitivities to other members of the family Asteraceae/Compositae. 
The symptoms experienced included abdominal cramps, thickness of the tongue and a tight 
sensation in the throat, angioedema of the lips and eyes, diffuse pruritus, a full sensation of 
the ears, generalised urticaria, upper airway obstruction, and pharyngeal oedema. 
Allergic skin reactions have been documented following external contact with chamomile. 
Consumption of chamomile tea may exacerbate existing allergic conditions and the use of a 
chamomile enema has been documented to cause asthma and urticaria. 1 Itching was 
experienced by Case 15, but this was thought to be more likely to be associated with 
fenugreek. 
Chamomile is reputed to be a uterine stimulant when used excessively and use during 
pregnancy is widely contraindicated.1 The herb was used, along with a multitude of others, 
by Case 23, who experienced an abortion. 
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